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Key messages 
 Published evidence on the clinical efficacy of SIRT compared to best supportive care in patients 
with unresectable, chemotherapy-refractory colorectal cancer is of limited quality and at risk of 
bias. Two retrospective studies report a survival benefit from SIRT of approximately 5 months. 
One small randomised controlled trial showed that disease progression was delayed; overall 
survival was not improved but the study was not designed to detect a statistically significant 
difference in this outcome. Adverse event rates were similar between the groups. Studies with 
no comparator group indicate that patients treated with SIRT live an average of 9.6 months. 
Patients’ quality of life during this time has not been adequately studied.  
 Patients with chemotherapy-refractory intrahepatic cholangiocarcinoma live for 15 months on 
average following SIRT. This is based on small published studies with no comparator group to 
show whether SIRT confers a survival advantage. 
 A new study based on data collected from patients treated recently with SIRT in the NHS was 
carried out (SIRT CtE registry study), and showed the following:  
o Patients with colorectal cancer who received SIRT lived for a median of 7.6 months, and 
progressed after 3.0 months; 30% of patients were alive at 12 months following 
treatment with SIRT. 
o Patients with intrahepatic cholangiocarcinoma lived for a median of 8.7 months after 
having SIRT, and progressed after 2.8 months; 37% of patients were alive at 12 months 
following treatment with SIRT.  
o The impact of SIRT on patients’ quality of life could not be reliably determined 
o Severe complications were uncommon. Most adverse events were mild, and the most 
common types were fatigue and abdominal pain. 
The reliability of the results from this study is limited by the absence of a comparator group and 
a study design which is at risk of bias.  
 A new cost-effectiveness model was created by the external assessment centre as part of the 
commissioning through evaluation project to compare SIRT to best supportive care in patients 
with colorectal cancer which has progressed following standard treatment. The model showed: 
o SIRT was likely to be clinically effective (increased quality adjusted life years) for an 
additional cost, but very unlikely to be cost-effective at a willingness to pay threshold of 
£30K. 
o The incremental cost-effectiveness ratio was £85K, which was mostly due to the cost of 
the SIRT procedure itself. 
The model is limited by the absence of high quality comparative data, and its results depend on 
the assumption that SIRT is clinically effective.  
 A published cost-effectiveness model created by a different research group (Pennington et al. 
2015) was more optimistic with an incremental cost-effectiveness ratio of £28K. The difference 
is due to the model authors using a lower procedure cost for SIRT and a longer survival time. 
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1 Executive summary 
1.1 Background 
1.1.1 Colorectal cancer 
Colorectal cancer (CRC) includes cancers of the colon, rectum, and appendix. CRC is the third most 
common cancer in the UK. Approximately 28% of patients diagnosed with CRC are at TNM stage IV 
where the cancer has metastasised outside of the primary location, which has a 5 year survival of 
3%. Systemic chemotherapy is the first choice treatment for unresectable metastatic disease, and 
NICE recommends a range of chemotherapy combinations for first and second line treatment of 
metastatic CRC (mCRC). For patients who have progressed following standard therapies, the aim of 
further treatments is to prolong life, improve symptoms and maintain quality of life. NICE 
recommends trifluridine-tipiracil for adults who have had previous treatment with available 
therapies.  
1.1.2 Intrahepatic cholangiocarcinoma 
Intrahepatic cholangiocarcinoma (ICC) is a rare type of primary liver cancer originating in the bile 
ducts. Fewer than 1,600 people in Great Britain are diagnosed with ICC each year. The 5 year survival 
rate for metastasised unresectable ICC is approximately 2%. Most patients are diagnosed with non-
resectable disease. For patients with advanced and inoperable ICC, cisplatin and gemcitabine is an 
effective first line systemic treatment. Second-line chemotherapy is not standard care in patients 
with ICC.  
1.1.3 Selective internal radiation therapy 
Selective internal radiation therapy (SIRT) is used to treat cancerous tumours in the liver. It involves 
delivering microspheres containing a beta-emitting radionuclide, such as yttrium-90, directly into 
the tumour by infusing them into the hepatic artery.  
1.2 Objective 
The objective of this Commissioning through Evaluation (CtE) project was to evaluate the clinical and 
cost-effectiveness of SIRT in the following patient groups: 
1. Patients with unresectable mCRC in the liver which has progressed following at least two 
lines of standard chemotherapy; 
2. Patients with unresectable primary ICC which has progressed following at least one previous 
chemotherapy line. 
Clinical outcomes of interest were overall survival (OS), progression free survival (PFS), liver-specific 
PFS (LPS), health related quality of life (HRQoL), and safety.  
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The CtE project included a review of published literature on the clinical and cost-effectiveness of 
SIRT compared to best supportive care (BSC), analysis of new data collected as part of the SIRT CtE 
registry study, and a de novo cost-effectiveness model produced by Cedar.  
1.3 Published clinical evidence 
A systematic review of evidence on the clinical efficacy of SIRT in the aforementioned patient groups 
was carried out in January 2017. Medline, EMBASE, Cochrane library, Scopus and EconLit were 
searched and a total of 1,170 articles were retrieved. In the CRC population, three systematic 
reviews and 24 primary studies, of which 3 were comparative, were selected for inclusion. In the ICC 
population, two systematic reviews and 10 non-comparative primary studies comprising a total of 
247 patients were included.  
1.3.1 Patients with colorectal cancer (CRC) treated with SIRT 
In the CRC population, two retrospective comparative studies found statistically significant 
improvements in OS when SIRT was compared to BSC. In one of these studies, patients receiving BSC 
survived for a median of 6.6 months compared with 11.9 months in patients who received SIRT (HR 
0.5; p=0.001). In the second study, patients receiving BSC had an OS of 3.5 months compared to 8.3 
months for patients who received SIRT (HR 0.26; p<0.001). Retrospective matched-pair studies such 
as these are at risk of bias from imbalanced prognostic factors, poor standardisation of control arm 
treatments, and variability in outcome measures.  
In a small randomised controlled trial comparing fluorouracil chemotherapy alone to SIRT plus 
chemotherapy, PFS and LPFS were improved in the SIRT arm (PFS 2.1 vs 4.5 months; HR 0.51; 
p=0.03; LPFS 2.1 vs 5.5 months; HR 0.38; p=0.003) demonstrating prolonged control of liver tumour 
growth. In this trial, patients were permitted to cross-over following progression. No statistically 
significant improvement in OS was observed (7.3 vs 10.0 months; HR: 0.92; p=0.80) but this trial was 
not powered to detect a change in this outcome, and the cross-over design may obscure any survival 
benefit. Severe adverse event rates were low in the RCT and not significantly different between 
groups. Mild abdominal pain, nausea, and fatigue were the most common events in patients treated 
with SIRT in comparative studies.  
A large body of evidence from single-arm observational studies on CRC patients was identified. OS 
was reported in all 23 comparative and non-comparative studies selected (2,517 patients) and 
ranged from 6.0 to 12.7 months (weighted mean 9.6 months [95% CIs 8.9-10.4]). PFS was reported in 
9 studies (437 patients) and ranged from 2.8 to 9.2 months (weighted mean 4.0 months). LPFS was 
reported in 8 studies (376 patients) and ranged from 2.0 to 9.0 months (weighted mean 4.4 months). 
HRQoL was an outcome in only one study of patients with CRC and was poorly reported. The non-
comparative, observational design of the majority of studies in this area can provide limited 
evidence on the clinical effectiveness of SIRT.  
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1.3.2 Patients with intrahepatic cholangiocarcinoma (ICC) treated with SIRT 
In the ICC population, two systematic reviews and 10 non-comparative primary studies comprising a 
total of 247 patients were included. No comparative studies were identified. Median OS ranged from 
9.0 to 22.0 months (weighted mean 15.3 months [95% CIs 12.0-18.7]). Median progression free 
survival was not reported in any of the studies. No studies reported HRQoL as an outcome. 
1.3.3 Patients with CRC or ICC treated with best supportive care 
A literature review was conducted to identify studies which reported survival estimates from 
patients with CRC or ICC (matching the population of interest) treated with BSC where the 
comparator was not SIRT. The purpose was to provide additional context to non-comparative data 
on SIRT. Direct comparisons to data from patients treated with SIRT in other studies should be 
avoided due to the high risk of bias. In the CRC population, seven RCTs were identified where BSC 
was the control treatment (1,156 BSC patients). BSC tended to be poorly defined and varied by 
institution; usually BSC aimed to provide palliative treatment without using investigational cancer 
therapies. Median OS in 7 studies ranged from 2.4 months to 6.6 months (weighted mean 5.3 
months [95% CIs 4.7-5.8]). Median PFS ranged from 1 month to 7.3 months in 5 studies (weighted 
mean 3.2 months [95% CIs 2.9-3.5]).  No studies were identified which reported OS in patients with 
chemotherapy-refractory ICC who received BSC.  
1.4 Ongoing or recently completed trials 
Nine ongoing or recently completed and unpublished studies were identified which were related to 
the SIRT CtE evaluation. Of these, 7 were RCTs and 2 were registries. No studies were identified 
which matched the chemotherapy-refractory CRC or ICC populations, and therefore none were 
directly relevant to the decision problem. A conference abstract recently reported results from a 
large combined analysis of RCT data from chemotherapy-naive patients, indicating that SIRT does 
not provide an additional survival benefit to first-line chemotherapy in this population. 
Generalisability of these results in generally chemotherapy-sensitive patients to the CtE decision 
problem is limited since the CtE population is chemotherapy-refractory or chemotherapy-intolerant.  
1.5 Analysis of data from the SIRT CtE registry study 
1.5.1 Methods 
A single-arm, observational, service evaluation study aimed to evaluate SIRT in ten NHS centres in 
England was carried out between December 2013 and March 2017. The two eligible populations 
were adults with i) unresectable, chemotherapy-refractory CRC liver metastases; and ii) 
unresectable, chemotherapy-refractory primary ICC. Data on baseline characteristics, the SIRT 
procedure, safety, survival, and HRQoL were collected on an on-line registry. OS was the primary 
outcome.  
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1.5.2 Results 
A total of 399 patients with CRC and 61 with ICC were included in the analysis of the SIRT CtE 
registry. Most patients had an ECOG performance status of 0 or 1 (93% CRC cohort; 91% ICC cohort). 
In the CRC group, 60% of patients did not show evidence of extrahepatic metastatic disease and 78% 
had received two or three previous lines of chemotherapy. The majority of ICC patients had received 
one or two lines of chemotherapy prior to SIRT (81%). In the CRC group 72% of patients had a single 
SIRT procedure which was of palliative intent; this value was 56% for the ICC group. Patients 
required hospitalisation for 1 or 2 nights for the SIRT procedure. A minority of patients (35% of CRC 
cases; 12% of ICC cases) received concomitant chemotherapy and some patients also received 
chemotherapy following SIRT (22% of CRC cases; 15% of ICC cases). 
Patients were followed-up for a median of 14.3 months (95% CIs 9.2-19.4). At the end of the study, 
240 (60%) CRC deaths were recorded and 33 (54%) deaths in the ICC cohort. Median OS was 7.6 
months (95% CIs 6.9 – 8.3) in the CRC cohort, and 8.7 months (95% CIs 5.3-12.1) in the ICC cohort. 
Survival at 12 months following SIRT was 30% in the CRC group and 37% in the ICC group. PFS was 
3.0 months (95% CIs 2.8-3.1) in the CRC cohort, and 2.8 months (95% CIs 2.6-3.1) in the ICC cohort. 
LPFS in the CRC cohort was 3.7 months (95% CIs 3.2-4.3) and 3.1 months (95% CIs 1.3-4.8) in the ICC 
group. Of the patients who had hepatic and extrahepatic progression dates recorded, these occurred 
at the same time in 81% and 82% of CRC and ICC patients, respectively; extrahepatic progression 
occurred before hepatic progression in 16% and 9% of CRC and ICC patients, respectively. Subgroup 
analyses identified covariates associated with a survival benefit in the CRC group: absence of 
extrahepatic disease, fewer liver tumours, smaller tumour to liver volume percentage, and being 
male.  
HRQoL measured using EQ-5D-5L and EQ-VAS remained relatively high and constant between 
baseline and follow-up time points in the CRC group. A statistically significant reduction in HRQoL 
was observed between baseline and 3-months after SIRT but this was small and not clinically 
relevant. Methodological weaknesses meant that reliable conclusions about the impact of SIRT on 
patients’ quality of life cannot be drawn from this study.  
Severe complications on the day of treatment (no grade was recorded in the registry) were reported 
in 11 CRC patients (3%) and 1 ICC patient (2%). During the follow-up period 36% of CRC patients 
experienced an adverse event, of which 8% of the events were grade ≥3.  In the ICC cohort, 49% of 
patients experienced an adverse event during the follow-up period, or which 7% were grade ≥3. The 
most frequently reported adverse events were mild (grade 1-2) fatigue and abdominal pain in both 
cohorts. 
1.5.3 Discussion 
This large, pragmatic, observational study is likely to reflect real-life practice in the NHS but is limited 
by the absence of a comparator treatment group. OS, PFS, and LPFS results from the CRC cohort are 
within the lower range of previously published estimates. The reliability of the study’s findings is 
limited by high levels of missing data for certain outcomes, the absence of external data validation 
(in the form of triangulation with routinely collected data or against source documents), and 
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variability in how outcomes were measured and treatment techniques arising from the absence of a 
research protocol.  
1.6 Published cost-effectiveness evidence on SIRT 
A systematic review of economic literature on the cost-effectiveness of SIRT yielded 144 studies, of 
which one was relevant and was included in the review (Pennington et al. 2015). This modelled the 
cost-effectiveness of SIRT compared to BSC in patients with unresectable, chemotherapy-refractory 
CRC. The model demonstrated a total cost of £35,487 for SIRT and £12,730 for BSC; the difference 
was driven primarily by the initial cost of the SIRT procedure and the monthly costs for monitoring 
and treatment during the additional survival time in SIRT patients. The model calculated an increase 
in quality adjusted life years (QALYs) in the SIRT group of 0.81 compared to BSC (1.50 vs 0.69), and 
the improved survival resulted in a cost per QALY gained (or incremental cost-effectiveness ratio 
[ICER]) of £28,216. The model used an appropriate structure and described most assumptions. The 
lack of high quality comparative evidence limits the reliability of the model results. The overall 
survival time used for SIRT patients was longer than in alternative studies, and this is likely to favour 
SIRT. Sensitivity analysis was carried out to test the robustness of the model’s results to changes in 
key inputs, although the cost of SIRT (another key driver) was inadequately explored. The choice of 
inputs and ranges used for sensitivity analysis may underestimate the overall cost per QALY and ICER 
and the uncertainty reported in the model. Alternative approaches used in external assessment 
centre model highlight the impact of these choices.  
1.7 De novo cost-effectiveness model of SIRT compared to best supportive care by the 
external assessment centre 
1.7.1 Methods 
A new model was created by the external assessment centre to estimate the cost-effectiveness of 
SIRT compared with BSC in patients with unresectable, chemotherapy-refractory CRC. The SIRT CtE 
registry data, published studies, and clinicial opinion were used as sources of model inputs. The 
model used a 3-state partitioned survival analysis. Kaplan-Meier curves from the SIRT CtE registry 
data for OS and PFS were extrapolated and hazard ratios were taken from available published 
comparative studies to create a survival curve for the BSC arm of the model. A SIRT procedure cost 
of £21,870, based on NHS England tariff, was used. Costs for chemotherapy, patient monitoring, and 
treating adverse events were applied to both SIRT and BSC arms. Published utility values were 
applied to the progression-free and progressed states.  
1.7.2 Results 
The ICER for SIRT was £85,350 in the base case of the external assessment centre model.  Treatment 
with SIRT resulted in an increase in QALYs of 0.32 (0.58 vs 0.26). The model showed that SIRT was 
£27,406 more expensive than BSC (£31,028 vs £3,623 discounted costs). This was primarily due to 
high initial procedure costs in the SIRT arm. The cost of the SIRT procedure and the survival time 
were the main drivers in the model. Probabilistic sensitivity analysis showed that all simulations 
 
 
Page 15 of 175 
 
Commissioning through Evaluation: SIRT 
Final evaluation report 
resulted in additional benefits in QALYs from SIRT compared to BSC for additional costs. From 3,000 
simulations, 0.7% fell under a £30K willingness to pay threshold and 11.0% fell under the £50K 
threshold.  
1.7.3 Discussion 
The de novo cost-effectiveness model by the external assessment centre demonstrates that SIRT is 
unlikely to be considered cost effective in the UK (by the usual threshold used by NICE) when the 
technology is used in patients with CRC which has failed standard available therapies. The ICER for 
SIRT compared to BSC may be lower when used in patients with a longer life expectancy where the 
initial procedure cost is spread over a longer period. The model was limited by the absence of a 
control group in the SIRT CtE registry data. The model uses a hazard ratio which in turn assumes 
clinical effectiveness of SIRT (a QALY benefit at additional cost). This may not be a reliable 
assumption.   
The higher base case ICER in the current de novo model (£85K) compared to Pennington et al. (£28K) 
can be attributed to a higher cost for the SIRT procedure and shorter OS estimate used in the de 
novo model.  
There is inadequate data to make a reliable conclusion about the generalisability of the model to the 
ICC population.  
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2 Scope & project management 
2.1 Project objective 
To evaluate the clinical and cost-effectiveness of selective internal radiation therapy (SIRT) in 
treating patients with: 
1. unresectable, chemotherapy-refractory, metastatic colorectal cancer (mCRC) in the liver, or 
2. unresectable, chemotherapy-refractory, primary intrahepatic cholangiocarcinoma (ICC). 
2.2 Project scope 
The scope for the SIRT CtE evaluation is outlined below (Table 2.1). 
Table 2.1. Scope for SIRT CtE project evaluation   
Intervention Selective internal radiation therapy 
Population 1. People with unresectable, liver-dominant, metastatic colorectal cancer which 
has progressed following at least two lines of standard chemotherapy (i.e. 
irinotecan and oxaliplatin based chemotherapy) or those for whom standard 
chemotherapy is not suitable.  
2. People with unresectable intrahepatic cholangiocarcinoma which has 
progressed following at least one line of standard chemotherapy or those for 
whom standard chemotherapy is not suitable. 
Comparators Best supportive care (this may include active symptom management using 
chemotherapy) 
Outcomes The outcome measures to be considered include: 
 overall survival (primary outcome) 
 progression-free survival 
 liver-specific progression free survival 
 response rates 
 adverse effects of treatment 
 health-related quality of life 
Economic 
analysis 
In line with the NICE reference case, a cost-effectiveness modelling approach has 
been selected with incremental cost per quality-adjusted life year (QALY) as the key 
outcome measure. The model will compare SIRT to best supportive care. Due to a 
paucity of evidence relevant to the ICC population, cost-effectiveness modelling will 
be carried out for the colorectal cancer population only.  
2.3  Project background 
Commissioning through Evaluation (CtE) is a NHS England (NHSE) programme which enables new 
treatments with limited evidence to be commissioned in a small number of centres with a planned 
evaluation. In 2013, SIRT was selected for evaluation under the CtE programme in two patient 
populations. Ten centres in England were appointed to undertake a total of approximately 165-220 
procedures each year over approximately 3 years. Each centre collected data from SIRT procedures 
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conducted as part of the CtE project onto a registry hosted by the British Society for Interventional 
Radiologists (BSIR). The ten centres were: 
- Cambridge University Hospitals NHS Foundation Trust 
- Kings College Hospital NHS Foundation Trust 
- Leeds Teaching Hospitals NHS Trust 
- Newcastle-upon-Tyne Hospitals NHS Trust 
- Nottingham University Hospitals NHS Trust 
- Oxford University Hospitals NHS Foundation Trust 
- The Christie NHS Foundation Trust 
- The Royal Free London NHS Foundation Trust 
- University Hospital Southampton NHS Foundation Trust 
- University Hospitals Birmingham NHS Foundation Trust 
NICE was commissioned to undertake the evaluation of the SIRT CtE project and appointed one of its 
external assessment centres, Birmingham & Brunel Consortium, to lead this work. In April/May 
2015, a different centre, Cedar (Cardiff & Vale University Health Board & Cardiff University) was 
reallocated the evaluation project.  
Cedar’s role was to independently evaluate the SIRT CtE project in order to answer the following 
questions from NHS England: 
1. Does treatment with SIRT for the clinical indications covered within the CtE scheme increase 
overall survival? 
2. Does treatment with SIRT for the clinical indications covered within the CtE scheme increase 
liver and wider progression free survival? 
3. What is the patient experience of treatment with SIRT for the clinical indications covered 
within the CtE programme? 
4. What is the actual cost, and relative cost-effectiveness, of treatment with SIRT for the 
clinical indications covered within the CtE programme? 
5. Does the data suggest any differential benefit for particular cohorts of patients within the 
wider clinical indications covered within the scheme? 
6. Are there any factors from the experience of provision within centres participating in the 
scheme that should be taken into account in terms of future service provision, should the 
service become routinely commissioned by the NHS? 
7. Are there any research findings that have become available during the course of the CtE 
scheme that should be considered alongside the evaluative findings of the CtE scheme? 
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3 Background  
3.1 Metastatic colorectal cancer 
Colorectal cancer includes cancers of the colon (large bowel), rectum, and appendix. Most colorectal 
cancers are adenocarcinomas. Metastatic CRC is TNM (tumour node metastases) stage IV or Dukes’ 
D stage, and is also referred to as advanced colorectal cancer. CRC may be classified as TNM stage 
IVA where the metastasis is confined to one organ or site, or TNM stage IVB where there are 
metastases in more than one organ/site or the peritoneum. Approximately 28% of patients 
diagnosed with CRC are at TNM stage IV. The most common metastatic sites are the regional lymph 
nodes, liver, lungs, and peritoneum.  
 
CRC is the third most common cancer in the UK and in 2014 there were 41,265 new cases of bowel 
cancer diagnosed (Cancer Research UK 2017). The lifetime risk of developing CRC is approximately 1 
in 18 for men and 1 in 21 for women in England and Wales (NICE 2014a). In 2014, 15,903 people 
died from bowel cancer in the UK; 80% were in people aged 65 and over. The 5 year survival of 
patients diagnosed with TNM stage IV CRC is 3%. 
 
A key risk factor for CRC is age, and 90% of bowel cancer cases occur in people aged 60 or over (NHS 
Choices 2016b). Diet, weight, activity levels, alcohol, smoking, and family history are other risk 
factors for CRC.  
3.1.1 Current care pathway for advanced metastatic colorectal cancer 
NICE recommends that control of symptoms should be the priority for managing mCRC (NICE 2014a). 
This may involve the use of surgery, chemotherapy, radiotherapy and supportive care. Resection of 
the primary or metastatic tumours is considered where possible but the majority (70-80%) of 
patients are unsuitable for resection due to clinical or technical reasons such as severe co-mobidities 
or unresectable extra-hepatic disease (Zampino et al. 2016).  
Systemic chemotherapy is the first choice treatment for unresectable metastatic disease. 
Locoregional therapies such as transarterial chemoembolisation (TACE), hepatic artery infusion (HAI) 
chemotherapy, ablative therapies, and SIRT, may also be considered.  
NICE recommends one of the following chemotherapy combinations as first-line treatments for CRC 
(NICE 2014a):  
- FOLFOX (folinic acid plus fluorouracil plus oxaliplatin) as first-line treatment then single 
agent irinotecan as second-line treatment or 
- FOLFOX as first-line treatment then FOLFIRI (folinic acid plus fluorouracil plus irinotecan) as 
second-line treatment or 
- XELOX (capecitabine plus oxaliplatin) as first-line treatment then FOLFIRI (folinic acid plus 
fluorouracil plus irinotecan) as second-line treatment. 
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Chemotherapy may be combined with biological agents such as EGFR (epidermal growth factor 
receptor) inhibitors (cetuximab or panitumumab) or VEGF (vascular endothelial growth factor) 
inhibitors (bevacizumab). NICE recommends raltitrexed only for patients with advanced colorectal 
cancer who are intolerant to 5‑fluorouracil and folinic acid, or for whom these drugs are not 
suitable. 
For patients who have progressed following standard first and second line therapies for advanced 
mCRC the aim of third line treatments is to prolong life, improve symptoms and maintain quality of 
life. Currently there are limited options available for patients with chemotherapy refractory 
advanced mCRC.  
In 2016, NICE recommended trifluridine-tipiracil for adults who have had previous treatment with 
available therapies including fluoropyrimidine-, oxaliplatin- or irinotecan-based chemotherapies, 
anti-vascular endothelial growth factor agents and anti-epidermal growth factor receptor agents, or 
when these therapies are not suitable1 (NICE 2016). NICE’s recommendation was based on two 
randomised controlled trials comparing trifluridine-tipiracil to placebo plus best supportive care in 
patients who had mCRC which had progressed following at least two previous lines of standard 
chemotherapy. Compared with placebo, trifluridine–tipiracil increased median overall survival by 2.4 
months (Yoshino et al. 2012) and by 2.0 months (Mayer et al. 2015). The committee considered this 
increase in survival to be small but clinically meaningful.  
According to the NICE pathway for advanced mCRC, subsequent treatment options after trifluridine-
tipiracil are supportive and palliative care (Figure 3.1).  
Bevacizumab, cetuximab and panitumumab are not recommended by NICE at third line or beyond 
(NICE 2012) and were removed from the cancer drugs fund (CDF) approved list on 4 November 2015 
(source: NICE committee papers for TA405). Regorafenib is licensed for patients with mCRC who 
have been treated with standard therapies (or for whom these are unsuitable) but is not 
recommended by NICE because of a non-submission of evidence by the manufacturer (NICE 2015).  
3.1.2 Number of patients with unresectable chemotherapy-refractory mCRC in the UK  
In the manufacturer submission for the NICE technology appraisal TA405 (NICE 2016) they estimate 
that 2,600 patients each year would reach the stage of third-line therapy for mCRC and be motivated 
to receive further treatment (England only). The sponsor acknowledged that a significant proportion 
of these patients may opt to enter clinical trials. Importantly, the evidence review group noted that 
this estimate which is based partly on clinical opinion may be unreliable. The population eligible to 
receive SIRT in a chemotherapy-refractory setting may be further reduced because only patients 
with liver-dominant mCRC would be suitable. Further technical considerations and the development 
of other third-line therapies approved by NICE (e.g. trifluridine-tipiracil) may also reduce the 
population eligible for SIRT in a chemotherapy-refractory setting.  
  
                                                          
1
 NICE recommend this therapy only when the company provides trifluridine–tipiracil with the discount agreed 
in the patient access scheme 
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Figure 3.1 Treatment pathway for patients with advanced and metastatic colorectal, based on 
NICE guidance and adapted from NICE pathways. 
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3.2 Intrahepatic cholangiocarcinoma 
Cholangiocarcinomas (bile duct cancers) are primary liver cancers which arise from the epithelial 
cells of the bile ducts. These cancers are rare but are often lethal due to advanced stage at 
presentation. Most cholangiocarcinomas are too advanced for curative survival resection. ICCs can 
originate from either small intrahepatic ductules (peripheral cholangiocarcinomas) or large 
intrahepatic ducts proximal to the bifurcation of the right and left hepatic ducts. The majority of 
cholangiocarcinomas (>90 percent) are adenocarcinomas, squamous cell carcinoma comprise most 
of the remaining cases . 
 
Fewer than 1,600 people in Great Britain (Northern Ireland figures not available) are diagnosed with 
ICC each year. The 5 year survival rate for resectable ICC is between 20 and 40%; the 5 year survival 
rate for metastasised unresectable ICC is approximately 2% (Cancer Research UK 2015).  Risk factors 
for bile duct cancer include primary sclerosing cholangitis, bile duct abnormalities (e.g. 
fibropolycystic liver disease), biliary stones (hepatolithiasis), chronic liver disease (cirrhosis and viral 
infection), infection with a liver fluke parasite, exposure to certain chemicals and toxins (e.g. 
Thorotrast)(NHS Choices 2016a). Rates of ICC have been rising in Western countries which may be 
explained by factors such as improved detection and diagnosis, misclassification, migration, 
increasing burden of chronic liver disease, and the potential role of environmental toxins (Valle et al. 
2016).  
3.2.1 Current care pathway for intrahepatic cholangiocarcinoma  
Surgical resection with clear margins is the only potentially curative approach for patients with ICC. 
Most patients (>65%) however are diagnosed with non-resectable disease and have only palliative 
chemotherapy and supportive care as options (Bridgewater et al. 2014; Lamarca et al. 2014a; Valle 
et al. 2016). NICE has not produced clinical guidelines on the treatment of cholangiocarcinoma but 
has interventional procedures guidance (NICE 2005; NICE 2013b; NICE 2013c). The standard options 
for palliative treatment include chemotherapy, surgical bypass of the bile duct or the insertion of a 
stent using surgical, endoscopic or percutaneous techniques (NICE 2013b). 
Patients with unresectable ICC may also be suitable for loco-regional therapies such as radiation 
therapy, TACE, transarterial chemoinfusion (TACI), radiofrequency ablation, and SIRT. The evidence 
base for loco-regional therapies in ICC is weak and these approaches are not established 
(Bridgewater et al. 2014).   
For patients with advanced and inoperable ICC, cisplatin and gemcitabine has been demonstrated as 
an effective first line systemic treatment. The UK advanced biliary cancer 02 (ABC-02) clinical trial 
demonstrated a survival advantage of CisGem over gemcitabine alone (11.7 months vs 8.1 months; 
HR 0.64, 95% CI 0.52-0.80; p<0.001) and established CisGem as a reference regimen (Valle et al. 
2010).  Oxaliplatin is considered to be an appropriate alternative to cisplatin 
There is no randomised controlled trial evidence supporting the use of second-line chemotherapy 
for patients who have progressed following first line chemotherapy. Currently active symptom 
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control, including management of biliary tract obstruction and infection and other symptoms arising 
from tumour progression, is the standard of care (Bridgewater et al. 2014; Lamarca et al. 2014a).  
In a systematic review by Lamarca et al. (2014) the authors conclude that despite a paucity of quality 
evidence, second-line chemotherapy in advanced biliary cancers (including ICC) may be of potential 
benefit in selected patients such as those with good performance status. A phase III RCT (ABC-06 
NCT01926236) is underway in the UK comparing FOLFOX chemotherapy to active symptom control 
which will elucidate the role of second line chemotherapy in advanced biliary cancer.  
3.2.2 Number of patients with unresectable chemotherapy-refractory ICC in the UK  
Approximately 1,600 people are diagnosed with ICC in England, Wales, and Scotland each year. Of 
these 60-70% (960-1120 people) are unsuitable for resection (TNM Stage III or IV) (Bridgewater, et 
al. 2014) and would be offered first-line chemotherapy. Of these, approximately 15% (144-168) may 
be suitable for second line treatments; this value is based on the number of patients in the ABC-02 
trial who progressed to second-line treatment (Valle et al. 2010). It is unclear how many of these 
patients would meet the eligibility criteria for SIRT.   
3.3 Selective internal radiation therapy 
SIRT, also called transarterial radioembolisation (TARE) or radioembolisation (RE), is a form of intra-
arterial brachytherapy used to treat tumours in the liver. These may be primary tumours (e.g. from 
ICC or hepatic cholangiocarcinoma) or metastatic tumours from primary cancers such as CRC. SIRT 
involves delivering microspheres containing a beta-emitting radionuclide, such as yttrium-90 (Y-90), 
directly into the tumour via the hepatic artery (Giammarile et al. 2011). This is carried out using a 
percutaneous transarterial approach. Microspheres are delivered preferentially to the tumour, 
limiting radiation damage to healthy surrounding tissue.  
During the SIRT procedure, radiolabeled microspheres are infused into the hepatic artery supplying 
the tumour via a microcatheter which is usually accessed through the femoral artery. SIRT can be 
applied to the whole liver in one session through infusion in the right hepatic artery followed by 
infusion in the left hepatic artery, or to separate lobes a few weeks apart. This choice depends on 
the patient’s liver function, tumour burden and prior chemotherapy exposure. The procedure is 
performed under local anaesthesia and oral or intravenous analgesia may be required. It takes about 
1 hour and is carried out under X-ray guidance and patients usually stay in hospital for 1 to 2 days 
after the procedure.  
A multidisciplinary team composed of specialists in interventional and diagnostic radiology; medical, 
radiation and surgical oncology; transplant surgery; nuclear medicine; hepatology; medical physics 
and radiation safety is necessary to provide a SIRT service.  
3.3.1 Pre-SIRT work-up procedures 
Before SIRT is undertaken, pre-treatment work-up and planning is carried out. Patients undergo 
general health checks, liver function tests, specialist imaging techniques and hepatic arteriography.  
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Selective coil embolisation of arteries to the stomach and duodenum is required in some patients to 
limit the delivery of microspheres outside the liver. The procedure is carried out under local 
anaesthesia in an angiography suite by an interventional radiologist. A trans-femoral catheter is 
placed under X-ray guidance to enable selective catheterisation of the hepatic artery.  
After embolisation, technetium-99m labelled macro-aggregated albumin (MAA) is injected through 
the catheter with the tip positioned at the level where the microspheres will be delivered and a 
nuclear medicine scan is done. This maps the distribution of the isotope in the liver, to determine 
the extent of arteriovenous shunting to the lungs, and to ensure that there is no extrahepatic uptake 
of the isotope. Patients may need an additional pre-SIRT embolisation procedure if there is evidence 
of extra-hepatic uptake. Although treatment planning aims to selectively deliver microspheres to the 
tumour, any SIRT procedure will invariably result in some degree of irradiation of normal liver tissue. 
3.3.2 SIRT medical devices 
Two Y-90 microspheres devices are currently CE marked for SIRT in liver tumours, SIR-Spheres (Sirtex 
Medical) and TheraSphere (Biocompatibles UK; Table 3.1). A third medical device, QuiremSpheres 
(Quirem Medical, The Netherlands), was recently CE marked for use in SIRT and is available in the 
UK. This device uses poly-L-lactic acid microspheres containing holmium-166. This device was not 
available in the UK when the SIRT CtE project started and therefore has not been included further in 
this report. 
 Table 3.1. Characteristics of SIRT Y-90 microspheres  
Characteristics SIR-Spheres TheraSphere 
Manufacturer  Sirtex Medical Biocompatibles UK 
Material Resin Glass 
Radionuclide Yttrium-90 Yttrium-90 
Diameter 20-60 μm 20-30 μm 
Specific gravity 1.6 g/dL 3.6 g/dL 
Activity per particle 40-70 Bq 2500 Bq 
Average number of microspheres per vial 40-80 million 1.2–8 million 
(Adapted from Giammarile et al. 2011) 
3.3.2.1 SIR-Spheres 
SIR-Spheres are sterile, single-use, resin microspheres containing yttrium-90. They are supplied at 3 
GBq Y-90 per vial in 5 ml water for injection in a shielded shipping vial. Each vial contains 40–80 
million microspheres, ranging from 20–60 micrometres in diameter (median diameter 32.5 
micrometres). The maximum range of beta emission in tissue is 11 mm with a mean of 2.5 mm. A 
typical treatment with SIR‑Spheres consists of infusing 1.4–2.0 GBq Y-90 (30–40 million resin 
microspheres), into the hepatic artery at the site of the tumour. The dose delivered to the patient's 
liver is calculated through the body surface area (BSA) method or through the partition model 
method.  The dose of beta radiation needed by the patient is used to calculate the volume of 
SIR‑Spheres needed. 
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SIR‑Spheres are supplied with the following accessories: 
- 1 single use SIR‑Spheres delivery system 
- a reusable acrylic delivery box 
- v-vial 
- v-vial holder. 
SIR‑Spheres are administered with the delivery system, using water for injection or 5% glucose to 
pulse push. Another syringe containing contrast medium can be connected to the delivery system, 
allowing intermittent contrast medium injection to assess and maintain forward flow throughout. 
The microspheres are infused into the delivery catheter from the v-vial using standard 10 ml or 20 ml 
syringes (Giammarile et al. 2011). 
3.3.2.2 TheraSphere 
TheraSphere consists of sterile, single-use, glass microspheres containing Y-90 as an integral 
component of the glass matrix. The steam sterilised microspheres have a mean diameter range of 
20–30 micrometres and a specific activity of 2,500 Bq per microsphere at calibration. They are 
supplied in 6 dose sizes: 3, 5, 7, 10, 15 or 20 GBq in 0.6 ml pyrogen‑free water supplied in a 1 ml vial, 
enclosed in an acrylic shield. Custom dose sizes are also available in increments of 0.5 GBq between 
3 and 20 GBq. A single treatment with TheraSphere contains 1.2–8 million microspheres. The 
recommended dose to the liver is 80 Gy to 150 Gy. The amount of radioactivity needed to deliver 
the desired dose (in Gy) to the liver is calculated from liver volume converted to liver mass.  
TheraSphere is supplied with the following accessories: 
- One single‑use TheraSphere administration set which includes a disposable tubing set and 1 
empty sterile vial.  
- One reusable non‑sterile administration accessory kit (supplied to each site), including an 
acrylic box base, top shield, removable side shield and bag hook.  
The administration set and administration accessory kit are used to deliver the microspheres in a 
volume of 60 ml saline (3 × 20 ml syringes).  
3.4 Position of SIRT in treatment pathway 
Currently, SIRT is not routinely commissioned in England for any indication (NHS England 2013). 
Before the CtE project began, SIRT was locally commissioned. 
3.4.1 Colorectal cancer 
The SIRT CtE study is designed to evaluate the efficacy of SIRT in patients with CRC who have 
previously been treated with at least two lines of standard chemotherapy (typically, oxaliplatin and 
irinotecan with fluoropyrimidines) or unless the patient has a specific contraindication to 
chemotherapy or cannot tolerate either regimen. This would position SIRT at an equivalent point in 
the care pathway as trifluridine-tipiracil which is recommended for adults who have had previous 
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treatment with available therapies including fluoropyrimidine-, oxaliplatin- or irinotecan-based 
chemotherapies, anti-vascular endothelial growth factor agents and anti-epidermal growth factor 
receptor agents, or when these therapies are not suitable (Figure 3.2). SIRT as a first line treatment 
for colorectal cancer has been evaluated by the SIRFLOX, FOXFIRE and FOXFIRE global trials, as a 
maintenance therapy by the SIR-step trial, and as a second line therapy by the EPOCH trial, 
respectively (see Section 6). 
3.4.2 Intrahepatic cholangiocarcinoma 
SIRT as a first line treatment for ICC is currently being evaluated by the SIRCCA clinical trial (see 
Section 6).  The SIRT CtE study is designed to evaluate the efficacy of SIRT in patients who have 
previously been treated with standard chemotherapy (typically cisplatin and gemcitabine) or 
patients with a specific contraindication to chemotherapy.  
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Figure 3.2. Proposed position of SIRT in the current care pathway for patients with advanced and 
metastatic colorectal cancer 
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4 Systematic review: Efficacy of SIRT for unresectable 
chemotherapy-refractory CRC liver metastases, and 
unresectable ICC 
4.1 Summary 
The purpose of this review was to systematically review and summarise the evidence on the efficacy 
of SIRT in patients with unresectable, liver-dominant, chemotherapy refractory CRC or ICC. The 
primary outcome was OS. A systematic literature search was conducted of Medline, EMBASE, 
Cochrane library, Scopus and EconLit and retrieved a total of 1,170 articles. Methodological 
weaknesses and considerable heterogeneity across included studies were identified.  
Colorectal cancer liver metastases: Three systematic reviews and 24 primary studies were selected 
for inclusion in this review. Twenty-one studies were non-comparative (14 retrospective, 7 
prospective) and three were comparative (2 retrospective observational, 1 randomised controlled 
trial).  There was some heterogeneity across included studies in several prognostic factors.  
Two retrospective comparative studies found statistically significant improvements in OS when SIRT 
was compared to standard therapy (11.9 vs 6.6 months [HR: 0.5]; 8.3 vs 3.5 months [HR: 0.26]). No 
statistically significant improvement in OS was observed in a small RCT comparing fluorouracil 
chemotherapy alone with SIRT plus chemotherapy (7.3 months vs 10.0 months [HR: 0.92]). Patients 
in the control arm were permitted to cross over to receive SIRT which may confound the OS 
estimate. PFS and LPFS were improved in the SIRT arm of the RCT (PFS 4.5 vs 2.1 months [HR: 0.51; 
p=0.03]; LPFS 5.5 vs 2.1 months [HR: 0.38; p=0.003]). No significant difference in severe adverse 
event rates was observed in the RCT. The most common adverse events in patients treated with SIRT 
in comparative studies were abdominal pain, fatigue, and nausea.    
OS was reported in all 23 comparative and non-comparative studies and ranged from 6.0 to 12.7 
months (weighted mean 9.6 months [95% CIs 8.9-10.4]). In a subset of 12 studies which reported OS 
in patients who had received at least two previous lines of chemotherapy, OS ranged from 7.0 to 
11.6 months (weighted mean 9.1 months [95% CIs 8.4-9.7]). Median PFS ranged from 2.8 to 9.2 
months in 9 studies (PFS weighted mean 4.0 months); LPFS was reported in 8 studies and ranged 
from 2.0 to 9.0 months (LPFS weighted mean 4.4 months). Survival proportions at 12 months ranged 
from 24% to 50% in 9 studies; survival at 24 months ranged from 0% to 25% in 6 studies. One study 
had health related quality of life (HRQoL) as an outcome although reporting was poor; anxiety levels, 
but not depression, reduced following SIRT. Results from this review were similar to those reported 
in three recent systematic reviews. 
Intrahepatic cholangiocarcinoma: Two systematic reviews and 10 non-comparative primary studies 
comprising a total of 247 patients were included in this review. Median OS ranged from 9.0 to 22.0 
months (weighted mean 15.3 months [95% CIs 12.0-18.7]). Median progression free survival was not 
reported in any of the studies. Survival proportions were reported in 4 studies, with survival at 12 
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months reported as between 33% and 68%. No studies reported HRQoL as an outcome. Results in 
this review were similar to those reported in two systematic reviews.  
Discussion: The single arm, observational design of the majority of studies in this area can provide 
important insights into safety and technical success; but limited evidence on the efficacy and 
effectiveness of SIRT. There is a substantial risk of unreliable outcome measures such as survival and 
disease response. Retrospectively matched comparative studies risk bias from imbalanced 
prognostic factors, poor standardisation of control arm treatments, and variability in outcome 
measures. Such studies risk producing unrelaible effect sizes and should be interpreted with caution.  
This review provides insights which are important to the SIRT CtE project. This review highlights the 
shortage of comparative studies, particularly prospectively designed studies such as RCTs. The 
impact of SIRT on patients’ quality of life is an under-researched area.  
Conclusions: This systematic review showed that patients with unresectable, chemotherapy-
refractory CRCLM treated with SIRT live an average of 9.6 months. Two retrospective studies showed 
that SIRT confers a survival advantage of approximately 5 months. Limited available evidence 
suggests that SIRT delays overall progression and liver-specific progression. Evidence on the impact 
of SIRT on patients’ quality of life is unreliable. Most studies on SIRT are observational with a 
substantial risk of bias. Patients with unresectable ICC treated with SIRT live between 9 and 22 
months. There is no comparative evidence on whether SIRT improves survival in this population, and 
no evidence on progression free survival.  Prospective and comparative studies (including 
measurement of HRQoL) are needed.  
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4.2 Introduction 
This review aims to provide an overview of published evidence on the efficacy or effectiveness2 of 
SIRT as a treatment for unresectable, liver dominant, chemotherapy-refractory CRCLM or 
unresectable ICC (i.e. populations which match those treated under SIRT CtE).  
The methods used to select studies were the same across both CRCLM and ICC populations and have 
been presented together in Section 4.3. The results for each population have been presented 
separately in Section 4.4 (CRC) and Section 4.5(ICC).  
4.3 Methods 
4.3.1 Literature search 
A systematic review of the evidence on the efficacy of SIRT for treating unresectable CRCLM or ICC 
was conducted. The searches conducted for the NICE interventional procedure overviews on SIRT 
(NICE 2013a; NICE 2013b) were reviewed and updated or adapted where necessary. As the searches 
for the interventional procedure overviews covered the period to February 2011, searches for this 
review were updated to cover the period January 2011 to January 2017.  
A strategy was developed in Ovid Medline (see Appendix 2) and was adapted to the following 
databases: Medline In-Process; Embase; Cochrane Library (components: CDSR, Other reviews, 
CENTRAL, NHS EED); EconLit; Scopus; Pubmed (epub ahead of press only). No language restriction 
was applied. Results of all searches were combined in a Reference Manager 12 database together 
with the references of studies included in both the IPOs. The reference lists of any relevant 
systematic reviews were checked for additional studies. 
4.3.2 Study selection 
After de-duplication, one reviewer (HM or JW) selected publications that were considered relevant 
based on titles or abstracts using the inclusion and exclusion criteria presented in Tables 4.1 and 4.2. 
In a second selection round, an independent reviewer (JW) looked at full text articles and selected 
studies to be included in the review. Uncertainties were discussed and agreed upon between two 
reviewers (HM and JW). 
The review search yielded 1,170 potentially relevant studies (Figure 4.1), 179 were retained for 
assessment of eligibility at full-text. Following this assessment 54 were retained for quality 
assessment and data extraction. 
 
 
 
                                                          
2
 In this instance the terms efficacy and effectiveness have been used interchangeably because the evidence 
does not adequately distinguish the terms. 
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Table 4.1 Inclusion and exclusion criteria for study selection of unresectable CRC 
Inclusion Exclusion 
 Patients with unresectable CRCLM 
 Treatment with yttrium-90 SIRT 
 Data on OS 
 Predominantly chemotherapy-naive patients 
(where SIRT is used as a first line treatment) 
AND results not stratified on number of 
previous lines of chemotherapy 
 Sample size <30 
 CRC patients are not analysed separately 
 Animal studies 
 Non-English language 
 Conference abstracts 
 
Table 4.2 Inclusion and exclusion criteria for study selection of ICC 
Inclusion Exclusion 
 Patients with unresectable ICC 
 Treatment with yttrium-90 SIRT 
 Data on OS 
 Only chemotherapy-naive patients (where 
SIRT is used as a first line treatment)  
 Sample size <10 
 ICC patients are not analysed separately 
 Animal studies 
 Non-English language 
 Conference abstracts 
 
4.3.3 Quality Assessment 
Following study selection, systematic reviews were assessed with the SURE (2013) critical appraisal 
checklist for systematic reviews and comparative studies were assessed using the SURE checklist for 
RCT and other experimental studies. Non-comparative studies were assessed using a series of 
questions derived from checklists for observational studies that were deemed applicable to non-
comparative studies, sources included the CASP checklist for Cohort Studies and Chan and Bhandari 
(2011).  Assessment was performed by either HM or JW. 
4.3.4 Data Extraction 
The following data were extracted by one reviewer (HM or JW) from the selected studies: study 
design, technology, concurrent therapy, patient characteristics (including number of previous 
chemotherapy lines, previous liver directed therapy, and proportion of patients with limited extra 
hepatic metastases). In a cohort of mixed primary origin, only CRCLM or ICC data were extracted. 
The primary outcome was median OS. Secondary outcomes were PFS, LPFS, HRQoL and tumour 
response rates. 
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4.3.5 Statistical methods 
Meta-analysis was not conducted due to high heterogeneity between studies, a lack of RCTs and 
comparative study designs. A pooled analysis was performed on studies reporting median OS, PFS, 
and LPFS to present a weighted mean of medians. Weight was applied based on the number of 
participants in each study. Pooled confidence intervals were also calculated.  
4.4 Results of systematic review - colorectal cancer  
4.4.1 Objective of current review  
The purpose of this review was to provide an updated overview of the efficacy of SIRT in patient 
with unresectable CRCLM. The focus was on patients who are refractory to chemotherapy and are 
receiving SIRT following progression on at least two lines of chemotherapy.  
4.4.2 Selected studies  
The systematic literature search yielded 1,170 potentially relevant studies (Figure 4.1). Thirty-five 
primary studies were selected for full data extraction. Eight primary studies were subsequently 
excluded because of a high likelihood of patients being included in later publications (Chua 2011; 
Fendler et al. 2013; Kennedy et al. 2006; Lewandowski 2014; Mulcahy et al. 2009; Sato et al. 2008; 
Shady et al. 2016a; Shady et al. 2016b). Three systematic reviews, 3 comparative studies, and 21 
non-comparative studies were included in this review (Table 4.3).  
Table 4.3. Studies included in this review (CRC population) 
Study types Studies included in this review  
Systematic reviews 3 studies: Rosenbaum 2013; Saxena et al. 2014; Zacharias 2015 
Comparative 3 studies: 1 RCT (Hendlisz et al. 2010), 2 retrospective comparative 
(Bester et al. 2012; Seidensticker et al. 2012) 
Non-comparative 21 studies: 7 prospective (Benson 2013; Cosimelli et al. 2010; Golfieri 
et al. 2015; Jakobs 2017; Maleux et al. 2015; Rosenbaum et al. 2016; 
Saxena et al. 2015) 
14 were retrospective(Cianni et al. 2009; Damm et al. 2016; Hickey et 
al. 2015; Jakobs et al. 2008; Janowski et al. 2017; Kalva et al. 2014; 
Kennedy et al. 2015; Lahti 2015; Lam et al. 2014; Sabet et al. 2015; 
Schmeel 2016; Schonewolf 2014; Smits 2013; Sofocleous 2015). 
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Figure 4.1. Flow diagram of selected studies 
 
4.4.3 Previous systematic reviews 
Ten reviews (including Health Technology Assessment reports) were identified and assessed for their 
relevance to this review. Three were recent (published since 2010) and relevant to this review and 
their findings have been summarised below (Rosenbaum 2013; Saxena et al. 2014; Zacharias 2015). 
There is substantial overlap in the studies included in the three systematic reviews.  
Zacharias et al. (2015) systematic review 
This review compared the effectiveness of hepatic artery based therapies (SIRT, HAI, and TACE) in 
patients with unresectable CRCLM. The authors searched only PubMed (May 2003-June 2013) with 
an appropriate range of search terms. Study selection criteria were clearly described, a flow diagram 
was included, and details of the authors’ quality appraisal findings were published. The majority of 
included studies were observational. 
Records identified through 
database searching. 
Duplicates removed. 
n=1152 
Studies included in NICE 
interventional procedures 
overview (IPO) 
n=18 
First screen (title and abstract) 
n=1170 
Records excluded 
n=991 
Second screen (full text) 
n=179 
Records excluded 
with reasons 
n=127 
Retained for quality appraisal 
and data extraction  
n=52 (CRC: 35; ICC: 17)  
Records excluded because 
overlap in patient cohort 
n=15 (CRC: 8; ICC: 5) 
Studies included in review (CRC) 
n=27 (systematic reviews 3; 
primary 24) 
Studies included in review (ICC) 
n=12 (systematic reviews 2; 
primary 10) 
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The review included 24 SIRT studies (with 1,268 patients), 52 HAI studies (3,000 patients) and 14 
TACE studies (1,038 patients). The majority of patients in the SIRT and TACE groups had received at 
least one prior line of chemotherapy (94% and 91% respectively).  
Median OS was 11.4 months (95% CI 10.2-12.6) for SIRT, 16.0 months (95% CI 14.7-16.4) for HAI, and 
21.0 (95% CI 20.6-22.4) for TACE as calculated by a random effects meta-analysis. For patients who 
had received at least one previous line of chemotherapy OS was 10.7 months (95% CI 9.5-12.0) for 
SIRT, 13.2 months (95% CI 12.2-14.2) for HAI, and 21.3 (95% CI 20.6-22.4) for TACE.  
Response rates (percentage of patients showing a partial or complete response) for the three 
treatment strategies were 36% (95% CI 25-47) for SIRT, 48% (95% CI 42-54) for HAI, and 29% (95% CI 
14-43) for TACE. Response rates were reduced in pre-treated patients: 32% (95% CI 24-39) for SIRT, 
35% (95% CI 24-45) for HAI, and 28% (95% CI 7-48) for TACE.  
Grade 3–4 toxicity was 55% in the HAI group, 26% in the SIRT group, and 17% in the TACE groups 
across all studies.  
The volume and quality of evidence across the three modalities was different, and there is likely to 
be considerable heterogeneity in populations which could make these comparisons unreliable; for 
example patients treated with SIRT are more likely to be pretreated and more likely to have extra-
hepatic disease. The authors conclude that the three liver directed therapies, SIRT, HAI, and TACE, 
are equally effective in patients with unresectable CRCLM. Relevance of the review to the SIRT CtE 
evaluation was limited because it included patients who had received ≤1 previous chemotherapy 
line.  
Saxena et al. (2014) systematic review  
This study reviewed the safety and efficacy (radiological response and survival outcomes) of SIRT in 
patients with unresectable, chemotherapy-refractory CRCLM.  The authors searched MEDLINE and 
PubMed (1966-2012) with a limited range of search terms. Selection criteria were clearly explained, 
a flow diagram was presented, and critical appraisal results were reported. Twenty studies (with 979 
patients) were included in the review. The median number of previous lines of chemotherapy was 3 
(range 2-5.1), and a median of 20% (range 0-92%) of patients had undergone previous liver 
resection. The majority of included studies were observational. 
Median OS was 12 months (range 8.3-36; reported in 11 studies; pooled analysis method not 
described). After SIRT treatment the median radiological response from 16 studies was as follows: 
complete response 0% (range 0-6%), partial response 31% (range 0-73%), stable disease 40.5% 
(range 17-76%), progressed disease 17.5% (range 6-50%). Median LPFS reported in 6 studies was 9 
months (range 6-16). Median PFS reported in 8 studies was 4.9 months (range 3.4-9.3). 
The overall median acute toxicity rate was 40.5% (range 11-100%). Most cases were mild (grade 1 or 
2) and resolved without intervention. The most common toxicities were fatigue (median 38.5%), 
abdominal pain (median 16%), and nausea/vomiting (median 19%).  
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The authors also summarised statistically significant and non-significant prognostic factors and 
reported that number of previous lines of chemotherapy (≥3), poor radiological response, extra-
hepatic disease, and extensive liver disease (≥25%) were the factors most commonly associated with 
poorer overall survival. These findings were derived from five studies (Chua 2011; Jakobs et al. 2008; 
Mulcahy et al. 2009; Nace 2011; Stubbs et al. 2006).  
The authors conclude that SIRT is a safe and effective treatment for CRCLM in the salvage setting.   
Rosenbaum et al. (2013) systematic review 
This study reviewed tumour response and survival data in patients with unresectable and 
chemorefractory with CRCLM. The authors searched a range of databases (December 2001 – 
September 2012) with an appropriate range of search terms. Selection criteria were clearly reported 
with a flow diagram was presented. Critical appraisal results were reported. The authors presented a 
forest plot of survival proportions at 12 months but did not calculate pooled statistics for any 
outcomes due to heterogeneity between studies. Twenty-six publications were included. The 
authors separated studies which report on SIRT as monotherapy (13 studies; 901 patients) and SIRT 
in combination with systemic or intrahepatic chemotherapy (13 studies; 472 patients).   
For SIRT as monotherapy, median OS ranged from 8.3 to 15.2 months (reported in 11 studies; no 
pooled analysis was conducted). Survival proportions at 12 months after treatment ranged from 37% 
to 59%. Tumour response rates (complete and partial response) ranged from 18% to 46% (from 10 
studies). Disease control rates (complete, partial response, and stable disease) ranged from 29% to 
90%. PFS ranged from 3.9 to 9.2 months (from 6 studies) 
For SIRT in combination with chemotherapy, median OS ranged from 10.0 to 29.4 months (reported 
in 10 studies). Survival proportions at 12 months after treatment ranged from 43% to 74%. Tumour 
response rates ranged from 8% to 90% (from 11 studies). Disease control rates ranged from 59% to 
100%.  
Adverse events and toxicities were not reported in the review.  
The authors conclude that approximately 50% of CRCLM salvage patients survive more than 12 
months after SIRT treatment as monotherapy or in combination with chemotherapy.   
4.4.4 Results from comparative studies (CRC) 
Three comparative studies were identified (Bester et al. 2012; Hendlisz et al. 2010; Seidensticker et 
al. 2012) with a total of 355 patients (of which 274 were treated with SIRT) (Tables 4.4 and 4.5).  
Hendlisz et al. (2010) was an open-label, multi-centre (Belgium) randomised phase III trial comparing 
fluorouracil (FU) protracted intravenous infusion (n=23) to SIRT plus intravenous FU (n=21). Ten 
patients in the control arm with documented progression were permitted to cross over to receive 
SIRT. Patients were followed up for a median of 24.8 months. The primary outcome of this trial was 
LPFS and a significant improvement in the SIRT group was reported (5.5 vs 2.1 months; HR 0.38 (95% 
CIs 0.28-0.94); p=0.003). An improvement in PFS was also shown in SIRT patients 4.5 vs 2.1 months 
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(HR 0.51 (0.28-0.94); p=0.03). There was a non-significant improvement in OS in the SIRT arm (10.0 
vs 7.3 months; HR 0.92 [95% CIs 0.47-1.78]; p=0.80). Toxicity analysis showed no significant 
difference in the proportion of patients who had grade 3 or 4 toxicities (6 patients in FU group; 1 
patient in SIRT group; p=0.10). The authors used time to liver progression (TTLP) and time to 
progression (TTP), but the description provided indicated that PFS and LPFS are in fact reported3. 
Hendlisz et al. was the highest quality study included in this review and demonstrated the difficulties 
in detecting large enough differences in OS so as to be statistically significant. The study may be 
subject to performance bias due to the open-label design, and cross-over of patients may obscure 
differences between the arms (Tables 4.4 and 4.5).  
Bester et al. (2012) was a single-institution (Australia), retrospective comparative study comparing 
SIRT therapy (n=224) with conventional therapy/supportive care (n=29) in patients with 
unresectable and chemotherapy-refractory, liver dominant CRCLM (Table 4.4). The study also 
included patients with non-CRC primary cancers and some analyses were not stratified for CRC. 
Patients in the standard care arm were selected from a population who were assessed for SIRT 
eligibility but were considered unsuitable due to anatomical contraindications or refusal of consent; 
they were provided with conservative treatment of continued supportive care. Some baseline 
characteristics were presented separately for CRC patients treated with SIRT. Baseline characteristics 
for the CRC-only patients who received standard care were not reported therefore differences could 
not be assessed. The study reports that 85% of patients were ECOG performance status 0, and 14% 
of patients treated with SIRT were chemotherapy naive. Length of follow-up was not reported. OS 
was improved in the SIRT group compared to standard care (11.9 vs 6.6 months; HR: 0.5; log rank 
test p=0.001; Table 4.5). Adverse events occurred in 22% of patients immediately after SIRT, which 
were minor abdominal pain, nausea, and vomiting. The authors report that at the 1-month follow-up 
after SIRT, adverse events were minor and easily medically managed, including once case of 
radiation induced liver disease (RILD). Adverse events in the supportive care arm were not reported. 
The retrospective and non-randomised nature of this study means that there is substantial risk of 
bias from inadequately matched prognostic factors, allocation bias, poorly defined standard care 
regimens, and heterogeneity in outcome measures across the arms (Tables 4.4 and 4.5).  
Seidensticker et al. (2012) was a multi-centre (Germany), retrospective comparative study 
comparing SIRT therapy (n=29) with a matched cohort of patients receiving BSC (n=29). BSC patients 
were matched on several criteria (prior treatment, tumour burden, liver involvement, 
synchronous/matachronous metastases, alkaline phosphatase (ALP) change, and carcinoembryonic 
antigen levels). The authors report that the groups were well-matched for baseline parameters. 
Patients treated with SIRT had a longer overall survival compared with BSC (8.3 vs 3.5 months; HR 
0.26 [95% CIs 0.15-0.48]; p<0.001). Some patients treated with SIRT (31%) went on to receive 
chemotherapy. PFS was 5.5 months in the SIRT arm and 2.1 months in the BSC arm. The same issues 
of bias as described for Bester et al. (2012) apply to this study (Tables 3.4 and 3.5). Adverse events of 
mild abdominal pain and nausea occurred after SIRT in 48% patients. Three cases of grade 3 RILD 
were reported. Adverse events in the comparator arm were not reported.  
                                                          
3
 Typically, dead patients are censored in PFS, whilst they are excluded in TTP.  
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Table 4.4. Patient characteristics of comparative studies of SIRT in patients with chemotherapy-refractory, unresectable metastatic colorectal cancer 
 
Author & 
year 
Sample 
size 
Country 
(study 
period) 
Intervention 
Comparat
or 
Study type Population Key QA issues Male Age (years) 
Previous chemo 
lines 
Chemo-
naive 
patients 
EHM 
Bester et al. 
2012 
224 
SIRT 
29 SC 
Australia 
(2006-
2011) 
SIRT (SIR-
spheres) 
SC not 
defined 
Retrospective 
comparative  
Unresectable, 
liver 
only/dominant
, CRCLM, 
chemotherapy
-refractory or 
anticipated 
poor response. 
Retrospective design limits reliability, and 
comparability between groups. Small 
patient numbers in SC group. Baseline 
demographics for SC group (and for some 
measures, SIRT also) were not presented 
for CRC group only. 
85% of SIRT group were ECOG 0, the 
performance status for SC group not was 
reported. Number of previous 
chemotherapy lines not reported. AEs not 
reported for SC group. Survival was 
calculated from the date of SIRT procedure, 
and for SC group from time patients were 
consulted at clinic for SIRT eligibility. SC 
patients selected on the basis of anatomical 
ineligibility for SIRT, or refusal of consent. 
The authors state the groups were 
comparable.   
63% SIRT 
69% SC 
(incl. 
non-CRC) 
67 SIRT 
66 SC (incl. 
non-CRC) 
median 
 
86% SIRT: ≥1 
92% SC: ≥1 
(incl. non-CRC)  
 
14% SIRT 
8% SC (incl. 
non-CRC)  
 
38% SIRT 
33% SC 
(incl. non-
CRC) 
Seidensticke
r et al. 
(2012) 
29 SIRT 
29 SC 
Germany 
(2005-
2008) 
SIRT (SIR-
spheres) 
BSC – 
palliative 
care with 
intent to 
maximise 
quality of 
life 
Matched-pair 
retrospective  
Unresectable, 
liver dominant 
CRCLM, 
chemotherapy
-refractory or 
refused.  
Retrospective design limits reliability, and 
comparability between groups. Small 
patient numbers. Consecutive patient 
enrolment. SIRT patients matched to cohort 
of patients who received BSC only. 31% 
SIRT patients also received chemotherapy 
following SIRT. Unclear whether BSC 
patients also received chemotherapy. 
Matching process described. OS measured 
from date of previous progression to death 
(although unclear in description). PFS 
measured from previous progression to 
further progression. Progression 
measurement in BSC arm at discretion of 
treating clinician (imaging not mandatory), 
whereas RECIST used in SIRT group. Both 
groups were ECOG 0-2 and equal median 
(equivalent Karnofsky score). AEs not 
reported for BSC group. 
76% SIRT 
79% BSC 
Mean:  
62 SIRT 
61 BSC 
Median: 3 SIRT, 
5 BSC 
0% SIRT, 0% 
BSC: 1 previous 
line 
28% SIRT, 24% 
BSC: 2 lines 
31% SIRT, 38% 
BSC:3 lines 
41% SIRT, 38% 
BSC: ≥4  
0% SIRT, 
0% BSC 
48% SIRT, 
48% BSC 
Hendlisz  et 
al. (2010) 
21 SIRT 
+ FU 
23 FU 
alone 
Belgium 
(2004-
2007) 
SIRT (SIR-
spheres) plus 
FU 
chemotherap
y 
FU alone 
Randomised 
controlled trial 
Unresectable, 
liver dominant 
CRCLM, 
chemotherapy
-refractory or 
intolerant to 
standard 
chemotherapy
. ECOG 0-2. 
Higher quality study, although small patient 
numbers and open label design limit 
reliability. Ten FU alone patients crossed 
over to SIRT arm which confounds survival 
estimates. 9 patietns in SIRT group received 
further therapy after SIRT. Majority of 
patients in both arms were ECOG 0 (71% 
SIRT+FU, 74% FU). RECIST criteria used to 
document progression in both groups. Time 
48% SIRT 
+ FU, 
78% FU 
Median: 62 
SIRT + FU, 
62 FU 
NR 
0% SIRT + 
FU, 0% FU 
0% both 
groups 
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to progression (TTP) defined as time to 
progression or death or loss to follow-up.   
 
AE, adverse event; BSC, best supportive care; CRC, colorectal cancer; CRCLM, colorectal cancer liver metastases; ECOG, Eastern Cooperative Oncology Group; EHM, extrahepatic metastases; 
FU, fluorouracil; NR, not reported; OS, overall survival; PFS, progression-free survival; RECIST, Response Evaluation Criteria In Solid Tumors; SC, standard care; TTP, time to progression.  
 
 
Table 4.5. Survival and tumour response results from comparative studies of SIRT in patients unresectable metastatic colorectal cancer 
Author & 
year 
Sample 
size 
Median overall 
survival (months; 95% 
CI) 
Median follow-
up (months; 
95% CI) 
Median LPFS 
(months; 95% CIs) 
Median PFS  
(months; 95% CIs) 
Survival Tumour response (RECIST criteria) 
6 
months 
12 
months 
24 
months 
36 
months 
Complete 
response 
(CR) 
 
Partial 
response 
(PR) 
Stable 
disease 
(SD) 
Progressive 
disease 
(PD) 
Bester et al. 
(2012) 
224 SIRT 
29 SC 
11.9 (10.1-14.9) SIRT, 
6.6 (CIs NR) SC, 
Log rank p=0.001 
HR estimate 0.5 
NR NR NR NR NR NR NR NR NR NR NR 
Seidensticker 
et al. (2012) 
29 SIRT 
29 SC 
8.3 (NR) SIRT, 
3.5 (NR) BSC, 
HR 0.26 (0.15-0.48), 
p<0.001 
NR NR 
5.5 (NR) SIRT, 
2.1 (NR) BSC 
64% 
SIRT, 
NR for 
BSC 
24% 
SIRT, 
0% BSC 
NR NR 
0% SIRT, 
NR for 
BSC 
41% 
SIRT, 
NR for 
BSC 
17% 
SIRT, 
NR for 
BSC 
38% SIRT, 
NR for BSC 
Hendlisz  et 
al. (2010) 
21 SIRT + 
FU 
23 FU 
alone 
10 (NR) SIRT + FU, 7.3 
(NR) FU 
HR 0.92 (0.47-1.78), 
p=0.80 
24.8 (range 2-
41) 
 
5.5 (NR) SIRT + 
FU, 2.1 FU (NR) 
HR 0.38 (0.20-
0.72) p=0.003 
4.5 (NR) SIRT + FU, 
2.1 (NR) FU 
HR 0.51 (0.28-0.94) 
p=0.03 
NR NR NR NR 
0% SIRT + 
FU, 0% 
FU 
10% SIRT 
+ FU, 0% 
FU 
(p=0.22) 
76% 
SIRT + 
FU, 35% 
FU 
(p=0.001 
for PR + 
CR) 
10% SIRT + 
FU, 61% FU 
BSC, best supportive care; CI, confidence interval; FU, fluorouracil; HR, hazard ratio; LPFS, liver-specific progression free survival; NR, not reported; PFS, progression-free survival; SC, 
standard care. 
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4.4.5 Results from non-comparative primary studies (CRC) 
Overall, 23 studies comprising 2,517 patients treated with SIRT were included in the non-
comparative section of this review (Table 4.6). Two comparative studies (only data from SIRT 
patients) and 21 non-comparative studies were included. The results from Bester et al. (2012) were 
not included in the main non-comparative data extraction table because patients treated with SIRT 
were also included in Saxena et al. (2015). There is a risk that some of the 61 CRC patients in Benson 
et al. (2013) are also included in Hickey et al. (2015)1. Six large studies with more than 100 patients 
were included, the largest of which included 606 patients. Nine studies were conducted in the US, 13 
in Europe, and 1 in Australia (Table 4.6).  
All studies included patients with chemotherapy-refractory, unresectable CRCLM (although one 
study did not clearly define the hepatic tumours as unresectable). Studies enrolled patients with 
either liver-only (no extrahepatic metastases) or liver-dominant metastases (four studies did not 
report whether patients had liver-dominant metastases).  Five studies did not report the percentage 
of patients with extra-hepatic metastases but described the population as liver dominant. The 
majority of studies included only chemotherapy refractory patients (i.e. patients’ disease had 
progressed following at least one line of chemotherapy) or they were intolerant to chemotherapy. 
Only two studies did not report any information on the number of previous lines of chemotherapy 
administered to CRC patients (Hendlisz et al. 2010; Smits et al. 2013), but these described the 
patient population as chemotherapy refractory and therefore were included in this review. Two 
studies reported that a small proportion of chemotherapy naive patients were included: Hickey et al. 
(2015) had 3% and Kennedy et al. (2015) had 6%. Fifteen studies reported previous liver-directed 
therapies including resection, ablation, HAI, or TACE (7 studies did not report this) (Table 4.6). Nine 
studies included patients with an ECOG (Eastern Cooperative Oncology Group) performance status 
of 0-2, three studies included patients with ECOG status 0-1, 2 studies included patients with an 
ECOG status of 0-3, and nine studies did not report ECOG performance status range as an inclusion 
criteria.   
Twelve studies reported the proportion of patients who required more than 1 SIRT procedure (one 
of these reported the median number of sessions required per patient). Of the studies which 
reported this outcome, the proportion of patients who required ≥2 SIRT sessions ranged from 3% to 
55%). 
Median length of follow-up was reported in 12 of the 23 studies and ranged from 2.9 to 31.2 months 
(Table 4.7).  
Overall survival  
OS was reported in all 23 studies from a total of 2,517 patients. The pooled OS estimate from the 
included studies was 9.6 months (weighted mean; 95% CIs 8.9-10.4) and ranged from 6.0 to 12.7 
months (Table 4.7).  
In order to focus on a chemotherapy-refractory population which would more closely represent the 
SIRT CtE cohort (i.e. to exclude chemotherapy-naive patients and patients who had failed only 1 line 
                                                          
1
 although this was not confirmed when the author was contacted 
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of chemotherapy), OS from studies in which patients who received at least 2 previous lines of 
chemotherapy were presented (Table 4.8). Twelve studies were identified in which the cohort was 
≥95% patients who had failed ≥2 previous lines of chemotherapy, or presented such patients in a 
subgroup analysis. A total of 1258 patients were reported in these studies. The pooled OS was 9.1 
months (95% CIs 8.4-9.7), and the range across these studies was 7.0 to 11.6 months (Table 4.8).  
Progression-free survival (PFS) 
PFS was reported in 9 studies (437 patients) and ranged from 2.8 to 9.2 months (weighted mean 4.0 
months). LPFS was reported in 8 studies (376 patients) and ranged from 2.0 to 9.0 months (weighted 
mean 4.4 months) (Table 4.7).  
Tumour response  
Tumour response rates measured using the RECIST criteria were reported in 12 studies (although 2 
studies did not report the category of progressive disease). Complete response (CR) rates ranged 
from 0% to 5% in patients treated with SIRT; partial response (PR) rates ranged from 5% to 41%; 
stable disease (SD) rates ranged from 17% to 86%; progressive disease (PD) rates ranged from 10% 
to 44% (Table 4.7).  
Survival proportion 
Survival proportions at 12 and 24 months were reported in 9 and 6 studies respectively. Survival at 
12 months ranged from 24% to 50%, and survival at 24 months ranged from 0% to 25% (Table 4.7).  
Quality of life 
One study included in the review reported quality of life as an outcome (Cosimelli et al. 2010). 
Patients were assessed prior to SIRT and 6 weeks after treatment using disease-specific quality of life 
tools EORTC QLQ C30, EORTC QLQ CR38, EORTC QLQ LMC-21), and the hospital anxiety and 
depression evaluation scale (HADs). Patient satisfaction was also assessed using EORTC QLQ SAT-32. 
Results from these assessments were poorly reported. The authors state that 14 of 50 patients were 
not adversely affected by SIRT but do not state by which measure. Patients reported a mean HADs 
score of 8 for anxiety and 9 for depression before SIRT treatment which indicated a “borderline 
abnormal” score. Six weeks after SIRT, patients’ anxiety levels were significantly reduced (P<0.01); 
with no significant change in depression score. 
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Table 4.6. Patient demographics from 23 studies on SIRT (non-comparative data only presented) – colorectal cancer population 
Author & 
year 
Sample 
size1 
Country 
(study 
period) 
Y-90 
technology 
Study type Population Key QA issues Male 
Age 
(mean) 
Previous chemo 
lines 
Chemo-
naive 
patients 
EHM 
Previous liver-
directed 
therapy 
Multiple SIRT 
procedures 
Jakobs et al. 
(2017) 
104 
Germany 
(no 
dates) 
SIR-spheres 
Prospective 
non-
comparative 
Unresectable, liver 
dominant CRCLM, 
chemotherapy-
refractory. ECOG not 
reported. 
Number of previous lines not 
reported in detail. 
Consecutive recruitment. 
Previous liver-directed 
therapies not described. PFS 
not reported. 
70% 64 
All patients 
progressed 
following FU, IRI, 
and OXA. 46% had 
prior BEV or CET 
0% 55% NR NR 
Damm et al. 
(2016) 
106 
Germany 
(2006-
2010) 
SIR-spheres 
Retrospective 
non-
comparative 
Unresectable, liver 
dominant CRCLM, 
chemotherapy-
refractory. ECOG not 
reported. 
Includes patients who have 
failed 1 previous line of 
chemo. 
66% 
63 
(median) 
Median 3 lines 
(range 1-5) 
8%: 1 previous line 
33%: 2 
32%: 3 
26%: ≥4 
0% 28% 
28% resection 
or ablation 
Median 2 
sessions per 
patient (range 
1-5) 
Janowski et 
al. (2016) 
58 
USA 
(2011-
2015) 
SIR-spheres 
Retrospective 
non-
comparative 
Unresectable, CRCLM, 
chemotherapy-
refractory. Mostly 
ECOG 0-2.  
Includes patients who have 
failed 1 previous line of 
chemo. Not reported 
whether metastases were 
liver dominant. 
50% 
56 
median  
Median 2 lines 
(range 1-5) 
21%: 1 previous line 
50%: 2 
2%: ≥3 
0% 67% NR 55%: 2 sessions 
Rosenbaum 
et al. (2016) 
42 
Netherla
nds (no 
dates) 
SIR-spheres 
Prospective 
non-
comparative 
Unresectable, CRCLM, 
chemotherapy-
refractory. ECOG 0-2. 
Includes patients who have 
failed 1 previous line of 
chemo. Includes patients 
where EHM may not be liver 
dominant.  
69% 62 
36%: 1 previous line 
38%: 2 
26%: ≥3 
0% 29% 
12% 
segmentectomy
; 10% ablation; 
7% 
hemihepatecto
my; 3% other. 
4%: 2 sessions 
Schmeel et 
al. (2016) 
44 
Germany 
(no 
dates) 
Both 
Retrospective 
non-
comparative 
Unresectable, liver 
predominant CRCLM, 
chemotherapy-
refractory. ECOG not 
reported.  
 61% 61 
All had at least 2 
lines of IRI and OXA.  
0% 44% 
0% local 
intrahepatic 
therapies 
23%: ≥2 
sessions 
Hickey et al. 
(2015)2 
531 
USA 
(2001-
2014) 
TheraSphere 
Retrospective 
non-
comparative 
Unresectable, liver 
dominant CRCLM, 
progressed on chemo 
and loco-regional 
therapy. ECOG 0-2. 
Includes patients who have 
failed 0 & 1 previous lines of 
chemotherapy 
 
59% NR 
41% had 1-2 
previous cytotoxic 
drugs (5FU, OXA, or 
IRI); 56% had 3 
previous drugs 
3% 38% 
18% resection; 
14% ablation; 
4% TACE 
NR 
Saxena et al. 
(2015)3 
302 
Australia 
(2006-
2013) 
SIR-spheres 
Prospective 
non-
comparative 
Unresectable, liver 
dominant CRCLM, 
chemotherapy-
refractory. ECOG 0-3. 
Majority of patients failed 1 
line previous chemotherapy, 
Subgroup analysis for 2 lines 
and >3 lines 
65% 64 
53%: 1 previous line 
30%: 2 
17%: ≥3 
0% 41% 
27% resection; 
4% ablation; 
0.7% TACE 
NR 
                                                          
1
 CRC patient receiving SIRT 
2 Includes data from patients reported in Lewondowski 2014; Mulcahy 2009; Sato 2008.  
33 Includes data from patients reported in Bester 2012; Chua 2011 
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Author & 
year 
Sample 
size1 
Country 
(study 
period) 
Y-90 
technology 
Study type Population Key QA issues Male 
Age 
(mean) 
Previous chemo 
lines 
Chemo-
naive 
patients 
EHM 
Previous liver-
directed 
therapy 
Multiple SIRT 
procedures 
Kennedy et 
al. (2015)1 
606 
USA 
(2002-
2011) 
SIR-spheres 
Retrospective 
non-
comparative 
Unresectable, liver 
dominant CRCLM, 
progressed on ≥1 
previous line of 
chemotherapy. ECOG 
0-3. 
Includes patients who have 
failed 0 & 1 previous lines of 
chemotherapy, although 
results have been stratified 
 
62% 62 
Median 2 lines 
(range 0-6) 
6%: chemo naive 
35%: 1 previous line 
32%: 2 
27%: ≥3 
6% 35% 
28% resection/ 
ablation; 6% 
HAI/ TACE/TAE 
Median of 2 
sessions. 
Sabet et al. 
(2015) 
51 
Germany 
(NR) 
TheraSphere 
& SIR-sphere 
Retrospective 
non-
comparative 
Unresectable, liver 
dominant CRCLM, 
chemotherapy-
refractory. ECOG ≥1  
26%; ECOG <1 75%. 
Focus of study is prognostic 
factors 
65% 61 
All patients 
progressed on ≥2 
previous lines of 
chemotherapy 
0% 49% NR NR 
Golfieri et al. 
(2015) 
52 
Italy 
(2005-
2011) 
SIR-spheres 
Prospective 
non-
comparative 
Unresectable, liver 
dominant CRCLM, 
chemotherapy-
refractory. ECOG 0-1. 
Choi criteria used to assess 
tumour response.  (13% 
received chemo after SIRT) 
77% 63 
5%: 1 previous line 
49%: 2 
46%: ≥3 
0% 23% 
48% resection; 
2% HAI 
NR 
Sofocleous 
et al. (2015) 
53 
USA 
(2009-
2013) 
SIR-spheres 
Retrospective 
non-
comparative 
Unresectable, liver 
dominant CRCLM, 
chemotherapy-
refractory. ECOG 0-2. 
Not clear how many patients 
received only 1 previous line. 
Majority of patients received 
treatment after SIRT. 
57% 
54 
(median) 
All patients heavily 
pretreated 
28%: ≥3 previous 
lines 
NR 77% 
49% liver 
surgery; 29% 
HAIP 
34%: 2 sessions 
Lahti et al. 
(2015) 
104 
USA 
(2007-
2014) 
SIR-spheres 
Retrospective 
non-
comparative 
Unresectable, liver 
dominant CRCLM, 
chemotherapy-
refractory (SIRT used 
as 3rd line therapy). 
ECOG 0-2. 
Focus on KRAS status. 51% 
patients received 
chemotherapy after SIRT 
67% 
63 
(median) 
Median 5 previous 
chemotherapy 
agents (range 1-8) 
15%: 1 previous line 
85%: ≥2 
0% NR 
32% resection; 
16% HAI; 9% 
TACE 
NR 
Maleux et al. 
(2015) 
71 
Belgium 
(2005-
2014) 
SIR-spheres 
Prospective 
non-
comparative 
Unresectable, liver 
dominant CRCLM, 
chemotherapy-
refractory. ECOG 0-1. 
 72% 62.5 
38%: 2 previous 
lines 
62%: 3 
0% 31% 
14% resection; 
8% ablation 
0% 
Kalva et al. 
(2014) 
45 
USA 
(2005-
2011) 
SIR-spheres 
Retrospective 
non-
comparative 
CRCLM which failed at 
least 1 previous line of 
chemotherapy. ECOG 
0-2. 
Does not report whether 
tumours were resectable. 
Includes patients with just 
previous chemotherapy line. 
Includes patients where EHM 
may not be liver dominant. 
53% 
67 
(median) 
All patients received 
chemotherapy 
before SIRT. Ranged 
from 1-9 prior 
regimens, median 3. 
0% 64%  
13% ablation; 
4% 
radiotherapy; 
13% TACE 
11%: 2 sessions 
Lam et al. 
(2014) 
45 
USA 
(2004-
2011) 
SIR-spheres 
Retrospective 
non-
comparative 
Unresectable 
(probably), liver 
dominant CRCLM, 
salvage setting. ECOG 
0-1. 
All patients termed salvage 
but not clear how many 
previous lines. Focus on 
dosimetry. Not clear 
whether extrahepatic mets 
present. 
53% 58 
98% pts had 
previous 
chemotherapy 
NR (2%?) NR 
38% resection; 
24% ablation; 
2% TAE 
NR 
                                                          
1 Includes data from patients in Kennedy et al. 2006 
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Author & 
year 
Sample 
size1 
Country 
(study 
period) 
Y-90 
technology 
Study type Population Key QA issues Male 
Age 
(mean) 
Previous chemo 
lines 
Chemo-
naive 
patients 
EHM 
Previous liver-
directed 
therapy 
Multiple SIRT 
procedures 
Schonewolf 
et al. (2014) 
30 
USA 
(2007-
NR) 
SIR-spheres 
Retrospective 
non-
comparative 
Unresectable, liver 
dominant CRCLM, 
failed 1, 2, or 3 
previous 
chemotherapy lines. 
ECOG not reported.  
 60% 61 
Mean 2.1 (range 0-
5) 
0% (1 
patient?) 
NR 13% ablation 
53%: sequential 
sessions 
Benson et al. 
(2013) 
61 
USA 
(2007-
2009) 
TheraSphere 
Prospective 
non-
comparative 
Unresectable, liver 
dominant metastases 
of mixed primaries 
(results stratified). 
Disease progression 
under standard 
treatment. ECOG 0-2. 
Demographics not stratified 
for CRC. 1 chemotherapy-
naive patient included. 
Potential overlap in patients 
with Hickey et al. (2015) 
study. Company is a co-
author. 
NR NR 
2%: 0 previous lines 
39%: 1 previous line 
59%: ≥2 
 
2% 
NR 
(not 
stratifi
ed) 
NR NR 
Smits et al. 
(2013) 
30 
(CRC 
patient
s part 
of a 
larger 
cohort) 
Netherla
nds 
(2009-
2012) 
SIR-spheres 
Retrospective 
non-
comparative 
Unresectable, liver 
dominant metastases 
of mixed primaries 
(results stratified). 
Disease progression 
with systemic 
treatment or 
contraindicated. ECOG 
not reported. 
Demographics not stratified 
for CRC. Previous lines of 
chemotherapy not reported 
for CRC cohort. 
NR NR NR NR NR NR 
17%: sequential 
sessions 
Seidensticke
r et al (2012) 
29 
(pairs) 
Germany 
(2005-
2008) 
SIR-spheres 
Retrospective 
comparative 
Unresectable, liver 
dominant CRCLM, 
chemotherapy-
refractory or refused. 
ECOG 0-2. 
Comparative study 
comparing SIRT with 
standard care. 31% pts 
received chemotherapy after 
SIRT 
76% 
SIRT 
only 
62 for 
SIRT only 
Median 3 
0%: 1 previous line 
28%: 2 
31%:3 
41%: ≥4 
10% 48% 
24% resection; 
3% ablation; 3% 
TACE; 14% 
brachytherapy  
31%: sequential 
sessions 
Cosimelli et 
al. (2010) 
50 Italy (NR) SIR-spheres 
Prospective 
non-
comparative 
Unresectable, liver 
dominant CRCLM, 
chemotherapy-
refractory. ECOG 0-2. 
28% pts received 
chemotherapy after SIRT 
74% 64 
0%: 1 previous line 
0%: 2 
24%:3 
76%: ≥4 
0% 22% 24% resection 3%: 2 sessions 
Hendlisz et 
al. (2010) 
21 
(SIRT 
patient
s) 
Belgium 
(2004-
2007) 
SIR-spheres 
Randomised 
controlled 
trial 
Unresectable, liver 
dominant CRCLM, 
chemotherapy-
refractory or 
intolerant to standard 
chemotherapy. ECOG 
0-2. 
Compared FU infusion alone 
to FU+SIRT. Patients on FU 
alone permitted to cross 
over to SIRT arm. Previous 
chemotherapy was not 
reported. 
48% 
62 
(median) 
NR 
0% 
(probably
) 
0% 
(exclusi
on) 
0% TAE; 0% HAI NR 
Cianni et al. 
(2009) 
41 
Italy 
(2005-
2008) 
SIR-spheres 
Retrospective 
non-
comparative 
Unresectable, liver 
dominant CRCLM, 
chemotherapy- 
refractory. Median 
ECOG 0.7. 
Previous number of 
chemotherapy lines not 
reported 
73% 61 
Text suggest at least 
3 but not clear 
0% 10% NR 17%: 2 sessions 
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Author & 
year 
Sample 
size1 
Country 
(study 
period) 
Y-90 
technology 
Study type Population Key QA issues Male 
Age 
(mean) 
Previous chemo 
lines 
Chemo-
naive 
patients 
EHM 
Previous liver-
directed 
therapy 
Multiple SIRT 
procedures 
Jakobs et al. 
(2008)1 
41 
Germany 
(2003-
2007) 
SIR-spheres 
Retrospective 
non-
comparative 
Unresectable, liver 
dominant CRCLM, 
failed currently  
available therapies. 
ECOG not reported.  
 73% 61 
Mean 2.8 
7%: 1 previous line 
85%: 2 
0% (not 
clear) 
17% 
29% resection; 
20% ablation; 
5% TACE 
NR 
BEV, bevacizumab; CRC, colorectal cancer; CET, cetuximab; CRCLM, colorectal cancer liver metastases; ECOG, Eastern Cooperative Oncology Group score;  EHM, extrahepatic metastases; 
5FU, fluorouracil; HAI(P), hepatic arterial infusion (pump); IRI: irinotecan; KRAS, Kirsten rat sarcoma (gene mutation), NR, Not reported; OXA, oxaliplatin; QA, quality appraisal; SIRT, selective 
internal radiation therapy; TAE, trans arterial embolisation; TACE, trans arterial chemo-embolisation; Y-90, yttrium-90.  
  
                                                          
1 Includes data reported in Fendler 2013 
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Table 4.7. Survival and response statistics from 23 studies on SIRT (non comparative data only) – colorectal cancer population 
Author & year 
Samp
le 
size 
Median OS 
(months; 95% 
CI) 
Median 
follow-up 
(months; 95% 
CI) 
Median LPFS 
(95% CIs) 
Median PFS 
(months; 95% 
CIs) 
Survival (months) Tumour response (RECIST criteria) 
6 12 24 36 CR PR SD PD 
Jakobs et al. (2017) 104 10.2 (7.8-13.0) All died NR NR NR NR NR NR NR NR NR NR 
Damm et al. (2016) 106 6.7 (NR) 
6.0 (range 1-
48) 
NR 3.5 NR NR NR NR NR NR NR NR 
Janowski et al. 
(2016) 
58 6 (4.5-7.5) NR 2 (0.3-3.7) NR NR 33% NR NR 0% 19% 43% 38% 
Rosenbaum et al. 
(2016) 
42 9.2 (6.1-12.4) NR NR NR 71% NR NR NR 0% NR NR NR 
Schmeel et al. 
(2016) 
44 8 (6-10) NR NR NR NR NR NR NR 0% 2% 86% 11% 
Hickey et al. (2015)
1
 531 10.6 (8.8-12.4) NR NR NR NR NR NR NR NR NR NR NR 
Saxena et al. (2015)
2
 302 10.5 (NR) 7.2 (0.2-72.8) NR NR 66% 42% 17% 13% 1% 37% 32% 28% 
Kennedy et al. 
(2015)
3
 
606 9.6 (9.0-11.1) 8.6 (0.1-77.7) NR NR NR NR NR NR NR NR NR NR 
Sabet et al. (2015) 51 7 (5-8) 11.0 (±9) NR NR NR NR NR NR NR NR NR NR 
Golfieri et al. (2015) 52 11.0 (8.0-14.0) 7.0 NR NR NR NR NR NR 0%
4
 65% 18% 18% 
Sofocleous et al. 
(2015) 
53 12.7 (5.2-20.2) 15.0 4.7 (3.5-5.8) NR NR 50% 25% NR 
0% (12 
wks) 
7% (12 
wks) 
61% 
(12 
wks) 
33% 
(12 
wks) 
Lahti et al. (2015) 104 6.9 (5.4-8.4) 31.2 NR NR NR NR NR NR NR NR NR NR 
Maleux et al. (2015) 71 8 (7-9) NR 4 3 65% 30% 6% NR NR NR NR NR 
Kalva et al. (2014) 45 6.1 (4.9-9.1) 
4.9 (range 7d – 
4.7 y) 
NR NR 53% 29% NR NR 0% 2% 71% 13%
5
 
Lam et al. (2014) 45 11.2 (NR) 2.9 NR NR NR NR NR NR 0%  
17% 
(includ
es CR) 
46%  NR 
Schonewolf et al. 
(2014) 
30 9.4 (6.4-15.2) 7.0 NR 3.2 (1.1-7.2) NR NR NR NR NR NR NR NR 
                                                          
1
 Includes data from patients reported in Lewondowski 2014; Mulcahy 2009; Sati 2008. 
2
 Includes data from patients reported in Bester 2012; Chua 2011 
3
 Includes data from patients in Kennedy et al. 2006 
4
 Choi criteria 
5
 Excluding 7 patients who died before follow-up 
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Author & year 
Samp
le 
size 
Median OS 
(months; 95% 
CI) 
Median 
follow-up 
(months; 95% 
CI) 
Median LPFS 
(95% CIs) 
Median PFS 
(months; 95% 
CIs) 
Survival (months) Tumour response (RECIST criteria) 
6 12 24 36 CR PR SD PD 
Benson et al. (2013) 61 8.8 (6.6-11.9) NR 3.0 (2.0-5.8) 2.9 (1.3-3.1) NR NR NR NR 0% 5% 53% NR 
Smits et al. (2013) 30 8.9 (6.9-10.9) NR 3.0 (2.8-3.3) 2.8 (2.2-3.3) NR NR NR NR NR NR NR NR 
Seidensticker et al 
(2012) 
29 8.3 (NR) NR NR 5.5 (NR) 64% 24% NR NR 0% 41% 17% 38% 
Cosimelli et al. 
(2010) 
50 12.6 (7-18.3) 11.0 NR 3.7 (2.6-4.9) 85% 50% 19.5% NR 2% 22% 24% 44% 
Hendlisz et al. 
(2010) 
21 10 (NR) 24.8 5.5 (NR) 4.5 (NR) NR NR NR NR 0% 10% 76% 10% 
Cianni et al. (2009) 41 11.6 (NR) NR 9 9.2 90%
1
 44%
12
 0%
12
 0%
12
 5% 41% 34% 20% 
Jakobs et al. (2008)
2
 41 10.5 (1.3-38.3) 7.9 5.9 (NR) NR 68%
12
 40%
12
 21%
12
 14%
12
 0% 17% 61% 10% 
Summary (pooled 
results) 
2517 
9.6 (8.9-10.4) 
n=2517 
- 
4.4 (3.6-5.2)  
n=376 
4.0 (3.3-4.7)  
n=437 
- - - - - - - - 
CI, confidence intervals; CR, complete response; LPFS: liver-specific progression free survival; OS, overall survival; NR, not reported; PFS: progression free survival; PD, progressed disease; 
PR, partial response; RESIST, Response Evaluation Criteria in Solid Tumors; SD, stable disease.  
 
                                                          
1
 Data taken from Saxena et al. (2014) systematic review 
2
 Includes data reported in Fendler 2013 
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Commissioning through Evaluation: SIRT 
Full evaluation report 
Table 4.8. Summary of overall survival estimates from 12 studies on patients who received ≥2 
previous lines of chemotherapy 1 
Study author 
and year 
n OS in months 
(95% CIs) 
Previous chemotherapy lines (from whole cohort or 
subgroup analysis) 
Jakobs et al. 
(2017) 
104 10.2 (7.8-13.0) Data from whole cohort. All patients progressed following FU, 
IRI, and OXA.  
Schmeel et al. 
(2016) 
44 8.0 (6.0-10.0) Data from whole cohort. All patients progressed following at 
least 2 lines of IRI and OXA. 
Hickey et al. 
(2015) 
295 9.2 (7.8-10.6) Data from subgroup of patients (56%) who received 3 
previous cytotoxic drugs (assumed to equate to ≥2 previous 
lines of chemotherapy). 
Saxena et al. 
(2015) 
91 10.5 (NR; 2 
previous lines) 
Data from subgroup of patients who received 2 previous lines 
(30%). 
52 5.6 (NR; ≥3 
previous lines) 
Data from subgroup of patients who received 2 previous lines 
≥3 previous lines (17%) 
 Weighted mean 
for ≥2 lines 
OS=8.7
2
 
No combined analysis of ≥2 previous lines presented. 
Weights calculated from number of patients in subgroups. 
Kennedy et al. 
(2015) 
184 
 
9.0 (7.8-11.0; 2 
previous lines) 
Data from subgroup of patients who received 2 previous lines 
(32%). 
158 8.1 (6.4-9.3; ≥3 
previous lines) 
Data from subgroup of patients who received ≥3 previous 
lines (27%) 
 Weighted mean 
for ≥2 lines 
OS=8.6
1
 
No combined analysis of ≥2 previous lines presented. 
Weights calculated from number of patients in subgroups. 
Sabet et al. 
(2015) 
51 7 (5-8) Data from whole cohort: patients progressed on ≥2 previous 
lines (no further information on number of lines provided) 
Golfieri et al. 
(2015) 
52 11.0 (8.0-14.0) Data from whole cohort (95%); patients progressed on ≥2 
previous lines.  
Maleux et al. 
(2015) 
71 8 (7-9) Data from whole cohort, patients progressed on ≥2 previous 
lines. 38% of patients received 2 previous lines, 62% 
progressed after 3 lines). 
Benson et al. 
(2013) 
36 7.4 (5.3-9.9) Data from subgroup of patients (59%) who received ≥2 
previous lines. 
Seidensticker et 
al. (2012) 
29 8.3 (NR) Data from whole cohort: patients progressed on ≥2 previous 
lines (28% =2 lines, 31% =3 lines, 41% ≥4 lines). 
Cosimelli et al. 
(2010) 
50 12.6 (7-18.3) Data from whole cohort: patients progressed on ≥3 previous 
lines (24% =3 lines,  74% ≥4 lines) 
Cianni et al. 
(2009) 
41 11.6 (NR) Text suggests that whole cohort progressed on ≥3 previous 
lines but not clear. 
Summary 
(pooled results) 
1258 Weighted mean OS: 9.1 months (95% CIs 8.4-9.7) 
Range: 7.0-12.6 
FU, fluorouracil; IRI, irinotecan; OS, overall survival; OXA, oxaliplatin; NR, not reported.  
                                                          
1
 Studies in which ≥95% of patients received ≥2 previous lines of chemotherapy or those with subgroup 
analysis of patients who received ≥2 previous chemotherapy lines. 
2
 Weights calculated from number of patients in subgroups.  
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Full evaluation report 
4.5 Results of systematic review - intrahepatic cholangiocarcinoma 
4.5.1 Objective of current review  
The purpose of this review was to provide an updated overview of the efficacy of SIRT in patients 
with unresectable ICC. The focus was on patients who are refractory to chemotherapy, although 
studies with a high proportion of chemotherapy naive patients were also included because of a 
paucity of evidence.  
4.5.2 Selected studies  
Two systematic reviews and 10 primary studies were included in this review. 
4.5.3 Previous systematic reviews (ICC) 
Two systematic reviews (Al-Adra 2015; Boehm 2015) were identified and deemed to be relevant to 
this review (Table 4.9).  
Table 4.9. Details of systematic reviews of SIRT for the treatment of ICC 
Author 
(year) 
Description of systematic review 
Al-Adra 
(2015) 
Systematic review of evidence for the treatment of unresectable ICCS with 
yttrium-90 micropsheres 
Boehm 
(2015) 
Systematic review and meta-anlysis on the comparative effectiveness of 
HAT- hepatic artery infusion (HAI), transcatheter arterial 
chemoembolization (TACE), drug‐eluding bead TACE (DEB‐TACE), and 
Yttrium90 radioembolization (Y‐90) for unresectable ICC. 
 
Al-Adra (2015) Systematic review 
This review examined the treatment of unresectable ICCs with Y-90 SIRT. A good selection of 
databases covering the periods 2000 to 2013 were searched. Study selection criteria were well 
described and a flow diagram was included. However no quality assessment of studies was 
performed or considered. Twelve studies were included, 7 of these were conference abstracts and 3 
had <10 participants. All the studies were non-comparative studies. Of the studies that were 
reported in full-text, Hyder et al. (2013) did not provide patient details for each intra-arterial therapy 
(IAT; 46/198 patients were SIRT) that was investigated, and Mouli et al. (2013) did not present OS for 
the whole group only by tumour morphology. Not all the studies reported the type of SIRT that was 
used. 
The majority of patients had undergone previous treatment for their ICC; 54% had received 
chemotherapy and/or surgical resection (33%). 
Weighted median OS was 15.5 months (range 7-22.2). Only 6 studies reported response rates 
(RECIST criteria or mRECIST/PERCIST), a weighted mean partial response was observed in 28% and 
stable disease in 54% of patients at 3 months. 
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Full evaluation report 
The authors conclude that OS of patients with ICC after treatment with SIRT is higher than historical 
survival rates and is similar to those treated with systemic chemotherapy and/or trans arterial 
chemoemolization therapy. They report that the complication profile of SIRT is similar to that of 
other intra-arterial treatment modalities. The authors state that randomised controlled trials 
comparing systemic chemotherapy, TACE and local radiation are required to identify the optimal 
treatment modaility for unresectable ICC. 
Boehm (2015) systematic review  
This review examined the comparative effectiveness of hepatic artery based therapies, including Y-
90 micropsheres, for unresectable ICCs. Only one database (PubMed) was searched to identify 
evidence from between 1990 and 2013; it would appear that all relevant studies have been included. 
Study selection criteria were described and a flow diagram was included; studies with < 10 patients 
were excluded. Quality assessment of the studies was performed and details provided. Five studies 
exploring the treatment of unresectable ICCs with SIRT were included; all were non-comparative 
studies. Four studies involved SIR-Spheres and one TheraSpheres. It is possible that 2 of the studies 
(Haug et al. 2011; Hoffamn et al. 2012) included overlapping patient populations. The authors of the 
review conducted a meta-analysis even though all the included studies were non-comparative 
studies and therefore subject to a high risk of bias and the patient populations were 
hetereogeneous. The forest plot of the meta-analysis indicates that there is hetereogeneity in the 
studies. Details of previous treatment regimens were not provided. 
The median OS, using a random effects model, for SIRT was 13.9 months (95% CI 9.5 – 18.3). Overall 
response (partial or complete) was observed in 27.4% (95% CI 17.4 – 37.5) of patients and stable 
disease in 54.8% (95% CI 45.2 – 56.7) of patients.  
Comparison of SIRT with other hepatic artery based therapies such as hepatic arterial infusion (HAI), 
transcatheter arterial chemoembolisation (TACE), drug‐eluting bead TACE (DEB‐TACE) were as 
follows. Median OS was highest for for HAI (22.8, 95% CIs 9.8–35.8) months versus SIRT (13.9, 95% 
CIs 9.5–18.3) months versus TACE (12.4, 95% CIs 10.9–13.9) months versus DEB‐TACE (12.3, 95% CIs 
11–13.5) months. The grade 3 or 4 toxicity (events per patient) was highest for HAI (0.35, 95% CIs 
0.22–0.48) versus TACE (0.26, 95% CIs 0.21–0.32) versus DEB- TACE (0.32, 95% CIs 0.17–0.48). 
The authors concluded that hepatic artery therapies appear promising for improving patient 
outcomes with unresectable ICC. 
4.5.4 Results from primary studies (ICC) 
Fifteen primary studies were selected for full data extraction, however 5 were subsequently 
excluded. The reasons for excluding the studies were as follows: Haug et al. (2011) possibly had an 
overlapping patient population with Hoffman et al. (2102) therefore the latter was retained as it had 
a slightly larger cohort; Hyder et al. (2013) did not provide patient details for each intra-arterial 
therapy that was investigated; (Mouli et al. 2013) did not present OS for the whole group; for Xing et 
al. (2016) it appeared that the patient population overlapped with Camacho et al. (2014), which was 
retained, was not specific for ICC and didn’t report OS for the whole group; Rayer et al. (2015) 
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Overall 10 studies (Beuzit et al. 2016; Camacho 2014; Filippi et al. 2015; Hoffmann 2012; Ibrahim et 
al. 2008; Jia 2016; Mosconi et al. 2016; Rafi et al. 2013; Saxena et al. 2010; Soydal et al. 2016) 
comprising 247 patients were included in this review; all were non-comparative studies and 
therefore subject to a high risk of bias (Table 4.10). Five studies were prospectively conducted and 
five were retrospective.  
The studies only included patients with unresectable ICC; one study did not report the percentage of 
patients with extra-hepatic metastases. Overall 78% of patients were chemotherapy-refractory (i.e. 
they had progressed following at least one previous line of chemotherapy). The number of lines of 
chemotherapy was not reported in any of the studies. Only Ibrahim et al. (2008) had a majority of 
chemo-naive patients, 71% (17/24). Eight studies reported previous liver-directed therapies with 
resection being the most common other therapies included ablation and TACE (Table 4.10). 
Median or mean length of follow-up was reported in 7 of the 10 studies and ranged from 8.0 to 
(Table 4.11).  
Overall survival  
OS was reported in 9 studies with a total of 230 patients (Filippi et al. (2015) was excluded because 
only mean OS was reported). The weighted mean of median OS across 9 studies was 15.3 months 
(95% confidence intervals 12.0-18.7) with a range of 9.0 to 22 months (Table 3.11). The addition of 
the mean OS estimate from Filippi et al. (2015) to the pooled estimate did no alter the result.   
Progression-free survival (PFS) 
Median PFS was not reported in any of the studies (Table 3.11). Beuzit et al. (2016) presented a 
comparison of PFS between subgroups but did not report PFS for the entire cohort. 
Tumour response  
Tumour response rates measured using the RECIST criteria were reported in 8 studies (one study 
used the WHO criteria). Complete response rates were zero in all 8 studies; partial response rates 
ranged from 0% to 82.4%%; stable disease rates ranged from 17.6% to 71%; progressive disease 
rates ranged from 0% to 55% (Table 4.11).  
Survival proportion 
Survival proportions were reported in 4 studies. Survival at 12 months following SIRT treatment 
ranged from 33% to 68%, and survival at 24 months ranged from 20% to 27% (Table 4.11). 
Health related quality of life 
None of studies identified reported HRQoL or patient satisfaction as an outcome. 
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Table 4.10. Study details and patient demographics from 10 non-comparative studies of SIRT in unresectable intrahepatic cholangiocarcinoma  
ECOG, Eastern Cooperative Oncology Group; ICC, intrahepatic cholangiocarcinoma; NR, not reported.  
  
Author & year 
Sample 
size 
(SIRT) 
Country 
(study 
period) 
Y-90 
technology 
Study type Population Key quality appraisal issues Male  
Age 
(mean 
years) 
Chemo-
naive 
patients  
EHM   
Previous liver-
directed therapy 
Number of 
SIRT 
procedures 
Beuzit et al. (2016) 45 
France 
(2010-
2014) 
TheraSphere 
Retrospective, 
non-
comparative 
Unresectable, 
chemorefractory ICC. 
ECOG 0-2. 
Includes chemotherapy naive patients. 53% 
64 
(median) 
8% 0% 
2% 
chemoembolisati
on; 4% ablation 
22%: 2 session 
4%: 3 sessions 
Jia et al. (2016) 24 
China & 
?USA 
(2006-
2015) 
SIR-sphere 
Retrospective, 
non-
comparative 
Unresectable, 
chemorefractory ICC. 
ECOG 0-1. 
All patients had received first-line 
cisplatin and gemcitabine 
33% 62 0% 13% NR 13%:2 sessions 
Mosconi et al. 
(2016) 
23 
Italy 
(2010-
2015) 
SIR-sphere 
Retrospective, 
non-
comparative 
Unresectable ICC. ECOG 
0-2. 
Includes chemotherapy naive patients. 61% 65 48% 9% 
17% TAC; 17% 
TAE; 44% 
resection; 26% 
lobectomy 
13% repeated 
procedure 
Soydal et al. (2016) 16 
Turkey 
(2008 –
2014) 
SIR-spheres 
Retrospective, 
non-
comparative 
Unresectable ICC. ECOG 
not reported.  
Follow-up time was to endpoint (death). 
Includes chemotherapy naive patients. 50% 55  44% 31% 
13% resection; 6% 
TACE 
NR 
Filippi et al. (2015) 17 Italy (NR) SIR-spheres 
Prospective, 
non-
comparative 
Unresectable, 
chemorefractory ICC. 
ECOG 0-2. 
Patient characteristics not fully reported 
for ICC as not stratified. Method of 
enrolment not reported. Follow-up time 
was to endpoint (24 months or death). 
Median OS not reported (only mean). 
Includes chemotherapy naive patients. 
35% 59  12% 24% 24% resection 
18%: sequential 
sessions 
Camacho et al. 
(2014) 
21 
USA 
(2009 – 
2012) 
SIR-spheres 
Prospective, 
non-
comparative 
Unresectable mass-like 
ICC refractory to 
standard 
chemotherapy. ECOG 0-
2. 
Patient characteristics not fully reported 
for ICC as not stratified. Follow-up time 
was to endpoint (death) but median not 
reported. 
 
62% 
63 
(median) 
0% NR 
48% resection 
(biliary surgery) 
NR 
Rafi et al. (2013) 19 
USA 
(2002 – 
2010) 
SIR-spheres 
Prospective, 
non-
comparative 
Unresectable ICC, 
refractory to standard 
chemotherapy. ECOG 0-
2. 
 Follow-up time was to endpoint (death). 
Includes chemotherapy naive patients. 
37% 63 0% 58% 21% TACE 
16%: 2 
sessions; 5% 3 
sessions. 
Hoffman et al. 
(2012) 
33 
Germany 
(2007 – 
2010) 
SIR-spheres 
Retrospective, 
non-
comparative 
Unresectable ICC or 
chemorefractory liver 
metastases from ICC. 
ECOG 0-2. 
Includes chemotherapy naive patients. 55% 65 18% 24% 
36% resection; 6% 
ablation; 9% TACE 
0% 
Saxena et al. (2010) 25 
Australia 
(2004 - 
2009) 
SIR-spheres 
Prospective, 
non-
comparative 
Unresectable ICC. ECOG 
0-2. 
Method of enrolment not reported. 
Follow-up time was to endpoint (death). 
Includes chemotherapy naive patients. 
52% 57 
28% or 32% 
(discrepanc
y in paper) 
48% 
40% resection; 8% 
ablation; 8% TACE 
NR 
Ibrahim et al. 
(2008) 
24 USA (NR) TheraSphere 
Prospective, 
non-
comparative 
Unresectable ICC. ECOG 
0-2. 
Method of enrolment not reported. 
Includes chemotherapy naive patients. 
67% 
68media
n 
71% 33% NR 
38%: 2 sessions 
25%: ≥3 
sessions  
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Table 4.11. Survival and response statistics from non-comparative studies of SIRT in intrahepatic cholangiocarcinoma 
Author & year n 
Median OS 
(months; 95% CI) 
Median 
follow-up 
(months) 
Median L  PFS 
(months; 95% 
CIs) 
Median 
PFS 
(months; 
95% CIs) 
Survival Tumour response (RESIST criteria) 
6 months 12 months 24 months 36 months CR PR SD PD 
Beuzit et al. 
(2016) 
45 19.0 (8.6-29.3) NR NR NR NR NR NR NR 
0% (best 
response) 
13% (best 
response) 
71% (best 
response) 
16% (best 
response) 
Jia et al. (2016) 24 9.0 (5.6-12.4) 
11.3 
(mean; 
range 3-
36) 
NR NR 70% 33% 20% 
20% (30 
months) 
0% (3 months) 36% (3 months) 46% (3 months) 18% (3 months) 
Mosconi et al. 
(2016) 
23 17.9 (14.3-21.4) 
16 (range 
2-52) 
NR NR NR 68% 21% NR 
0% (3 months) 
5% (mRECIST) 
15% (3 months) 
40% (mRECIST) 
30% (3 months) 
15% (mRECIST) 
55% (3 months) 
40% (mRECIST) 
Soydal et al. 
(2016) 
 
16 
9.6  ±2.3 (5.1-
14.2) 
8.0 (3.2-
27.6 
NR NR NR NR NR NR NR NR NR NR 
Filippi et al. 
(2015) 
17 
Mean OS 64.5 
weeks (54.7-74.4) 
NR 
 
NR NR NR NR NR NR 0 82% 18% 0 
Camacho et al. 
(2014) 
21 16.3 (7.2-25.4) NR NR NR NR NR NR NR 
0% ( 1 month 
for n=21)                        
0% (3 month 
for n=16) 
5% ( 1 month 
for n=21)                        
0% (3 month 
for n=16) 
57% ( 1 month 
for n=21)                        
63% (3 month 
for n=16) 
38% ( 1 month 
for n=21)                        
38% (3 month 
for n=16) 
Rafi et al. 
(2013) 
 
19 
11.5 (3.2-19.8) as 
stated in main 
text 
15 NR NR 67% 56% 
17% (18 
months) 
NR 
0% (at 3 
months) 
11% (at 3 
months) 
68% (at 3 
months) 
21% (at 3 
months) 
Hoffman et al. 
(2012) 
33 22 (7.9–29.4) 
10 (range 
3.1-44) 
NR NR NR NR NR NR 0% (at 3 
months) 
36% (at 3 
months) 
52% (at 3 
months) 
15% (at 3 
months) 
Saxena et al. 
(2010) 
 
25 9.3 (NR) 
8.1 (range 
0.4-56) 
NR NR 56% 40% 27% 13% 0 24% 48% 20% 
Ibrahim et al. 
(2008) 
24 14.9 (NR) 17.7 NR NR NR NR NR NR 0% (WHO 
criteria; n=22) 
27% (WHO 
criteria; n=22) 
68% (WHO 
criteria; n=22) 
5% (WHO 
criteria; n=22) 
CI, confidence intervals; CR, complete response; EHM, extrahepatic metastases; ICC, intrahepatic cholangiocarcinoma; NR, Not reported; OS, overall survival; PD: progressed disease; PR, 
partial response; RESIST, Response Evaluation Criteria in Solid Tumors; QA, quality appraisal; SD, stable disease; SIRT, selective internal radiation therapy; TAE, trans arterial embolisation; Y-
90, yttrium-90. 
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4.6 Discussion 
4.6.1 Colorectal cancer population 
Three comparative studies of SIRT in patients with unresectable, chemotherapy refractory CRCLM 
were identified in our literature search. Two retrospective studies compared SIRT to standard 
therapy (6.6 vs 11.9 months; 3.5 vs 8.3 months) and found statistically significant improvements in 
OS. In the case of Seidenticker et al. BSC patients were matched retrospectively on several matching 
criteria, and the authors report similar baseline characteristics. Like most retrospective studies, the 
results are subject to outcome measurement variability and poorer quality retrospective data 
collection methods. The date from which OS is calculated may not be comparable between groups 
and may result in bias in favour of the standard care arm. Bester et al. (2012) retrospectively 
compared survival outcomes in patients treated with SIRT with those from patients who were 
ineligible for SIRT. Whilst the authors of both studies made efforts to select a comparison group 
which did not have more advanced disease and was well matched to the SIRT group, retrospective 
and non-randomised studies such as Bester et al. and Seidensticker et al. are at risk of bias if 
important prognostic factors are inadequately matched between groups. Poor standardisation and 
definitions of BSC and standard care in comparative studies also limits interpretation and 
generalisability of their results. Zafar and colleagues (2008) point out that BSC is often at the 
discretion of the treating investigator.  
The results of this systematic review on the efficacy of SIRT as a treatment for unresectable, 
chemotherapy-refractory CRCLM are in line with other recently published reviews. Median OS, the 
primary outcome of this review, in 23 included studies ranged from 6.0 to 12.7 months. A total of 
2,517 patients were included, most of whom had unresectable, liver-dominant CRCLM. We excluded 
studies where a substantial proportion of the patients were chemotherapy naive.   
A recent systematic review by Zacharias and colleagues (2015) reported a pooled OS of 10.7 months 
in unresectable CRCLM (in patients who had failed at least one previous line of chemotherapy). 
Saxena et al. (2014) reported a pooled median overall of 12 months across 11 studies. Whilst the 
patient population was described as unresectable, chemotherapy-refractory CRCLM, the authors 
included studies in which the number of previous lines of chemotherapy was not reported which 
may account for a higher OS estimate. Finally, Rosenbaum et al. (2013) reported a range of OS from 
8.3 to 15.2 months in patients with unresectable, chemotherapy refractory CRCLM who received 
SIRT as monotherapy, and a range of 10.0-29.4 months in patients who received SIRT in combination 
with chemotherapy. This current review provides a useful update on the three previous reviews 
(searches in 2012 and 2013) because it captures several large studies published recently, including 6 
studies with at least 100 patients. In addition, we have excluded small studies (n<30) and studies 
where previous chemotherapy is not reported. As such, we have produced a reliable review, noting 
the study design limitations, that includes the most recent evidence of SIRT for unresectable, 
chemotherapy refractory CRCLM.  
We provided additional analyses in this review focusing on studies where OS results were presented 
for patients who had received at least two previous lines of chemotherapy. Weighted mean of 
median OS was 9.1 months (n=1258) in this group. Rosenbaum et al. points out that knowledge of 
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previous systemic treatments are important and encourage better reporting of this. The author 
states:  “on one hand, heavily pretreated patients generally have more advanced disease and will 
possibly benefit less from [SIRT]. On the other hand, patients who have not yet received all standard 
available systemic treatment regimens may do so after [SIRT], thereby obscuring [its] survival 
benefit”. 
Improved HRQoL is often described as a potential benefit of SIRT. NICE’s Interventional Procedures 
Guidance (IPG401) calls for more evidence on the impact of SIRT on HRQoL as well as OS. Only one 
study identified for this review used QoL as a secondary outcome measure (Cosimelli et al. 2010). 
The results of these assessments were poorly reported; a reduction in anxiety levels following SIRT 
was the only adequately described outcome. Two RCTs, Gray et al (2001) and Van Hazel et al. (2004) 
report quality of life as an outcome. These studies were excluded from this review because they 
included only chemotherapy-naive patients and therefore were not relevant to the CtE project.  
This report is limited by a paucity of high quality comparative evidence. It relies in large part on 
single arm observational studies, the majority of which are retrospective. Such studies do provide 
important information on the safety and technical success of SIRT. This new review incorporates 
large datasets spanning many years from established SIRT groups in the US (Hickey et al. 
2015;Kennedy et al. 2015) and Australia (Saxena et al. 2015), demonstrating widespread acceptance 
amongst specialists. However, the absence of a control group limits interpretation on the efficacy of 
SIRT in unresectable, chemotherapy refractory CRCLM. Heterogeneity across the studies in patient 
characteristics is also an issue.  
Choice of primary outcome is key to producing evidence which is relevant to patients and 
commissioners. Some studies choose to report outcomes which rely on response assessment such as 
PFS, instead of OS. Tumour response as defined by RECIST criteria (Eisenhauer et al. 2009) is useful 
as a consistent measure for what happens to a tumour during therapy (Booth and Eisenhauer 2012). 
However, PFS may not correspond to a measurable improvement in survival or quality of life, which 
are arguably the most meaningful outcomes to patients. A recent standards document provided a 
useful guide to consistent outcome measurement and reporting in studies of SIRT, to enable better 
comparison and interpretation of results (Salem et al. 2011).  
4.6.2 Intrahepatic cholangiocarcinoma population 
There is a lack of high quality evidence evaluating the efficacy of SIRT for unresectable ICC; no 
comparative studies were identified for this review. This review includes studies included in two 
previous systematic reviews (Al-Adra 2015; Boehm 2015) as well as more recently published studies. 
Median OS, the primary outcome of this review, across 9 studies was used to calculate a weighted 
mean of median OS of 15.3 months (range: 9.0-22 months) from a total of 230 patients ; this is 
similar to that published in the other reviews [15.5 months from Al-Adra et al., 2015 and 13.9 
months from Boehm et al., 2015].  It should be noted that there is heterogeneity between studies 
included in this review and therefore caution should be exhibited in using this value.  
NICE’s interventional procedure guidance (IPG459) calls for more evidence on the effect of SIRT on 
QoL in ICC patients. However, no studies were identified for this review which reported QoL as an 
outcome.  
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5 Literature review: survival estimates in patients with CRC and 
ICC treated with best supportive care 
5.1 Summary 
A rapid review was conducted to identify studies which report survival estimates from patients 
treated with BSC to provide context to non-comparative SIRT data. 
Colorectal cancer: Seven randomised controlled trials were identified where BSC was the control 
treatment (1156 BSC patients). BSC tended to be poorly defined and varied by institution; usually 
BSC aims to provide palliative treatment without using investigational cancer therapies. Median OS 
across seven studies ranged from 2.4 months to 6.6 months (weighted mean 5.3 months). Median 
PFS ranged from 1 month to 7.3 months across five studies (weighted mean 3.2 months).  
Intrahepatic cholangiocarcinoma: No studies were identified which reported overall survival in 
patients with chemotherapy-refractory ICC who received BSC. In the absence of relevant studies, a 
further non-systematic and directed search was conducted to identify useful information on survival. 
Extrapolated results indicated that patients with ICC following first-line progression survive 
approximately 4 months. A review of second line chemotherapy regimens in ICC patients reported 
an OS of 7.2 months.  
Direct comparisons of SIRT data (from observational studies and the CtE study) with BSC data from 
higher quality RCTs are not appropriate and should interpreted with extreme caution. Differences in 
patient selection criteria, data collection methodologies, and outcome measurements are likely to 
produce differences in results between RCTs and observational studies. 
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5.2 Introduction 
This section describes a literature review conducted to identify studies which report the survival of 
patients who have received best supportive care. This approach to gathering survival data from BSC-
treated patients was chosen to provide context (not a direct comparison) in the CtE evaluation to 
the non-comparative data captured on the SIRT registry and to results from published non-
comparative studies on SIRT. It is in recognition of the paucity of published comparative evidence on 
SIRT in both the CRC and ICC populations, and an absence of a comparator in the SIRT CtE registry. 
The patient populations have been chosen to reflect the eligibility criteria used to select patients to 
receive SIRT under the CtE arrangements.  
5.2.1 Aim of rapid review 
This rapid review was designed to identify studies which report median OS or median PFS in patients 
receiving BSC for chemotherapy refractory mCRC or ICC. Initial searches indicated that single arm 
studies on the effectiveness of BSC in this patient group are rare. As such a strategy was designed to 
encompass high quality comparative studies in which BSC was the control arm.   
5.3 Methodology 
A strategy was developed in Ovid Medline (Appendix 3) and was adapted to the following databases: 
Medline In-Process; Embase; Cochrane Library (components: CDSR, DARE, CENTRAL, NHS EED); 
EconLit; Scopus; Pubmed (epub ahead of press search only). Searches were performed in September 
2016. The searches were restricted to English language and from 2006 onwards. After de-
duplication, one reviewer (HM) selected publications that were considered relevant based on titles 
or abstracts using the inclusion and exclusion criteria presented in Table 5.1. In a second selection 
round, a different independent reviewer (JW) looked at full text articles and selected studies to be 
included in the review. 
Following study selection, comparative studies were assessed using the SURE checklist for RCT and 
other experimental studies. The following data were extracted by one reviewer (JW) from the 
selected studies: study design, intervention and control, patient characteristics including number of 
previous chemotherapy lines. Outcomes of interest were OS and PFS.  
A pooled analysis was performed on studies reporting median overall survival in patients treated 
with best supportive care in order to present a weighted mean of median overall survival figure. 
Weight was applied based on the number of participants in each study. 
Table 5.1 Inclusion and exclusion criteria 
 Include Exclude 
Population Patients with chemotherapy refractory 
CRC who have progressed following at 
least two lines of chemotherapy (or are 
resistant or intolerant to standard 
chemotherapy including fluorouracil with 
oxaliplatin and irinotecan) 
 Patients are candidates for 
resection/surgery 
 Majority of CRC participants 
have received 0 or 1 previous 
line of chemotherapy 
 Majority of ICC participants are 
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OR 
Patients with unresectable, chemotherapy 
refractory (disease progression following 
at least one previous line of 
chemotherapy) ICC. 
 
chemotherapy-naive 
Intervention (In this case the intervention of interest 
was standard care which in most studies 
identified was actually the control arm) 
 Best supportive care 
 Third line palliative chemotherapy 
 
Comparator Any  
Outcomes Only include studies which report overall 
survival or progression-free survival 
 Studies which don’t report over 
survival or progression-free 
survival 
Study selection  RCTs and prospective comparative 
studies 
 Systematic reviews 
 Prioritise UK and European studies and 
US 
 
 Non-comparative studies (CRC 
only) 
 Retrospective studies (CRC only) 
 Observational studies (CRC only) 
 Sample size <50 in BSC arm 
 Non-English language 
 Conference proceedings 
 Animal studies 
 
 
5.4 Results (CRC) 
5.4.1 Selected studies 
The systematic literature search yielded 362 potentially relevant studies (Figure 5.1) and 6 studies 
were identified from supplementary searching and input from clinical experts, 140 were retained for 
assessment of eligibility at full text. Two systematic reviews were identified and checked for 
additional primary studies not identified in our search (Hoyle et al. 2013a; Nielsen et al. 2014). Both 
systematic reviews were subsequently excluded because all primary studies were identified in this 
current review.  
Ten studies were retained for quality assessment and data extraction. Two phase II RCTs were 
excluded at this stage (Caballero-Baños et al. 2016; Jia et al. 2015) because the BSC arm had fewer 
than 50 patients, and because BSC was not defined. Two retrospective cohort studies were also 
excluded at this stage because of their inferior study design (Bester et al. 2013b; Seidensticker et al. 
2012). Both the studies compared SIRT with BSC and therefore were highly relevant to this topic. The 
results of these studies are reported in full in Section 4 of this report.  
Seven RCTs (6 phase III studies and 1 phase II study) were included in this review of best supportive 
care survival (Grothey et al. 2013; Hickish et al. 2017; Jonker et al. 2007; Li et al. 2015;Mayer, van 
Cutsem et al. 2015; van Cutsem et al. 2007; Yoshino et al. 2012; Table 5.2). These studies had a total 
of 3,271 patients of whom 1,235 were randomised to receive placebo plus BSC.  One study (Hickish 
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et al. 2017) included patients from the UK; three other studies were international and included 
patients in Europe. 
All seven RCTs studied the efficacy of an investigational medicinal product (IMP) plus BSC against 
BSC alone or with a placebo. The IMPs in the intervention arms were regorafenib (an oral multi-
kinase inhibitor), TAS-102 (an oral agent combining trifluridine and tipiracil hydrochloride), 
cetuximab,  panitumumab (both monoclonal antibodies against epidermal growth factor receptor), 
and MABp1 (an antibody which targets interleukin 1α; Table 5.2).  
In all studies, except Yoshino et al. (2012) where BSC was not defined, the control arm was BSC (with 
or without a placebo) which was described generally as best supportive care excluding 
investigational antitumour agents or antineoplastic chemotherapy, hormonal therapy or 
immunotherapy. In the case of Hickish et al. (2017), BSC also excluded immunosuppressive drugs or 
drugs that inhibit tumour necrosis factor α or interleukin 1; use of corticosteroids, megestrol, or 
stimulants, was restricted to events deemed medically necessary until the 8 week assessment was 
completed.  In the case of Van Cutsem et al. (2007) BSC was defined as “best palliative care as per 
investigator” (Table 5.2).  
The population across all seven studies included patients with chemotherapy refractory mCRC . 
Eligible patients had progressed following at least 2 previous lines of standard chemotherapy, which 
in most studies included fluoropyrimidine, irinotecan, and oxaliplatin, or were intolerant to standard 
chemotherapy. In the case of Grothey et al. (2013) and Jonker et al. (2007) a small number of 
patients had received only 1 previous line. Hepatic metastases were not an inclusion criteria in these 
studies. Only 2 studies reported the proportion of patients with hepatic metastases (58% and 67% in 
Yoshino et al. 2012; and 80% in Jonker et al. 2007). Three studies included patients with an ECOG 
performance status of 0 to1, three studies included patients with ECOG status 0 to 2, and one study 
included patients with ECOG status 1-2.  
Median length of follow-up was reported in five studies and ranged from 6.1 months to 14.6 months 
(Table 5.3). 
5.4.2 Overall survival 
OS of patients in the BSC arm reported in the seven studies (n=1,156) was 5.3 months (weighted 
mean; 95% CIs 4.7-5.8) and ranged from 2.4 months to 6.6 months (Table 5.3).  
In the study by Van Cutsem et al. (2007), 76% of patients randomised to the BSC subsequently 
crossed over the intervention arm to receive panitumumab, as such data from this trial may not 
provide a reliable estimate of survival for patients receiving only BSC. Patients randomised to receive 
BSC and placebo in Hickish et al. (2017) were also permitted to cross over, and the OS estimate in 
this group was based only on patients who did not cross over. As a result the OS estimate may be 
biased for shorter survival in the BSC group because these patients either progressed before the 8 
week assessment or they chose not to continue to the open label phase of the study.  
The pooled analysis was repeated with the Van Cutsem et al. (2007) and Hickish et al. (2017) 
omitted. The overall survival across the 5 studies was 5.2 months (range: 4.6 to 6.6 months).  
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5.4.3 Progression free survival 
PFS was reported in five studies (neither Jonker et al. or Hickish et al. reported this outcome) and 
ranged from 1 month to 7.3 months (Table 5.3). The pooled analysis of median PFS across these 
studies was 3.2 months (weighted mean [95% CIs 2.9-3.5]). Following exclusion of Van Cutsem et al. 
data (because a majority of BSC patients crossed over to the intervention arm), the median PFS 
across four studies was 1.6 months (weighted mean) and the range was 1 month to 1.7 months.  
 
 
Figure 5.1. Flow diagram of selected studies (CRC population) 
Records identified through database 
searching, duplicates & irrelevant records 
removed (n=362) plus supplementary 
searching and advice from experts (n=1) 
First screen: title/abstract (n=368) 
Second screen: assessed for eligibility at full 
text (n=140) 
Retained for quality appraisal and data 
extraction (n=11) 
Studies included in review of best 
supportive care (n=7) 
Records excluded 
(n=228) 
Full text articles 
excluded with reasons 
(n= 129) 
Studies excluded: (n=4; 
2 were too small and 
BSC not defined; 2 were 
retrospective cohorts of 
SIRT vs BSC and 
presented elsewhere) 
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Table 5.2. Study details from 7 included studies reporting survival of CRC patients receiving best supportive care 
Study n (i) 
n (c) 
(BSC) 
Country & 
study 
period 
Desig
n 
Population Intervention Control Male 
Age 
(median  
years) 
Previous 
lines of 
chemothera
py (i/c) 
QA issues & relevance to SIRT 
CtE 
Hickish et 
al. (2017) 
207 
(OS 
data 
for 
116) 
102 
(OS 
data 
for 
23) 
Internatio
nal (2014-
2015) 
RCT 
(phas
e III) 
Chemotherapy 
refractory mCRC with 
multiple symptoms 
associated with poor 
outcomes. Patients 
received ≥2 previous 
lines including IRI, 
and OXA. ECOG 1-2. 
MABp1 & BSC 
BSC* & 
placebo 
(other drugs 
also excluded 
– see text) 
62% 
(i), 
58% 
(c) 
64 (i), 63 
(c) 
2 lines: 
27%/28%; 3 
lines: 
27%/32%; ≥4 
lines: 
44%/40% 
Proportion of liver metastases 
not reported. OS and PFS not 
primary outcomes. OS available 
for only 23 patients in placebo 
group. Placebo patients were 
permitted to receive MABp1; OS 
data is only from placebo 
patients who progressed during 
first 8 weeks or elected not to 
continue. No independent 
review of imaging results. ECOG 
0 patients excluded. 
Li et al. 
(2015)  
CONCUR 
136 68 
China, HK, 
S Korea, 
Taiwan, 
Vietnam 
(2012-
2013) 
RCT 
(phas
e III) 
Chemotherapy 
refractory mCRC. 
Patients received ≥2 
previous lines 
including FP, IRI, and 
OXA. ECOG 0-1. 
Regorafenib & 
BSC 
BSC* & 
placebo 
63% 
(i), 
49% 
(c) 
58 (i), 56 
(c) 
2 lines: 
23%/21%; 3 
lines: 
24%/28%; ≥4 
lines: 
54%/51% 
Proportion of liver metastases 
not reported. No European 
patients.  No independent review 
of imaging results. ECOG 2 
patients excluded. 
Mayer et 
al. (2015) 
RECOURSE 
534 266 
Internatio
nal (2012-
2013) 
RCT 
(phas
e III) 
Chemotherapy 
refractory mCRC. 
Patients received ≥2 
regimens of standard 
chemotherapies. 
Must have received 
FP, IRI, OXA, BEV, 
(and CET or PAN if 
KRAS WT). ECOG 0-1. 
TAS-102 & BSC 
BSC* & 
placebo 
61% 
(i), 
62% 
(c) 
63 (i), 63 
(c) 
2 lines: 
18%/17%; 3 
lines: 
22%/20%; ≥4 
lines 
60%/63%. 
Proportion of liver metastases 
not reported. 42% of patients 
received additional systemic 
therapy after participation in the 
trial. ECOG 2 patients excluded. 
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Grothey et 
al. (2013) 
CORRECT 
505 225 
Internatio
nal (2010-
2011) 
RCT 
(phas
e III) 
Chemotherapy 
refractory mCRC.  
Patients had to have 
progressed on 
licensed standard 
therapies or have 
stopped due to side 
effects (including FP, 
IRI, OXA, BEV, and 
CET or PAN if KRAS 
WT). ECOG 0-1. 
Regorafenib & 
BSC 
BSC* & 
placebo 
62% 
(i), 
60% 
(c) 
61 (i), 61 
(c) 
1 line: 
3%/2%; 2 
lines: 
24%/23%; 3 
lines: 
25%/28%; ≥4 
lines: 
49%/47%. 
Proportion of liver metastases 
not reported. Small minority 
received only 1 previous line. No 
independent review of imaging 
results. Some patients received 
anti-cancer treatments after 
progression. ECOG 2 patients 
excluded. 
Yoshino et 
al. (2012) 
112 57 
Japan 
(2009-
2010) 
RCT 
(phas
e II) 
Unresectable, 
chemotherapy 
refractory mCRC. 
Previous treatment 
of ≥2 standard 
chemotherapy 
regimens and were 
refractory or 
intolerant to FP, IRI, 
and OXA. ECOG 0-2. 
TAS-102 & BSC 
BSC & 
placebo (not 
defined) 
57% 
(i), 
49% 
(c) 
63 (i) and 
62 (c) 
2 lines: 
15%/23%; ≥3 
lines: 
85%/77% 
Only 58% and 67% had liver 
metastases. Patients in both 
groups had subsequent cancer 
treatment. All patients were 
Japanese. BSC treatment not 
defined. 
Jonker et 
al. (2012) 
287 285 
Canada & 
Australia 
(2003-
2005) 
RCT 
(phas
e III) 
Chemotherapy 
refractory mCRC. 
ECGR positive. 
Disease progression 
on  FP, IRI, and OXA, 
or contraindications. 
ECOG 0-2. 
Cetuximab & 
BSC 
BSC* 
(measures to 
provide 
palliation of 
symptoms 
and improve 
QOL) 
65% 
(i), 
64% 
(c) 
63 (i) and 
64 (c) 
1 or 2 lines: 
17%/19%; 3 
lines: 
38%/38%; 4 
lines: 
30%/25%; 
≥5: 14%/18% 
80% had liver metastases and 
study included some patients 
with 1 previous line of chemo. 
Trial not blinded. No 
independent review of imaging 
results. 7% of BSC pts 
subsequently received 
cetuximab. 28% (I) and 23% (c) of 
patients received anticancer 
treatment after disease 
progression. 
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Van 
Cutsem et 
al. 
231 232 
Internatio
nal (2004-
2005) 
RCT 
(phas
e III) 
Chemotherapy 
refractory mCRC 
ECGR positive. 
Disease progression 
following last 
administration of FP, 
IRI, and OXA. ECOG 
0-2. 
Panitumumab 
& BSC 
BSC (best 
palliative 
care per 
investigator) 
63% 62 
2 lines: 
100%: 3 
lines: 37% 
76% of BSC pts crossed over to 
PAN. Proportion of pts with liver 
metastases not reported. Trial 
not blinded. 
* best supportive care excluding investigational antitumour agents or antineoplastic chemotherapy, hormonal therapy or immunotherapy 
BEV: bevacixumab; BSC: best supportive care; CI: confidence intervals; CET: cetuximab; ECOG: Eastern Cooperative Oncology Group; FP: fluoropyrimidine; HK: Hong Kong; 
IRI: irinotecan; KRAS WT: Kirsten Rat Sarcoma Viral Oncogene Homolog (Wild-type); OS: overall survival; OXA: oxaliplatin; PFS: progression free survival; PAN: 
pantiumumab; RCT: randomised controlled trial; TAS-102: a combination agent combining trifluridine and tipiracil hydrochloride.  
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Table 5.3. Survival statistics from included studies (CRC population) 
Study Year n (i) n (c) 
Median 
follow-
up 
(months) 
Median OS 
intervention 
arm (95% CIs) 
Median OS 
in BSC arm 
(95% CIs) 
Difference in OS 
between groups 
Median PFS 
intervention 
arm (95% 
CIs) 
Median PFS 
control arm 
(95% CIs) 
Difference in PFS 
between groups 
AEs 
reported 
QoL 
reported 
Hickish et al.  2017 
207 
(OS 
116) 
102 (OS 
23) 
6.1 
6.1 (IQR 4.4-
7.2) n=116 
2.4 (1.9-3.2)
 1
 
n=23 
Log rank p=0.0002 NR NR NR Y Y 
Li et al.  
(CONCUR) 
2015 136 68 7.4 8.8 (7.3-9.8) 6.3 (4.8-7.6) 
HR 0.55 (95% CI 
0.40-0.77; 
p=0.00016) 
3.2 (2.0-3.7) 1.7 (1.6-1.8) 
HR 0.31 (95% CI 
0.22-0.44; 
p<0.0001) 
Y Y 
Mayer et al.  
(RECOURSE) 
2015 534 266 11.8 7.1 (6.5-7.8) 5.3 (4.6-6.0) 
HR 0.68 (95% CI 
0.58-0.81; 
p<0.001) 
2.0 (1.9-2.1) 1.7 (1.7-1.8) 
HR 0.48 (95% CI 
0.41-0.57; p<0.001) 
Y N 
Grothey et al.  
(CORRECT) 
2013 505 225 NR 
6.4 (IQR 3.6-
11.8) 
5.0 (IQR 2.8-
10.4) 
HR 0.77 (95% CI 
0.64-0.97; 
p=0.0052) 
1.9 (IQR 1.6-
3.9) 
1.7 (IQR 1.4-
1.9) 
HR 0.49 (95% CI 
0.42-0.58; 
p<0.0001) 
Y Y 
Yoshino et al.  2012 112 57 11.3 9.0 (7.3-11.3) 6.6 (4.9-8.0) 
HR 0.56 (95% CI 
0.39-0.81) 
2.0 (1.9-2.8) 1.0 (1.0-1.0) 
HR 0.41 (95% CI 
0.28-0.59; 
p<0.0001) 
Y N 
Jonker et al.  2007 287 285 14.6 6.1m (NR) 4.6 (NR) 
HR: 0.77 (95% 
0.64-0.92; 
p=0.005) 
NR NR 
HR 0.68 (95% CI 
0.65-0.95; p=0.01) 
Y Y 
Van Cutsem 
et al.  
2007 231 232 8.1 
6.3 (from 
193d (NR)) 
6.0 (from 
184d (NR)) 
HR 1.00 (95% CI 
0.82-1.22; p=0.81) 
8 (7.9-8.4) 7.3 (7.1-7.7) 
HR 0.54 (95% CI 
0.44-0.66; 
p<0.0001) 
Y Y
2
 
AEs: adverse events: CI: confidence intervals; HR: hazard ratio; IQR: interquartile range; NR: not reported; OS: overall survival; PFS: progression free survival; QoL: quality of 
life. 
                                                          
1
 Placebo patients were permitted to cross-over to receive MABp1. Only placebo patients who did not cross-over were included in the survival analysis. These are patients 
that either progressed prior to the 8 week assessment or elected not to continue to the open label phase of the trial. The authors point out that there is a high risk of bias 
in the survival estimated of the placebo group for this reason. 
2
 Quality of life outcomes reported in Odom et al (2011) and Siena (2007) 
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5.5 Results (ICC) 
The systematic literature search yielded 753 potentially relevant studies.  None of the identified 
studies met the inclusion criteria (Table 5.1).  
5.5.1 Additional literature 
Given the absence of studies on chemotherapy-refractory ICC patients receiving best supportive 
care, a directed search of reviews which report the efficacy of second-line therapies in ICC patients 
was conducted to capture any useful information which may be presented in the discussion about 
the expected length of survival in patients receiving BSC.  
A systematic review of second-line chemotherapy in advanced ICC was conducted by Lamarca et al. 
(2014a). No comparative studies were identified and no studies of best supportive care were 
included. Twenty-five studies were included with a total of 761 patients. The mean OS was 7.2 
months (95% CIs 6.2-8.2) and PFS was 3.2 months (95% CIs 2.7-3.7).  
The authors of this review did not present any definitive data on OS in patients who receive BSC 
following progression on first line chemotherapy. However the authors extrapolated the results from 
an important trial of first-line chemotherapy to estimate the survival of patients following 
progression after which best supportive care was administered. Lamarca et al. (2014) estimated a 4 
month duration of overall survival in patients treated with BSC who have progressed following first-
line chemotherapy. This estimate should be interpreted cautiously as it has been secondarily 
extrapolated.    
Bridgewater et al. (2014) presented guidelines for the management of ICC. Their recommendation is 
that there is no significant evidence that further chemotherapy beyond progression of first-line 
chemotherapy improves survival. The authors report overall survival from two phase II non-
comparative studies of second-line chemotherapy: 4.1 months (Oh et al. 2011) and 6.7 months (Lee 
et al. 2009).   
A phase III randomised controlled trial comparing FOLFOX to active symptom control (ASC) is 
currently underway (ABC-06 trial; Lamarca et al. 2014b) which will provide valuable information on 
both the overall survival of patients receiving ACS and any survival benefit from second line 
chemotherapy. The sample size for ABC-06 trial is based on an improvement from 4 months in the 
ASC arm to 6.3 months in the FOLFOX arm.   
5.6 Discussion 
5.6.1 Colorectal cancer population 
The results of this rapid review on the length of survival in advanced, chemotherapy refractory 
mCRC patients receiving BSC demonstrate fairly consistent results across seven high quality RCTs. 
Patients in the control arm of interventional clinical trials in the salvage setting receiving BSC (with or 
without a placebo) had a median overall survival of between 2.4 months and 6.6 months.  The low 
OS estimate of 2.4 months observed in Hickish et al. (2017) is likely to be a reflection of the inclusion 
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criteria which aimed to recruit patients showing multiple symptoms associated with poor outcomes 
including an ECOG performance status of 1 or 2. In addition, the OS estimate may be biased to 
shorter survival because this was a subgroup who had progressed or chose not to cross-over to the 
intervention arm. Conversely, Van Cutsem et al. (2007) included patients who had crossed over in 
the OS estimate which may bias the result in favour of longer survival in BSC patients. Following 
exclusion of these studies the median OS remained at 5.3 months (range 4.6 to 6.6 months).  
Patients participating in the six studies included in this review were similar to those in the CtE 
population in that they had failed at least 2 previous lines of standard chemotherapy as treatment 
for mCRC. The ECOG performance status for the SIRT CtE cohort was 0-2; the 7 studies presented in 
this review also include patients captured in this range. Three studies include patients within the 
ECOG range of 0-2, three studies have an ECOG range of 0-1, and one has a range of 1-2. However, 
one important difference is that the presence of unresectable liver metastases was not an inclusion 
criterion for the BSC studies. Only two studies reported the proportion of liver metastases. The 
impact of this difference in the patient populations is uncertain.  
The results from this review may provide context to survival estimates from studies of SIRT used in 
the salvage setting, most of which are non-comparative. The SIRT CtE registry results also lacks 
comparative data. Direct comparison of results from single arm SIRT studies or the SIRT registry to 
survival estimates for BSC reported here is not appropriate. Survival and progression outcomes from 
patients who received BSC as part of tightly controlled clinical trials should be interpreted cautiously 
in the context of data gathered from patients who received SIRT as part of the CtE project (which 
was set up as a service evaluation) and in the context of lower quality observational studies. It is 
risky to compare data from studies which are substantially different in terms of study design, 
eligibility criteria, patient selection, geographical and temporal setting, outcome assessments, and 
length of follow-up.  
BSC is often poorly defined in clinical trials (Zafar et al. 2008); it varies across trials and in many cases 
is at the discretion of the investigator. Commonly the intention of BSC in trials is to provide palliative 
care for symptom control whilst excluding the use of antineoplastic agents. Variation in the 
definition of BSC and how it is administered is likely to be present in the studies included in this 
review. Furthermore, BSC from these studies may differ from the care typically provided to such 
patients  in the UK which limits the generalisability of these results to the NHS setting.  
5.6.2 Intrahepatic cholangiocarcinoma population 
The results of this review demonstrated the paucity of evidence on the efficacy of second line 
treatments for ICC, including best supportive care or active symptom control. No studies have 
directly studied the survival of patients receiving BSC. Authors of one review have estimated overall 
survival in BSC patients as 4 months. Such an estimate from a secondary extrapolation of trial data 
should be viewed very cautiously.  
For patients who receive second line chemotherapy, overall survival is reported as 7.2 months in a 
recent review. However, these patients may well be selected for continuing treatment due to their 
better performance status and prognosis. Their comparability to the SIRT CtE cohort is unclear and 
should be interpreted very cautiously.   
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6 Review of ongoing or recently completed clinical trials 
6.1 Summary  
Nine ongoing or recently completed and unpublished studies were identified which were relevant to 
the SIRT CtE evaluation. Of these, 7 were RCTs and 2 were registries. No studies were identified 
which matched the CtE population in patients with CRC or ICC.  
The generalisability of the identified RCTs to the SIRT CtE project will be limited because of the 
difference in population and study design.  
Results have recently been published in abstract form from the SIRFLOX, FOXFIRE, and FOXFIRE-
Global RCTs. These trials assessed whether the addition of SIRT to radiosensitising chemotherapy in 
chemotherapy-naive patients conferred additional benefits in the first-line setting. No improvement 
in OS, PFS, or HRQoL was observed, but the SIRT group showed significantly improved LPFS and 
response rates. Patients treated with SIRT in combination with chemotherapy experienced more 
severe adverse events than patients treated with chemotherapy alone. Generalisability of these 
results in generally chemotherapy-sensitive patients to the CtE decision problem is limited since the 
CtE population is chemotherapy-refractory or chemotherapy-intolerant.     
The two registry studies were CIRT and RESIN. CIRT is sponsored by the Cardiovascular and 
Interventional Radiological Society of Europe (CIRSE) and collects data, including QoL (using a 
disease-specific tool), on patients receiving SIRT for liver tumours of any primary origin. RESIN is a 
US-based registry with tumour response as the primary outcome. 
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6.2 Introduction 
The purpose of this section is to collate information about ongoing (or recently completed) studies 
which are potentially relevant to the evaluation of the SIRT CtE evaluation but which have not been 
published. Studies with populations different to that of CtE have been included as these provide 
useful context to the evidence directly relevant to CtE.   
6.3 Search method 
Three publically accessible clinical trial registries were searched (Table 6.1). Studies on patients with 
CRCLM or ICC treated with SIRT, and with outcomes relating to the efficacy of SIRT were considered 
relevant. The review focused on comparative studies or those with a registry design.  
Table 6.1. Clinical trial registries searched 
 
ClinicalTrials.gov ISRCTN 
WHO International Clinical 
Trials Registry Platform 
Search 
date 
1st Feb 2016 and updated 
on 19th January 2017 
28th April 2016 and updated 
on 19th January 2017 
28th April 2016 and updated 
on 19th January 2017 
Search 
terms 
Yttrium OR Therasphere OR 
SIR-spheres OR Selective 
internal radiotherapy OR  
Selective internal radiation 
therapy 
Yttrium OR Therasphere OR 
SIR-spheres OR Selective 
internal radiotherapy OR  
Selective internal radiation 
therapy 
 
In title: Yttrium OR 
Therasphere OR SIR-
spheres OR  Selective 
internal radiotherapy OR 
Selective internal radiation 
therapy; Condition: cancer. 
Studies 
retrieved 
261 clinical trial entries, or 
which 42 were potentially 
relevant 
One additional relevant 
trial 
83 clinical trial entries, of 
which 4 were potentially 
relevant 
 
 
6.4 Results 
6.4.1 Relevant ongoing or recently published clinical trials 
Published clinical trials were excluded from the list of relevant studies as these were captured during 
the systematic review of SIRT efficacy in Section 4. Nine relevant ongoing/unpublished clinical trials 
were identified (Table 6.2). 
The 9 relevant studies were comprised of 7 RCTs and 2 prospective, observational registry studies. 
The registry studies were non-comparative but were considered important because of similarities in 
methodology and study design to the SIRT CtE project.  
The remaining 11 studies were considered not to be of high relevance because they were non-
comparative, or had been withdrawn prior to recruitment. These are presented in Appendix 4. 
SIRFLOX 
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Full title: FOLFOX Plus SIR-SPHERES MICROSPHERES Versus FOLFOX Alone in Patients With Liver Mets 
From Primary Colorectal Cancer (NCT00724503) 
The SIRFLOX trial has been completed and published by van Hazel and colleagues (2016) (Van Hazel 
et al. 2004), see summary below. This publication does not report OS. This trial has been included 
here because its data will contribute to the FOXFIRE-global pooled analysis of overall survival.  
SIRFLOX was an international, multi-centre, open-label, RCT in chemotherapy-naïve pts with non-
resectable, liver only or liver dominant mCRC (Gibbs et al. 2014). The trial compared standard 
chemotherapy (mFOLFOX6: 5-fluorouracil, leucovorin and oxaliplatin) plus SIRT (SIR-spheres) to 
chemotherapy alone (bevacizumab was allowed at the discretion of the treating investigator). The 
primary outcome was progression free survival (PFS). Secondary outcomes included PFS in the liver, 
overall survival (OS), tumour response rate (liver and any site), health-related quality of life (HRQoL); 
toxicity and safety; and liver resection rate.  
The trial was sponsored by Sirtex Medical (the manufacturer of SIR-spheres) and was conducted in 
sites in USA, Europe, Australia, New Zealand and the Middle East. No UK sites were involved in this 
trial. A total of 530 patients were recruited to the study. 
FOXFIRE (UK Only) 
Full title:  An open-label randomised phase III trial of 5-Fluorouracil, OXaliplatin and Folinic acid +/- 
Interventional Radio-Embolisation as first line treatment for patients with unresectable liver-only or 
liver-predominant metastatic colorectal cancer (ISRCTN83867919) 
FOXFIRE is a UK-based, multi-centre, open-label, RCT in patients with non-resectable, liver only or 
liver dominant mCRC who have not received chemotherapy for metastatic disease (Dutton et al. 
2014). The trial compares standard chemotherapy (OxMdG: 5-fluorouracil, oxaliplatin and folinic 
acid) with SIRT (SIR-spheres) to chemotherapy alone. OxMdG is equivalent in drug doses to FOLFOX 
but uses a different delivery regimen with regard to the sequencing of drugs. The primary outcome 
is OS. Secondary outcomes include PFS, liver-specific PFS, patient-reported outcomes, safety, 
response rate, resection rate and cost-effectiveness. Patient-reported outcomes are assessed using 
the generic EORTC Quality of Life Questionnaire (QLQ-C30) and disease specific EORTC QLQ-LMC21. 
Health economic outcomes will be based upon utilities measured by EQ-5D and collection of health 
economic data including costs of chemotherapy and SIRT, hospital visits, imaging, surgical 
procedures, and in-patient lengths of stay.The trial is sponsored by the University of Oxford and is 
funded by Cancer Research UK. A total of 26 UK sites recruited a final total of 364 patients. The 
overall trial end date is October 2016. 
FOXFIRE-Global 
Full title: FOLFOX6m Plus SIR-Spheres Microspheres vs FOLFOX6m Alone in Patients With Liver Mets 
From Primary Colorectal Cancer (FOXFIREGlobal) (NCT01721954) 
FOXFIRE-Global is an international, multi-centre, open-label, RCT in chemotherapy-naïve pts with 
non-resectable, liver only or liver dominant mCRC. The trial compares standard chemotherapy 
(mFOLFOX6) with SIRT (SIR-spheres) to chemotherapy alone (bevacizumab is allowed). The primary 
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outcome is overall survival. FOXFIRE-Global study has been designed so that it may be combined 
with the SIRFLOX and FOXFIRE studies, allowing for the pooling of the 3 study's data on safety and 
efficacy outcomes, with the combined studies powered for overall survival.  
The trial is sponsored by Sirtex Medical (the manufacturer of SIR-spheres) and was conducted in 
sites in USA, Europe, Australia, New Zealand and the Middle East. No UK sites are involved in this 
trial. Enrolment to the FOXFIRE-Global trial is complete (estimated at 200 patients).  
Pooled analysis of SIRFLOX, FOXFIRE, and FOXFIRE-global 
The planned combined analysis of overall survival from SIRFLOX, FOXFIRE, and FOXFIRE-Global (FF-
SF-FFG) was recently published as a conference abstract (Sharma et al. 2017). The analysis included 
1,103 chemotherapy-naive mCRC patients. This evaluated whether the addition of SIRT to 
radiosensitising, first-line chemotherapy patients conferred additional benefits to first-line 
chemotherapy alone. Median follow-up was 43.3 months. A full quality appraisal has not been 
possible because this has been published as a conference abstract. The full paper is currently in 
press. 
In the published conference abstract, no difference in OS (HR 1.04; 95% CIs 0.90-1.19; p=0.609) or 
PFS (HR 0.90; 95% CI 0.79-1.02; p=0.108) was observed between the groups (chemotherapy-alone 
versus chemotherapy plus SIRT). LPFS was improved in the SIRT group (HR: 0.51; 95% CIs 0.43-0.62; 
p<0.001), as was the objective response rate (p=0.001). Severe adverse events were more common 
in the SIRT group (p=0.009) and no difference in HRQoL (measured using EQ-5D) was observed 
between the arms at 6, 12, or 24 months. Unpublished overall survival results from subgroup 
analyses indicate that patients with a primary tumour originating within the right side of the bowel 
may benefit significantly more from the addition of SIRT to chemotherapy, compared to other 
patients (University of Oxford website, 2017). Generalisability of these results in generally 
chemotherapy-sensitive patients to the CtE decision problem is limited since the CtE population is 
chemotherapy-refractory or chemotherapy-intolerant. 
EPOCH  
Full title: Efficacy Evaluation of TheraSphere Following Failed First Line Chemotherapy in Metastatic 
Colorectal Cancer (NCT01483027) 
EPOCH is an international, multi-centre, open-label, RCT in patients with liver-only mCRC of the liver 
who have failed first-line chemotherapy (Karpf et al. 2014). The trial compares standard 
chemotherapy (oxaliplatin or irinotecan based) plus SIRT (TheraSphere) with chemotherapy alone. 
The primary outcome is PFS and secondary outcomes are OS, tumour response, time to symptomatic 
progression, hepatic PFS, and quality of life (assessed using the disease specific tool, FACT-C). 
The trial, which is sponsored by BTG International UK Ltd (manufacturer of TheraSphere), is being 
conducted across several countries including 6 sites in the UK. The target enrolment is 340 patients, 
and is due to complete in late 2018/early 2019.  
SIR-Step trial 
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Full title: Comparing HAI-90Y (SIR-spheres) + Chemotx LV5FU2 Versus Chemotx LV5FU2 Alone to 
Treat Colorectal Cancer (NCT01895257) 
SIR-step is a Belgian, multicentre, open-label, RCT in patients with dominant or exclusive and 
unresectable liver mCRC controlled after 3-6 months of chemotherapy induction. The trial aims to 
evaluate a maintenance strategy comparing SIRT (SIR-spheres) plus continuing simplified 
chemotherapy (LV5FU2) with/without targeted therapy  (bevacizumab or cetuximab) versus 
continuing simplified chemotherapy with/without targeted therapy alone. The primary outcome is 
time to first progression (TTP1). Secondary outcomes are time to global progression (TTP1 + TTP2), 
Time to second progression (TTP2), TTP1 liver only, PFS, OS, safety, resection rate, quality of life 
(QoL).  
The trial is sponsored by Antwerp University and is being conducted in sites in Belgium. Enrolment is 
ongoing and aim is to recruit 162 patients. The study is due to complete in December 2018. 
Selective Internal Radiotherapy (SIRT) Versus Transarterial Chemoembolisation (TACE) for the 
Treatment of Cholangiocellular Carcinoma (CCC) 
This is a pilot randomised controlled trial (NCT01798147) at a single centre in Germany in 
chemotherapy naive patients with unresectable, liver-only ICC (Kloecker et al. 2014). The trial 
compares doxorubicin drug-eluting bead trans arterial chemo-embolization (DEB-TACE) to SIRT (SIR-
spheres). The primary outcome measure is PFS. Secondary outcomes include OS and TTP. The target 
study population is 24 patients, 12 patients in each group. The trial is sponsored by Johannes 
Gutenberg University Mainz and is due to complete October 2016. The status of this trial is unknown 
as details on ClinicalTrials.gov have not been updated in at least 2 years.  
CIRT registry  
The CIRT registry (NCT02305459) was started in 2014 and is due to complete in 2019-20. The registry 
is a European-wide registry that aims to prospectively collect data on SIR-Spheres therapies. It is 
sponsored by the Cardiovascular and Interventional Radiological Society of Europe (CIRSE). The 
registry will collect data on patients receiving SIRT for liver tumours of any primary origin, and does 
not collect comparative data. It appears from the information available on the study website that 
SIRTEX medical are involved but the arrangements are not described.  
RESIN registry 
The RESIN registry (NCT02685631) was initiated in 2015 and is due to complete in 2020/21. The 
study is sponsored in the US by Vanderbilt University/Ingram Cancer. The study aims to collect data 
from 400 patients treated with Yttrium-90 SIRT; the available information does not specify a primary 
cancer type. The registry does not appear to collect data from comparator patients. The primary 
outcome measure is tumour response (modified Response Evaluation Criteria in Solid Tumors 
(mRECIST) or European Association for Study of Liver Cancer (EASL)). Secondary outcomes are 
Treatment related toxicity assessed using the National Cancer Institute Common Terminology 
Criteria for Adverse Events (CTCAE v4), overall survival, and time to progression. According to a press 
release from Vanderbilt University, the RESIN registry is a collaboration with 6 medical centres and 
SIRTEX medical.  
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SIRCCA study 
Full title: SIRT Followed by CIS-GEM Chemotherapy Versus CIS-GEM Chemotherapy Alone as 1st Line 
Treatment of Patients With Unresectable Intrahepatic Cholangiocarcinoma (NCT02807181) 
SIRCCA is an international, multi-centre, open-label RCT in patients with unresectable ICC. The trial 
compares the effect of SIRT prior to chemotherapy (cispaltin-gemcitabine) with chemotherapy 
alone. The primary outcome is survival at 18 months following randomisation. Secondary outcomes 
include liver-specific PFS, PFS, response rate, overall survival, surgery and resection rate, AEs and 
safety.  The trial aims to recruit 180 patients. The trial is sponsored by Sirtex Medical. 
6.5 Relevance of identified studies to the SIRT CtE project 
No studies were identified which match the CtE population in the third-line colorectal cancer 
population.  
The populations in FOXFIRE, SIRFLOX, and FOXFIRE-Global are chemotherapy-naive and SIRT is being 
added to first-line therapy. The applicability of the FF-SF-FFG combined analysis to the CtE 
evaluation is limited due to differences in the eligibility criteria. The FF-SF-FFG analysis was 
evaluating whether SIRT provided an additional benefit to chemotherapy.  Generalisability of these 
results in generally chemotherapy-sensitive patients to the CtE decision problem is limited since the 
CtE population is chemotherapy-refractory or chemotherapy-intolerant. Since cross-over in 
subsequent lines of therapy cannot be controlled in a first-line study, a survival advantage may be 
difficult to detect in a controlled prospective study with this design.    
In EPOCH, SIRT is used as a second-line treatment, and in SIR-step patients have not progressed 
following their first-line of chemotherapy. The generalisability of the results from the RCTs to the 
SIRT CtE project is limited because of the difference in population. In addition, these clinical trials 
will recruit a more homogenous population compared to the SIRT CtE project, and the treatment 
and observations will be more “protocolised” which may impact on the results.  
The SIRCCA study is of interest, but appears to use SIRT in chemo-naive patients (prior to 
chemotherapy) and therefore is of limited relevance to the SIRT CtE project.  
The CIRT registry may contain data from UK sites. Of particular interest is measurement of quality of 
life using disease-specific quality of life tools. 
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Table 4.2. Clinical trials relevant to the evaluation of SIRT CtE study 
Identifier Title Acronym Status 
Enrolm
ent 
Design 
Start 
date 
Estimated 
completion 
date 
Primary 
Completion 
Date 
Outcome 
measures 
Popula
tion 
Relevance Location 
NCT00724
503 
FOLFOX Plus SIR-SPHERES MICROSPHERES 
Versus FOLFOX Alone in Patients With Liver 
Mets From Primary Colorectal Cancer (Gibbs 
et al. 2014) 
SIRFLOX 
Part-
published 
518 RCT 2006 2018 2017 PFS CRC 
Different population 
(chemo naive) 
Internati
onal 
ISRCTN838
67919 
FOXFIRE: an open-label randomised phase III 
trial of 5-Fluorouracil, OXaliplatin and Folinic 
acid +/- Interventional Radio-Embolisation as 
first line treatment for patients with 
unresectable liver-only or liver-predominant 
metastatic colorectal cancer (Dutton et al. 
2014) 
FOXFIRE 
(UK only) 
Part-
published 
364 
(final) 
RCT 2008 2016 2016 
OS, PFS, safety 
and toxicity, 
costs, QoL, 
response rate, 
resection rate 
CRC 
Different population 
(chemo naive) 
UK 
NCT01798
147 
Selective Internal Radiotherapy (SIRT) Versus 
Transarterial Chemoembolisation (TACE) for 
the Treatment of Cholangiocellular Carcinoma 
(CCC) (Kloeckner et al. 2014) 
 
Status 
unknown 
24 RCT 2011 2016 2016 PFS, OS, TTP ICC 
Different population 
(chemo naive) 
German
y 
NCT01483
027 
Efficacy Evaluation of TheraSphere Following 
Failed First Line Chemotherapy in Metastatic 
Colorectal Cancer (Karpf 2015) 
EPOCH Recruiting 340 RCT 2012 2019 2018 PFS CRC 
Different population 
(2nd line) 
Internati
onal 
(incl UK) 
NCT01721
954 
FOLFOX6m Plus SIR-Spheres Microspheres vs 
FOLFOX6m Alone in Patients With Liver Mets 
From Primary Colorectal Cancer 
FOXFIRE
Global 
Part-
published 
200 RCT 2013 2019 2017 POS, PFS CRC 
Different population 
(chemo naive) 
Internati
onal 
NCT01895
257 
Comparing HAI-90Y (SIR-spheres)+Chemotx 
LV5FU2 Versus Chemotx LV5FU2 Alone to 
Treat Colorectal Cancer 
SIR-Step 
trial 
Recruiting 162 RCT 2013 2018 2017 
TTP, PFS, safety, 
resection rate, 
QoL, OS 
CRC 
Different population 
(mCRC controlled after 
3-6m chemotherapy) 
Belgium 
NCT02305
459 
CIRSE Registry for SIR-Spheres Therapy CIRT Recruiting 1200 
Prospective 
observational 
2014 2020 2019 QoL CRC Alternative registry Austria 
NCT02685
631 
Yttrium Y 90 Resin Microspheres Data 
Collection in Unresectable Liver Cancer: the 
RESIN Registry 
RESIN Recruiting 400 
Prospective 
observational 
2015 2021 2020 
Response rate, 
toxicity, OS, TTP 
Mixed Alternative registry USA 
NCT02807
181 
SIRT Followed by CIS-GEM Chemotherapy 
Versus CIS-GEM Chemotherapy Alone as 1st 
Line Treatment of Patients With Unresectable 
Intrahepatic Cholangiocarcinoma 
SIRCCA 
Not yet 
open for 
recruitmen
t 
180 RCT 2016 2019 2019 
Survival at 18m, 
PFS, response 
rate, OS 
ICC Yes (unresectable ICC) 
Internati
onal 
(incl UK) 
CRC, colorectal cancer; ICC, intrahepatic cholangiocarcinoma; mCRC, metastatic colorectal cancer; OS, overall survival; PFS, progression free survival; QoL, quality of life; 
RCT, randomised controlled trial; TTP, time to progression 
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7 Evaluation of SIRT CtE registry study 
7.1 Summary  
Methods: The SIRT CtE registry study was a single-arm, observational, service evaluation study to 
evaluate SIRT in ten NHS centres in England. Patients who met the inclusion criteria were eligible to 
receive SIRT as part of the CtE scheme and were treated between December 2013 and March 2017. 
Data were collected prospectively onto a registry and were extracted for analysis in early March 
2017. Patients treated most recently had very short follow-up periods. The median time to follow-up 
was 14.3 months. Overall survival was the primary outcome. Patients who did not have a date of 
death were censored at the latest point they were known to be alive, and patients missing this 
information were excluded from the analysis. Secondary outcomes were PFS, LPFS, HRQoL, 
procedural complications, and adverse events during follow-up. The two populations were adults 
with: i) unresectable, chemotherapy-refractory CRCLM; ii) unresectable, chemotherapy-refractory 
primary ICC.  
Results: A total of 399 patients with CRC and 61 with ICC were included in the analysis. Most of 
these patients had an ECOG performance status of 0 or 1. In the CRC group, most patients did not 
show evidence of extrahepatic metastatic disease and had received two previous lines of 
chemotherapy. Most ICC patients had received 1 or 2 lines of chemotherapy prior to SIRT. In both 
cohorts most patients had a single SIRT procedure of palliative intent. Patients required 
hospitalisation for 1 or 2 nights for their SIRT procedure; a minority of patients received concomitant 
chemotherapy (35% in CRC cohort; 12% in ICC cohort) with SIRT. Some patients also received 
chemotherapy following SIRT. 
Survival statistics were as follows: 
Outcome (median in months) 
CRC cohort 
(95% CIs) 
ICC cohort 
(95% CIs) 
OS from first SIRT procedure to death 
7.6 (6.9-8.3) 
(240 events) 
8.7 (5.3-12.1) 
(33 events) 
PFS from first SIRT procedure to earliest date of 
hepatic or extrahepatic disease progression (or death) 
3.0 (2.8-3.12) 
(331 events) 
2.8 (2.6-3.1) 
(47 events) 
LPFS survival from first SIRT procedure to earliest date 
of hepatic disease progression (or death) 
3.7 (3.2-4.3) 
(300 events) 
3.1 (1.3-4.8) 
(46 events) 
 
In subgroup analyses of the CRC group, patients with no extrahepatic disease showed a statistically 
significant longer overall survival compared with those with extrahepatic metastases; patients with 
fewer liver tumours survived longer than patients with more liver tumours; patients with smaller 
tumour to liver volume percentages also survived longer; and males had a longer OS than females.  
HRQoL measured using EQ-5D-5L and EQ-VAS remained relatively high and constant between 
baseline and follow-up time points (between 0.80 and 0.85 of a maximum of 1) in the CRC group. A 
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statistically significant reduction in HRQoL was observed from baseline to 3-months after SIRT but 
this was small (0.042 point change on a scale of approximately 0-1) and did not reach a minimally 
important difference threshold. Measurement time points and methodology were variable across 
sites with high levels of missing data; robust conclusions regarding the impact of SIRT on patients’ 
quality of life cannot be drawn.  
Severe complications on the day of treatment were reported in 11 CRC patients (3%) and 1 ICC 
patient (2%). During the follow-up period 36% of CRC patients experienced an adverse event, of 
which 8% of the events were grade ≥3.  In the ICC cohort, 49% of patients experienced an adverse 
event during the follow-up period, or which 7% were grade ≥3. The most frequently reported 
adverse events were mild (grade 1-2) fatigue and abdominal pain in both cohorts. No severe cases of 
radiation induced liver disease were recorded in either cohort. The most common abnormal 
laboratory value events were raised aspartarte aminotransferase and raised alanine 
aminotransferase. In the CRC cohort, 5% of laboratory events were grade ≥3, and 4% in the ICC 
cohort.  
Discussion: Results were within the range of previously published survival estimates of OS. The CtE 
CRC cohort was comparable to that presented in a published retrospective comparative study which 
demonstrated a statistically significant survival benefit of 5 months from SIRT compared to best 
supportive care. The paucity of published evidence from ICC patients makes interpretation and 
contextualisation of the CtE data even more challenging.  
This large, pragmatic, observational design is likely to reflect real-life practice in the NHS but is 
limited by the absence of a comparator treatment. Other limitations were that data were missing for 
most variables and reported data were not externally validated. Progression was recorded only at 
scheduled clinical assessments that took place in intervals of 2 to 3 months. Estimation of PFS with 
such interval-censored data is less reliable than if the dates of progression were exact.   
In the absence of comparator data, conclusions regarding a survival benefit from SIRT cannot be 
reliably drawn. Randomised controlled trials are required to distinguish the effects of treatment 
from the influence of prognostic factors, both known and unknown.  Such studies are required to 
support the suggestion of a survival benefit from SIRT reported from this and other observational 
studies.   
Conclusions: The present study reports overall survival in chemotherapy-refractory CRC and ICC 
patients treated with SIRT.  Severe adverse events following SIRT were rare. The impact of SIRT on 
patients’ HRQoL was not informed by this study. Survival estimates align with previously published 
observational studies. Existing evidence is not reliable enough in the ICC group to make a similar 
statement. Studies with observations from patients having received a comparator treatment are 
needed to inform the debate on the clinical effectiveness of SIRT.  
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7.2 Methods 
7.2.1 Study design 
Between December 20131 and February 2017 patients were treated with SIRT for liver tumours as 
part of a prospective, observational, non-comparative, service evaluation study. This project was 
part of NHS England’s CtE program, where new treatments were commissioned in the NHS with a 
planned evaluation.  The aim was to gather clinical and cost-effectiveness data on SIRT to inform a 
commissioning decision. The project was considered to be service evaluation and did not go through 
scientific review, ethical or global governance approvals. Institutional approval for the service 
evaluation at each of the sites providing SIRT was the responsibility of the clinical team at each site. 
SIRT was considered standard care at the provider centres and patient consent was sought using the 
sites’ established processes. The SIRT procedure (including related care) and data submission 
activities were funded by NHSE through the CtE scheme. Pseudonymised data relating to patient 
characteristics, treatment planning, the SIRT procedure, safety and adverse events, imaging results, 
survival, and HRQoL were prospectively collected by the clinical teams and submitted to a pre-
existing online SIRT registry (hosted by the British Society of Interventional Radiology [BSIR]).  This 
service evaluation project did not have a centralised protocol and was not prospectively registered 
on a clinical trials database.  
All patients who received a SIRT procedure until the end of February 2017 were included in the 
analysis. Data were extracted from the registry for analysis on 5th March 2017; therefore patients 
had unequal lengths of follow-up. Patients treated in the 2 to 3 months preceding the data 
extraction date may be missing most follow-up data. Patients continued to be treated under the CtE 
scheme until the end of March 2017; patients treated in the final month were not included in the 
analysis due to constraints on the evaluation timeline.  
Patients were treated at the following ten NHS institutions in England: Cambridge University 
Hospitals NHS Foundation Trust, Kings College Hospital NHS Foundation Trust, Leeds Teaching 
Hospitals NHS Trust, Newcastle-upon-Tyne Hospitals NHS Trust, Nottingham University Hospitals 
NHS Trust, Oxford University Hospitals NHS Foundation Trust, the Christie NHS Foundation Trust, the 
Royal Free London NHS Foundation Trust, University Hospital Southampton NHS Foundation Trust, 
University Hospitals Birmingham NHS Foundation Trust.  
7.2.2 Population  
 Two populations were eligible to receive SIRT under the CtE funding arrangements in the UK 
National Health Service (NHS): i) adults with unresectable, chemotherapy refractory, colorectal 
cancer (CRC) liver metastases; ii) adults with unresectable, chemotherapy refractory intrahepatic 
cholangiocarcinoma (ICC).  
The eligibility criteria established by NHSE for inclusion in the SIRT CtE cohort for the two 
populations were as follows. For the metastatic CRC (mCRC) population: i) histologically confirmed 
                                                          
1
 The SIRT CtE project started proper in Dec 2013 however the registry holds 4 cases which occurred before 
this date (3 patients from Southampton and 1 from Cambridge). 
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carcinoma with liver-specific or liver-dominant metastases not amenable to curative liver surgical 
resection; ii) unequivocal and measurable CT evidence of liver metastases which are not treatable by 
surgical resection or local ablation with curative intent at the time of CtE entry; iii) no clinical trial of 
SIRT available as alternative treatment; iv) WHO performance status of 0–2; v) life expectancy > 3 
months;  vi) evidence of clinical progression during or following both oxaliplatin-based and 
irinotecan-based chemotherapy, unless the patient has a specific contraindication to chemotherapy 
or did not tolerate either regimen; vii) adequate haematological and hepatic function as follows: 
serum bilirubin ≤ 1.5 x ULN; absolute neutrophil count > 1.5 x 109/L, platelets > 100 x 109/L; albumin 
≥ 30 g/L; viii) having the primary colorectal tumour in situ was not a exclusion criterion; ix) patients 
were permitted to have limited extra-hepatic disease that was not life threatening nor a cause for 
significant morbidity if the liver metastases could be controlled with locally direCtEd therapy, e.g. 
lung metastases, multiple lymph nodes or low-volume peritoneal disease; x) no central nervous 
system metastases or bone metastases; xi) no evidence of ascites, cirrhosis or portal; xii) no previous 
portal venous embolisation or previous chemo-embolisation;  xiii) no previous radiotherapy to the 
upper abdomen or the right lower thorax;  xiv) female patients were either  post-menopausal or 
using an acceptable method of contraception and were not pregnant or breast-feeding; xv) male 
patients, if sexually active with a pre-menopausal partner, had to be using an appropriate method of 
contraception.  
For the ICC population the same eligibility criteria were used except that there should be evidence of 
clinical progression during or following standard chemotherapy, unless the patient has a specific 
contraindication to chemotherapy. Unlike the mCRC population the type of chemotherapy and 
number of lines was not limited. Standard chemotherapy in this group would usually comprise one 
line of a combination of cisplatin and gemcitabine.  
7.2.3 Procedures 
Two brands of CE-marked active implantable medical devices were used to carry out the SIRT 
procedure: i) SIR-spheres (Sirtex Medical Ltd, Australia) use resin microspheres; ii) TheraSphere 
(Biocompatibles UK Ltd, UK) use glass microspheres. Both were Y-90 microspheres although this was 
not specified under the CtE funding arrangements1.  
The service evaluation design meant that each site followed their local process for undertaking SIRT 
procedures. All patients received a hepatic arteriogram and a liver-to-lung breakthrough nuclear 
medicine scan to ensure suitability for receiving this procedure, and to plan the delivery of the Y-90 
microspheres. Selective coil embolisation of arteries to the stomach, duodenum or other visceral 
structures may be carried out to limit the delivery of microspheres outside the liver. Dosing of SIR-
spheres and TheraSpheres was carried out as per manufacturer instructions. For SIR-spheres the 
dose was calculated through the body surface area (BSA) method or through the partition model 
method. For TheraSpheres the dose to the liver was calculated from liver volume converted to liver 
mass. A technical description of the SIRT procedure is provided in Section 3. 
                                                          
1
 A third medical device, QuiremSpheres (Quirem Medical, The Netherlands), is now CE-marked and became 
available after the start of the SIRT CtE project. No patients in the SIRT CtE study were treated using 
QuiremSpheres. 
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Administration of concomitant chemotherapy and post-SIRT chemotherapy was at the discretion of 
the treating clinician. 
As is standard practice in the UK, sites were expected to follow patients up every 2 to 3 months after 
their SIRT procedure until progression was detected (and later for survival data). Follow-up 
appointments would usually consist of an abdominal CT scan (plus chest and/or pelvis in patients 
with extrahepatic disease), and in some cases an MRI or PET scan was also carried out. In addition, 
sites invited patients to complete the generic HRQoL questionnaire, EQ-5D-5L (Herdman et al. 2011), 
prior to SIRT and every three months until progression. Follow-up assessments after progression 
were occasionally recorded in the registry. Throughout the follow-up period adverse events were 
assessed and recorded.   
7.2.4 Data collection and data analysis 
The pathway for data collection in a typical case in the SIRT CtE study is presented in Figure 7.1. Data 
were collected by the clinical teams at each site using their established processes and subsequently 
entered into the SIRT registry hosted by the BSIR (available at https://sirtregistry.co.uk/). At the 
study end, pseudonymised data from CtE cases were added to the registry. A full list of fields within 
the SIRT registry are provided in Appendix 5. All patient identifiers were replaced by a unique patient 
identifier. The final anonymised dataset was extracted from the registry by BSIR on 5th March 2017 
and sent to an independent research group, Cedar (Cardiff and Vale University Health Board), for 
analysis. Data were only collected on patients who received SIRT and no comparator data were 
available. Details of patients who received a work-up procedure but were ultimately ineligible for 
SIRT were not included. It was not possible to carry out external validation/triangulation of data 
entered onto the registry by clinical teams because of the anonymous nature of the dataset.  
Due to time constraints, there was no follow-up phase of the study after the last SIRT treatment. In 
order to maximize procedural data all patients who received a SIRT procedure were included in the 
analysis regardless of the duration of follow-up. As such, patients had unequal follow-up periods, 
and patients treated most recently would be missing some or all follow-up data. Missing data 
proportions were reported for all outcomes. Patients with a missing diagnosis or missing SIRT 
administration date were excluded from the analysis. Data from the CRC and ICC cohorts have been 
presented and analysed separately. No data from a comparator group was collected.  
Date of death was recorded in the SIRT registry by clinical teams using locally accessible data; at 
some sites date of death was obtained or validated using the NHS Spine portal where electronic 
records of patient information are accessible. OS was defined as the duration from the first SIRT 
procedure until death from any cause. Patients with no date of death recorded were right censored 
at the date at which they were lost to follow-up (LTFU) date. LTFU date was captured using the most 
recent date of imaging, or EQ-5D-5L administration, or follow-up visit, or chemotherapy 
administration, and in some cases sites specifically recorded the most recent date the patient was 
known to be alive. Patients with no date of death, no LTFU date, or a date of death prior to SIRT 
were excluded from OS analysis. Survival proportions at 3, 6, 12, 24, and 36 months were reported 
for patients for whom this data was available (for those most recently recruited these data were 
unavailable).   
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Hepatic and extrahepatic tumour response assessments were carried out locally by a radiologist and 
recorded separately in the SIRT registry. It is the standard practice to discuss treatment response in 
the multidisciplinary team meeting. Blinded assessment or validation by another radiologist was not 
routinely carried out. The evaluation criteria were noted in the registry (usually as the response 
evaluation criteria for solid tumours (RECIST) (Eisenhauer et al. 2009)). PFS was defined as the 
duration from the first SIRT administration to the earliest date of detection of progressive disease 
(PD; either hepatic or extrahepatic) by CT, MRI, or PET scan, or to the date of death from any cause if 
progression was not recorded. Patients with no PD recorded were censored at the most recent date 
of non-progression (complete response (CR) or partial response (PR) or stable disease (SD)). Cases 
where no imaging results were recorded were excluded from this analysis.  
LPFS was defined as the duration from the first SIRT administration to the date of progression in the 
liver or death from any cause. Patients with no PD in the liver were censored at the most recent date 
of non-progression in the liver. Cases with no hepatic imaging results were excluded from this 
analysis.  
A range of baseline and procedural parameters were recorded in the registry (Appendix 5) including 
haematologic, liver function, and blood biochemistry tests. Baseline albumin laboratory values were 
excluded if they were <15 g/L as these were assumed to be data entry errors (probably due to 
confusion of the unit of measurement). The following data were categorised: age at time of SIRT was 
categorised into <65 years and ≥65 years; number of liver tumours was categorised into 1-5, 6-10, 
>10, and uncountable; number of previous chemotherapy lines was categorised into 1, 2, 3, ≥4. 
Prior chemotherapy regimens were recorded in a free text field. A search of regimen synonyms was 
carried out to count the number of patients who received each type of chemotherapy prior to their 
SIRT administration and concomitantly to SIRT.   
The percentage tumour volume to liver volume was recorded for either the whole liver, or for right 
and left lobes separately. Where a whole liver measurement was absent, right and left values were 
added to produce a proxy for a whole liver measurement. Similarly, prescribed activity (from the Y-
90 microspheres) was recorded separately for the whole liver, and for right and left lobes. Prescribed 
activity was recorded in the registry using GBq as the unit of measurement, however some very high 
values were also recorded which were likely to be erroneous having been measured in MBq. 
Therefore any prescribed activity of >100 units was converted using a 0.001 conversion factor.  
Prescribed activity was also presented separately for the two brands of yttrium-90 microscpheres 
(SIR-spheres or TheraSphere).  
Severe complications that occurred during the treatment1 and subsequent AEs were recorded. AEs 
were graded; the criteria used for grading was not prescribed although it was assumed that most 
centres would use the Common Terminology Criteria for Adverse Events (CTCAE) system. The SIRT 
registry recorded the following AEs using a check box: abdominal pain, fatigue, fever, nausea, 
vomiting, gastritis, gastrointestinal (GI) ulcer, radiation-induced liver disease (RILD), radiation 
pneumonitis, radiation cholecystitis, radiation pancreatitis. The registry recorded the following 
                                                          
1
 The registry did not record a grade for day-of-treatment complications; instead the question was worded as 
“were any severe day of treatment complications experienced?” 
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abnormal laboratory results using a check box: hypoalbuminemia, hyperbilirubinemia, alanine 
aminotransferase (ALT) increased, aspartarte aminotransferase (AST) increased, INR increased, 
neutrophil count decreased, platelet count decreased. The registry also had an “other” category for 
free-text entries for both adverse events and abnormal laboratory results. Date and grade (grading 
system not specified in registry) were also recorded.  
The total number of all-causality AEs and total number of AEs of grade 3 or above were calculated by 
counting all recorded AEs in each follow-up entry on the registry. Common events recorded in the 
“other” category were presented; and all grade ≥3 events recorded in the “other” category were 
presented individually. The total number of all-causality abnormal laboratory results and total 
number of grade 3 or above laboratory events were counted from each follow-up entry on the 
registry.  
Incidents or complaints related to the radioactive microsphere product used in the procedure were 
recorded in the registry. The following question was used to capture this information “was there a 
product incident or complaint associated with the treatment?”.  
EQ-5D-5L and EQ-VAS data were collected on the registry. EQ-5D-5L is a patient reported outcome 
measure which consists of 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and 
anxiety/depression. Respondents rate their level of severity for each dimension using a five-point 
ordinal scale. The responses are converted to an index score between 0 and 1 (Herdman et al. 2011). 
The EQ-VAS (visual analogue score) forms the second part of the questionnaire in which patients are 
asked to mark their health status today on a scale between 0 and 100 (0 corresponds to "the worst 
health you can imagine", and 100 corresponds to "the best health you can imagine"). EQ-5D-5L and 
EQ-VAS scores were grouped according to time elapsed since SIRT administration (Table 7.1).  
Table 7.1 Categorisation of EQ-5D-5L and EQ-VAS scores according to time elapsed since SIRT 
procedure. 
Time since SIRT procedure when EQ-5D-5L 
and EQ-VAS were measured 
Time point group 
0-60 days prior to SIRT Baseline 
60 to 120 days after SIRT 3-month follow-up 
150-210 days after SIRT 6-month follow-up 
240-300 days after SIRT 9-month follow-up 
12 months (± 3 months) 12-month follow-up 
24 months (± 6 months) 24-month follow-up 
7.2.5 Statistical analysis 
All statistical analyses were conducted in IBM SPSS Statistics version 21.0.0.0 (IBM Corp. Armonk, 
NY) or R (R Foundation for Statistical Computing, Vienna, Austria; http://www.R-project.org/). 
Descriptive statistics (mean, median, standard deviation (SD), interquartile range (IQR), range, 95% 
confidence intervals) for continuous variables were reported as appropriate. Frequency counts were 
calculated for qualitative variables. For each statistical comparison, p-value and confidence intervals 
were reported. P-values at <0.05 were considered statistically significant and all tests were two-
sided. 
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OS, PFS, and LPFS were estimated using the Kaplan-Meier analysis (Kaplan and Meier 1958). Survival 
curves were presented with 95% confidence intervals (CIs) and numbers at risk displayed. 
Application of competing risk analysis was not considered to be appropriate. Potentially important 
baseline covariates were tested to identify statistically significant prognostic factors associated with 
survival in the CRC cohort using the pairwise log-rank test. The sample size was too small to analyse 
subgroups in the ICC cohort. Hazard ratios (HRs) for baseline covariates were estimated for overall 
survival by univariate Cox proportional hazards models. The following covariates were selected: 
number of previous lines of chemotherapy (categories: 0, 1, 2, 3, ≥4), ECOG performance status 
(categories: 0, 1, 2), age (either as continuous or categories: <65 years, ≥65 years), sex, primary 
tumour in situ or not, prior biological therapy (including bevacizumab, cetuximab, aflibercept, 
panitumumab),  presence of extrahepatic metastases (categories: yes, no), extent of liver 
involvement (continuous or categories: <25%, 25-50%, >50%), prior liver surgery (categories: yes, 
no), number of liver tumours (categories: 1-5, 6-10, >10). The reverse Kaplan-Meier method was 
used to calculate median follow-up time (this is a more robust method whereby the event indicator 
in the Kaplan-Meier survival curve is reversed) (Schemper and Smith 1996). Survival proportions 
were taken from the Kaplan-Meier life tables at 6, 12, 24, and 36 months.  Comparisons of EQ-5D-
5L/VAS scores from baseline to follow-up time points were calculated using a paired samples 
Student’s T-test (pre – post SIRT scores). Negative change scores indicate an improvement in HRQoL 
following SIRT.  
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HRQOL, health-related quality of life; LTFU, lost to follow up; VAS, visual analogue scale.  
Figure 7.1. Typical pathway and data collection process for patients in the SIRT CtE study.  
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7.3 Results 
A total of 514 patients were treated under the scheme until close of data entry at the end of 
February 2017 (self reported numbers). A total of 474 patients were added to the SIRT registry, of 
which 460 were valid data entries1 (cases with missing or ineligible diagnoses were excluded, and 
cases with no SIRT procedure date were also excluded). A total of 399 (87%) valid cases were in the 
CRC cohort and 61 (13%) in the ICC cohort. Across the 10 SIRT centres in England, the numbers of 
patients treated ranged from 15 to 120 (Table 7.2).  
Table 7.2 Number of patients treated and entered onto the registry from each of the 10 SIRT CtE 
provider centres in England by diagnosis type and total (ordered by total number of patients 
treated) 
Name of SIRT CtE provider hospital in England 
Number of patient entries2 added to 
the registry (%) 
CRC ICC Total 
Churchill Hospital (Oxford) 108 (27%) 12 (20%) 120 (26%) 
Christie's Hospital (Manchester) 63 (16%) 16 (26%) 79 (17%) 
Royal Free Hospital (London) 47 (12%) 10 (16%) 57 (12%) 
Nottingham City Hospital (Nottingham) 47 (12%) 5 (8%) 52 (11%) 
Freeman Hospital (Newcastle) 29 (7%) 6 (10%) 35 (8%) 
Southampton General Hospital (Southampton) 35 (10%) 1 (3%) 36 (8%) 
Addenbrooke's Hospital (Cambridge) 28 (7%) 5 (8%) 33 (7%) 
Queen Elizabeth Hospital (Birmingham) 18 (5%) 1 (2%) 19 (4%) 
King's College Hospital (London) 12 (3%) 2 (3%) 14 (3%) 
St James's Hospital (Leeds) 12 (3%) 3 (5%) 15 (3%) 
Total 399 (100%) 61 (100%) 460 (100%) 
 
Baseline characteristics and prior treatments 
Patients in the CRC cohort were 67% male and 33% female; they had a median age of 66 years. In 
the ICC cohort, 53% were male and 48% were female; the median age was 64 years (Table 7.3). Most 
patients had an ECOG performance score of 0 or 1 (93% CRC cohort; 91% ICC cohort) and the 
majority did not have extrahepatic metastatic disease (60% CRC; 59% ICC). Almost all patients had 
received prior systemic chemotherapy or biologics (98% CRC; 92% ICC). Most patients in the CRC 
cohort had received 2 or 3 lines of prior chemotherapy (78%) consisting predominantly of 
fluoropyrimidine-, oxaliplatin- or irinotecan-based regimens3. In the ICC cohort most patients had 
received 1 or 2 lines (81%) consisting mostly of cisplatin and gemcitabine (Table 7.3). Most patients 
had not received prior hepatic procedures (72% CRC; 84% ICC). The median duration from primary 
diagnosis to the first SIRT procedure was 2.1 years in the CRC cohort and 1.1 years in the ICC cohort.  
                                                          
1
 Patients treated within the final weeks of the project were not added to the registry because time constraints 
meant that the data cut-off was before the procedures were undertaken.  
2
 Only valid entries included; cases with no diagnosis or no SIRT procedure date were excluded. 
3
 Patients who were intolerant to standard chemotherapy were eligible to receive SIRT which may explain the 
9% of CRC patient who received only one previous line of chemotherapy. This cannot be verified using data 
collected in the SIRT registry.  
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In the CRC group, the median time from diagnosis of metastatic disease to SIRT was 1.8 years. Very 
few patients had ascites or liver cirrhosis (Table 7.3).  
Table 7.3. Baseline patient characteristics of CRC and ICC cohorts treated with SIRT 
Parameter Data from CRC cohort Data from ICC cohort 
Total n=399 n=61 
Age at time of procedure (years)  n=398 
Median 66 (IQR 57-72) 
Mean 64 (SD 12) 
n=61 
Median 64 (IQR 55-72) 
Mean 62 (SD 12) 
Age (<75 years / ≥75 years) 333 (84%) / 65 (16%) 53 (87%) / 8 (13%) 
Male/Female (%) 133 (33%)/266 (67%)/133 
(33%) 
32 (53%)/29 (48%) 
Baseline ECOG score 
0-Fully Active 201 (50%) 32 (53%) 
1-Restricted 170 (43%) 23 (38%) 
2-Ambulatory 13 (3%) 2 (3%) 
3-Capable 1 (0.3%) 0 
Missing 14 (4%) 4 (7%) 
Limited extrahepatic disease 
Yes 159 (40%) 22 (36%) 
No 236 (60%) 36 (59%) 
Missing 0 3 (5%) 
Location of metastatic disease1 
Lung 106 8 
Lymph nodes 40 14 
Bone 2 0 
Brain 0 0 
Other 32 4 
Primary tumour resected 
Yes 226 (57%) 0 
No 123 (31%) 2 (3%) 
Missing 50 (13%) 59 (97%) 
Time from primary diagnosis to SIRT 
procedure (years) 
n=321 
Median 2.1 (IQR 1.5-3.2) 
n=53 
Median 1.1 (IQR 0.7-1.4) 
Time from metastatic diagnosis to SIRT 
procedure (years) 
n=313 
Median 1.8 (IQR 1.2-2.6) 
N/A 
Prior systemic chemotherapy (including biologics) 
Yes 391 (98%) 56 (92%) 
No 8 (2%) 3 (5%) 
Missing 0 2 (3%) 
Number of previous chemotherapy lines 
1 34 (9%) 40 (66%) 
2 222 (56%) 9 (15%) 
3 87 (22%) 1 (2%) 
≥4 34 (9%) 2 (3%) 
Missing 22 (6%) 9 (15%) 
Prior chemotherapy received (including biologics)1 
                                                          
1
 Multiple tumour locations permitted. 
 
 
Page 83 of 175 
 
Commissioning through Evaluation: SIRT 
Full evaluation report 
Fluoropyrimidine-based 282 (71%) 3 (5%) 
Oxaliplatin 303 (76%) 5 (8%) 
Irinotecan 302 (76%) - 
Capacitabine 155 (39%) 2 (3%) 
Cisplatin - 48 (79%) 
Gemcitabine - 49 (80%) 
Bevacizumab 119 (30%) - 
Cetuximab 109 (27%) - 
Aflibercept 25 (6%) - 
No chemotherapy recorded 53 (13%) 11 (18%) 
Prior adjuvant therapy2 
Yes 85 (21%) 3 (5%) 
No 303 (76%) 55 (90%) 
Missing 11 (3%) 3 (5%) 
Prior hepatic procedures 
Yes 110 (28%) 9 (15%) 
No 289 (72%) 51 (84%) 
Missing 0 1 (2%) 
Portal vein thrombosis 
Patent 390 (98%) 55 (90%) 
Lobar thrombosis 3 (1%) 2 (3%) 
Segmental thrombosis 3 (1%) 2 (3%) 
Missing 3 (1%) 2 (3%) 
Ascites 
Yes 3 (1%) 4 (7%) 
No 394 (99%) 55 (90%) 
Missing 2 (0.5%) 2 (3%) 
Cirrhosis 
Yes 0 0 
No 397 (100%) 59 (97%) 
Missing 2 (0.5%) 2 (3%) 
ECOG, Eastern Cooperative Oncology Group; IQR, interquartile range; N/A, not applicable; SD, standard 
deviation.  
Treatment and procedure 
In the CRC cohort, 29% of patients had 1-5 tumours, 13% had 6-10 tumours, and 44% had >10 
tumours. In the ICC cohort, 51% of patients had 1-5 tumours, 15% had 6-10 tumours, and 21% >10 
tumours. Most patients had bilobar tumours (76% CRC; 64% ICC). Median bilirubin values prior to 
SIRT were 9.0 µmol/L (IQR 6.0-12.0) in the CRC cohort and 8.0 µmol/L (IQR 5.3-11.8) in the ICC 
cohort. Median baseline albumin values prior to SIRT were 37.0 g/L (IQR 33.0-41.0) in the CRC cohort 
and 38.0 g/L (IQR 33.5-42.5) in the ICC cohort (Table 7.4). Arteries were embolised during the work-
up procedure in 52% of CRC patients and 34% in ICC patients. In the majority of patients (72% CRC; 
56% ICC) the intent of the SIRT procedure was palliative (high levels of missing data was an issue for 
this measure).  
                                                                                                                                                                                    
1
 Only chemotherapy drugs reported in at least 2% of patients are presented. 
2
 29 patients had dates for prior adjuvant therapy (median 32 [IQR 20-38] months prior to SIRT).   
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Most CRC patients received SIRT as a single procedure targeting the whole liver (52% split 
microsphere administration; 17% single microsphere administration) or the right lobe (15%). A small 
proportion (3%) of CRC patients had sequential lobes treated in two (or more) sessions1. In the ICC 
cohort, 52% of patients received SIRT as a single procedure targeting the whole liver (26% split 
administration; 26% single administration). Within the ICC cohort, 8% of patients received two 
sessions (Table 7.4).  
The majority of SIRT procedures were conducted using the resin Y-90 microspheres, SIR-spheres 
(86% of CRC cases; 74% of ICC cases). The remaining procedures were carried out using glass Y-90 
microspheres, TheraSpheres (by BTG). Mean prescribed activity was 2.00 GBq (SD 2.22) for CRC 
patients and 2.38 GBq (SD 3.03) for ICC patients. The median overall tumour to liver volume ratio 
was reported for 270 (68%) CRC patients as whole liver measurements, and 32 (52%) ICC cases. The 
median tumour to liver volume ratio was 15% (IQR 7-27%) in the CRC cohort, and 17% (IQR 8-27%) in 
the ICC cohort. Most patients had a hospital stay of 1 night (CRC 66%; ICC 66%) or 2 nights (CRC 22%; 
ICC 23%) for their SIRT procedure (Table 7.4).  
Chemotherapy was delivered concomitantly with SIRT in 35% of CRC cases (predominantly 5-FU and 
oxaliplatin) and 12% of ICC cases. Post-SIRT, a minority of cases went on to receive further 
chemotherapy during their follow-up phase (22% of CRC cases; 15% of ICC cases)2 (Table 7.4). 
Table 7.4 Treatment planning and procedure in the CRC and ICC cohorts 
Parameter Data from CRC cohort Data from ICC cohort 
Location of liver tumour(s) 
Bilobar 304 (76%) 39 (64%) 
Left 28 (7%) 0 
Right 59 (15%) 17 (28%) 
Missing 8 (2%) 5 (8%) 
Number of liver tumours 
1-5 114 (29%) 31 (51%) 
6-10 52 (13%) 9 (15%) 
>10 174 (44%) 13 (21%) 
Uncountable 33 (8%) 3 (5%) 
Missing 26 (7%) 5 (8%) 
Bilirubin (µmol/L) prior to SIRT 
n=384 
Mean 10.3 (SD 6.3) 
Median 9.0 (IQR 6.0-12.0) 
n=60 
Mean 9.3 (SD 5.5) 
Median 8.0 (IQR 5.3-11.8) 
Albumin (g/L) prior to SIRT 
n=3593 
Mean 36.5 (SD 6.0) 
Median 37.0 (IQR 33.0-41.0) 
n=574 
Mean 38.1 (SD 5.7) 
Median 38.0 (IQR 33.5-42.5) 
Arteries embolized before SIRT therapy 
Yes 208 (52%) 21 (34%) 
                                                          
1
 This measure may be an underestimate because of inconsistencies in recording within the registry. 
2
 This estimate may be unreliable due to missing follow-up entries due to repatriation of patients to their 
referring centres.  
3
 29 cases excluded because data error suspected (entries below 15 g/L were excluded as we assumed this was 
a data entry error due to unit ambiguity in the registry). 
4
 3 cases excluded as entries below 15 g/L albumin. 
 
 
Page 85 of 175 
 
Commissioning through Evaluation: SIRT 
Full evaluation report 
No  108 (27%) 22 (36%) 
Missing 83 (21%) 18 (30%) 
Intent of SIRT procedure 
Palliative 289 (72%) 34 (56%) 
Down-staging 7 (2%) 1 (2%) 
Bridge to surgery 1 (0.3%) 0 
Missing 102 (26%) 26 (43%) 
SIRT procedure target/type 
Whole liver (split 
administration in single 
session) 
206 (52%) 16 (26%) 
Whole liver (single catheter) 68 (17%) 16 (26%) 
Whole Liver (sequential 
lobar/ two sessions) 
13 (3%) 5 (8%) 
Right lobe 61 (15%) 16 (26%) 
Left lobe 20 (5%) 0 
Segmental 20 (5%) 6 (10%) 
Missing 11 (3%) 2 (3%) 
Number of administrations 
1 172 (43%) 29 (48%) 
2 101 (25%) 11 (18%) 
3 9 (2%) 1 (2%) 
Missing 117 (29%) 20 (33%) 
SIRT microsphere brand 
SIR-spheres (resin) 343 (86%) 45 (74%) 
TheraSphere (glass) 53 (13%) 16 (26%) 
Missing 3 (0.8%) 0 
Liver measured as whole or lobes 
Whole 120 (30%) 33 (54%) 
Right and left separately 255 (64%) 23 (38%) 
Missing 24 (6%) 5 (8%) 
Percentage tumour to liver volume 
(whole liver measurements only) 
n=270 
Mean 18.9 (SD 15.1) 
Median 15.0 (IQR 7.0-27.3) 
n=32 
Mean 19.0 (SD 14.6) 
Median 17.0 (IQR 8.2-26.7) 
Percentage tumour to liver volume 
(whole liver measurements, 
measurements where left and right 
are combined1) 
n=341 
Mean 21.1 (SD 18.5) 
Median 15.0 (IQR 7.0-30.0) 
n=46 
Mean 20.3 (SD 15.9) 
Median 17.0 (IQR 8.0-28.5) 
Prescribed activity (GBq)2 
n=308 
Mean 2.00 (SD 2.22) 
Median 1.70 (IQR 1.30-2.05) 
n=42 
Mean 2.38 (SD 3.03) 
Median 1.63 (IQR 1.30-2.16) 
Prescribed activity (GBq) for  SIR-
spheres 
n=271 
Mean 1.74 (SD 2.13) 
Median 1.64 (IQR 1.28-1.93) 
n=31 
Mean 1.51 (SD 0.43) 
Median 1.50 (IQR 1.19-1.79) 
Prescribed activity (GBq) for  
TheraSphere 
n=34 
Mean 4.18 (SD 1.71) 
n=11 
Mean 4.85 (SD 5.29) 
                                                          
1
 Advice from two clinicians was that right and left lobe measurements can be added to produce a whole liver 
measurement, however there is uncertainty about how these fields were interpreted by sites.   
2
 Values of >100 were assumed to be in MBq and were converted to GBq.  
 
 
Page 86 of 175 
 
Commissioning through Evaluation: SIRT 
Full evaluation report 
Median 3.91 (3.45-5.31) Median 2.81 (IQR 2.03-5.34) 
Length of stay in hospital following SIRT procedure 
1 night 265 (66%) 40 (66%) 
2 nights 87 (22%) 14 (23%) 
3 nights 12 (3%) 1 (2%) 
4 nights 8 (2%) 2 (3%) 
>4 nights 10 (3%) 2 (3%) 
Concomitant chemotherapy administered with SIRT 
Yes 141 (35%) 7 (12%) 
No 242 (61%) 52 (85%) 
Missing 16 (4%) 2 (3%) 
Concomitant chemotherapy received1 
5-FU 99 (25%) 5 (8%) 
Oxaliplatin 31 (8%) 4 (7%) 
Irinotecan 24 (6%) 1 (2%) 
Capacitabine 9 (2%) 0 
Cisplatin 0 1 (2%) 
Cetuximab 7 (2%) 0 
Post-SIRT chemotherapy received during follow-up 
Yes 89 (22%) 9 (15%) 
No 214 (54%) 37 (61%) 
Missing 96 (24%) 15 (25%) 
IQR, interquartile range; N/A, not applicable; SD, standard deviation.  
7.3.1 Follow-up visits 
Using reverse Kaplan-Meier estimator (Schemper & Smith 1996), patients were followed up for a 
median of 14.3 months (95% CIs 9.2-19.4) in the CRC cohort, and for 13.9 months (95% CIs 9.6-18.1) 
in the ICC cohort. Reverse KM is a more robust method than the simple median among patients with 
censored data (3.9 months [IQR 2.8-6.4] and 5.1 months [IQR 2.9-10.8]) for the CRC and ICC cohorts, 
respectively 2. 
In the entire study cohort, a total of 388 patients (84%) had at least 1 follow-up visit; the majority of 
patients had 1 or 2 follow-up visits (Table 7.5). The median number of days between the first SIRT 
procedure and the first follow-up visit was 71 days (IQR 33-71).  
Imaging scans were recorded separately from follow-up visits in the registry.  A total of 367 patients 
(80%) had at least one imaging scan recorded in the registry; and the majority had 1 or 2 imaging 
scans (Table 7.5). The median number of days between the first SIRT procedure and the first imaging 
visit was 78 days (IQR 67-88). 
  
                                                          
1
 Only chemotherapy drugs reported in at least 2% of patients are presented 
2
 The simple median of follow-up time from censored patients systematically underestimates the follow-up 
period because “longer follow-up times have a higher likelihood of being unavailable because of intermittent 
deaths than short individual follow-ups”. Using reverse Kaplan-Meier estimator, “the unobservable follow-up 
time of a deceased patient is interpreted as the follow-up time that potentially would have been observed had 
that patient not died” (Shemper & Smith, 1996).  
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Table 7.5 Number of follow-up visits and visits for imaging scans recorded for patients from the 
entire study cohort 
Number of 
visits 
Number of patients (n=460 entire cohort) 
Follow-up visits Imaging scan visits 
0 72 (16%) 93 (20%) 
1 166 (36%) 195 (42%) 
2 102 (22%) 111 (24%) 
3 78 (17%) 36 (8%) 
4 22 (5%) 14 (3%) 
At least 5 20 (4%) 11 (2%) 
7.3.2 Overall survival  
At the conclusion of the study, 240 (60%) CRC deaths were recorded and 33 (54%) deaths in the ICC 
cohort. A total of 139 (35%) of CRC patients and 23 (38%) of ICC patients were censored at their last 
recorded follow-up date. The survival status of 20 CRC patients and 5 ICC patients were not 
established (missing data) (Table 7.6).   
Table 7.6. Number of events recorded in CRC and ICC cohorts for OS, PFS, and LPFS. Numbers of 
patients with missing and censored data also shown.  
Measure 
Number of events in CRC cohort (n=399) Number of events in ICC cohort (n=61) 
Event recorded Censored Missing Event recorded Censored Missing 
OS  240 (60%) 139 (35%) 20 (5%) 33 (54%) 23 (38%) 5 (8%) 
PFS 
269 (67%) 
progressed 
62 (16%) died 
24 (6%) 41 (10%) 
40 (66%) 
progressed 
7 (11%) died 
7 (11%) 7 (11%) 
LPFS 
209 (52%) 
progressed 
91 (23%) died 
53 (13%) 46 (12%) 
33 (54%) 
progressed 
13 (21%) died 
8 (13%) 7 (11%) 
CRC, colorectal cancer; ICC, intrahepatic cholangiocarcinoma; LPFS, liver-specific progression-free survival; OS, 
overall survival; PFS, progression-free survival 
In the CRC cohort, median OS was 7.6 months (95% CIs 6.9 – 8.3) (Table 7.7; Figure 7.2). The survival 
rates for the CRC cohort were 92% at 3 months post-SIRT, 83% at 6 months, 30% at 12 months, and 
7% at 24 months. No patients survived to 36 months in either cohort. The reason for death was not 
recorded for 69% of CRC patients and 67% of ICC patients; this high proportion of missing data made 
this measure unreliable.  
In the ICC cohort, median OS was 8.7 months (95% CIs 5.3-12.1) (Table 7.2; Figure 7.3). Survival 
proportions for the ICC cohort were 89% at 3 months post SIRT, 85% at 6 months, 37% at 12 months, 
and 7% at 24 months. No patients survived to 36 months in either cohort (although some were 
censored).  
The impact of short follow-up periods was evaluated in a restricted cohort of patients treated prior 
to 28th Feb 2016 (1 year before study closure). In this restricted cohort, median overall survival was 
7.8 months (95% CIs 7.1-8.5) in 238 CRC patients (82% died, 18% censored), and 8.7 months (95% CIs 
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5.2-12.2) in 40 ICC patients (73% died, 28% censored).  These results indicate that the survival 
estimates are robust to changes in the distribution of follow-up period.  
Table 7.7. Summary of survival outcomes for CRC and ICC populations 
Outcome (median) CRC cohort ICC cohort 
Overall survival (months) 7.6 (95% CIs 6.9 – 8.3) 8.7 (95% CIs 5.3-12.1) 
Progression free survival (months) 3.0 (95% CIs 2.8-3.12) 2.8 (95% CIs 2.6-3.1) 
Liver-specific progression free survival 
(months) 
3.7 (95% CIs 3.2-4.3) 3.1 (95% CIs 1.3-4.8) 
CRC, colorectal cancer; ICC, intrahepatic cholangiocarcinoma. 
7.3.3 Progression free survival 
Progression was observed in a total of 269 (68%) CRC patients and 40 (66%) ICC patients.  The RECIST 
criteria were used to document progression in 85% of scans in the CRC group (14% did not record 
the criteria); in the ICC cohort RECIST was used in 94% of scans. A total of 331 (84%) CRC patients 
and 47 (77%) ICC patients were recorded as having progressed or died (Table 7.6). In total, 24 (6%) 
CRC patients and 7 (12%) ICC patients were censored at the last imaging date when no progression 
was recorded. Median PFS was 3.0 months (95% CIs 2.8-3.1) in the CRC cohort (Table 7.7; Figure 
7.4). Median PFS was 2.8 months (95% CIs 2.6-3.1) in the ICC cohort (Table 7.7; Figure 7.4). 
7.3.4 Liver-specific progression free survival 
A total of 209 (52%) hepatic progression events were recorded in the CRC cohort, and 33 (54%) in 
the ICC cohort (Table 7.6). In the LPFS analysis for the CRC cohort 299 (75%) events (hepatic 
progression or death) were recorded, 53 (13%) patients were censored, and 43 (11%) were 
excluded. The median LPFS in the CRC cohort was 3.7 months (95% CIs 3.2-4.3) (Table 7.7; Figure 
7.4). In the ICC cohort, 75% patients progressed or died, 13% were censored, and 11% were 
excluded. The median LPFS was 3.1 months (95% CIs 1.3-4.8) in the ICC group (Table 7.7; Figure 7.5). 
In the CRC group, 153 patients had dates recorded for both hepatic progression and extrahepatic 
progression. Of these, hepatic and extrahepatic progression was recorded on the same date in 124 
patients (81%); extrahepatic progression occurred before hepatic progression in 24 patients (16%); 
and hepatic progression occurred prior to extrahepatic progression in 5 patients (3%). In the ICC 
group, 22 patients had dates recorded for both intra- and extrahepatic progression. In 18 patients 
(82%) these dates were the same, in 2 patients (9%) extrahepatic progression occurred first, and in 2 
patients (9%) hepatic progression occurred first.  
7.3.5 Subgroup analysis (overall survival) 
Subgroup analysis identified four covariates that resulted in a statistically significant difference in 
median overall survival in the CRC cohort. No subgroup analyses were carried out on the ICC cohort 
because of the small sample size. OS in the CRC group differed significantly between patients who 
had extrahepatic metastasis and those who did not (log-rank test, p-value=0.021); the HR was 0.74 
(95% CIs 0.57-0.96; univariate Cox proportional hazards p-value=0.022) (Table 7.8; Figure 7.6). OS 
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also differed significantly between the categories of number of liver tumours (log-rank test, p-
value=0.008); the HR was 1.67 (95% CIs 1.06-2.62; p=0.027) when the group of 6-10 tumours was 
compared to the reference group of 1-5 tumours; the HR was 1.61 (95% 1.17-2.21) when the group 
of >10 tumours was compared to the reference group (Figure 7.7).  OS was longer in males 
compared to females (log-rank test, p-value=0.012); the HR was 1.389 (95% CIs 1.073-1.800; 
p=0.013) (Figure 7.8). OS was also related to the percentage tumour to liver volume measurements 
at baseline (log rank test, p<0.001); the HR was 1.955 (95% CIs 1.424-2.685) comparing the category 
of tumour to liver volume >25% to 50% with the reference category of ≤25%; the HR was 2.994 
(1.791-5.005) when the category of >50% was compared to the reference category (Figure 7.9). No 
significant difference in survival was observed using the covariates of prior chemotherapy lines, 
ECOG performance status, age, and prior liver procedures (Table 7.8).  
7.3.6 Health related quality of life  
Measurement of changes in HRQoL from baseline to follow-up was hindered by high levels of 
missing data at all follow-up periods. In the CRC cohort, only 32% of patients had an EQ-5D-5L 
measurement at 3 months which dropped further to 3% at 12 months. Reasons include short follow-
up of recently treated patients, poor implementation of the EQ-5D-5L measurement tool across 
sites, and anecdotal reports of challenges in recruiting patients to participate.  
The available data showed that EQ-5D-5L remained relatively constant across time points from 
baseline (0-60 days prior to SIRT) to 12 months (±3 months) post SIRT in the CRC population where 
scores ranged from the highest value of 0.832 at baseline to 0.743 at 12 months post SIRT (Figure 
7.10). The overall health scores (EQ-VAS) ranged from the highest value of 80 at 9 months post-SIRT 
to 69 at 12 months post SIRT. There was only one reported score at 24 months post SIRT for both 
EQ-5D-5L and EQ-VAS scores in the CRC group.  
In the ICC cohort EQ-5D-5L scores were only reported at baseline and 3 months post-SIRT (Figure 
7.11); EQ-5D-5L scores were 0.810 and 0.836 respectively. Overall health scores using the EQ-VAS 
scale were 75 at baseline and 77 at 3 months post SIRT.  
A small but statistically significant reduction in EQ-5D-5L-measured HRQoL was reported from 
baseline (score 0.85) to 3 months post-SIRT (score 0.81) in the CRC group: difference in score 0.042 
(95% CIs 0.012-0.072); p=0.006 (Table 7.9). A similar reduction was observed in the overall health 
score measured by EQ-VAS from baseline (score 76.8) to 3 months post SIRT (score 73.7); the 
difference in scores was 3.05 (95% CIs 0.22-5.88; p=0.035) (Table 7.10). Changes in EQ-5D-5L scores 
and EQ-VAS from baseline to 6 months and 12 months post SIRT were not statistically significant. No 
patients had baseline and 24 month post SIRT scores. In the ICC population changes in EQ-5D-5L 
scores and EQ-VAS from baseline to 3 months post SIRT were not statistically significant (Tables 6.11 
and 6.12). Too few patients had scores at 6, 12, and 24 months post SIRT to enable a comparison 
with baseline.  
EQ-5D-5L scores were summarised separately prior to progression and after progression. The mean 
pre- and post-progression scores in the CRC cohort were 0.82 (SD 0.17; n=68) and 0.77 (SD 0.16; 
n=105), respectively. In the ICC cohort, the mean pre- and post-progression scores in the CRC cohort 
were 0.80 (SD 0.17; n=10) and 0.80 (SD 0.17; n=12), respectively. 
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Figure 7.2. Kaplan-Meier curve of overall survival following SIRT in the CRC cohort (95% CIs shown 
shaded; numbers at risk at 3 month intervals displayed) 
 
Months 0 3 6 9 12 15 18 21 24 27 30 33 36 
Number 
at risk 
379 302 163 92 61 37 22 12 9 3 1 0 0 
 
Figure 7.3. Kaplan-Meier curve of overall survival following SIRT in the ICC cohort (95% CIs shown 
shaded; numbers at risk at 3 month intervals displayed) 
 
Months 0 3 6 9 12 15 18 21 24 27 30 33 36 
Number 
at risk 
56 43 26 17 12 7 3 2 1 1 1 1 0 
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Figure 7.4. Kaplan-Meier curve of progression free survival and liver only progression free survival 
in patients with metastatic colorectal cancer following SIRT (95% CIs shown shaded; numbers at 
risk 3 at month intervals displayed) 
 
Months 0 3 6 9 12 15 18 21 24 27 30 
Number at 
risk  (PFS) 
354 157 59 23 14 6 4 1 0 0 0 
Number at 
risk  (LPFS) 
352 196 88 35 24 8 5 2 1 1 0 
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Figure 7.5. Kaplan-Meier curve of progression free survival and liver only progression free survival 
in patients with intrahepatic cholangiocarcinoma following SIRT (95% CIs shown shaded; numbers 
at risk at 3 month intervals displayed) 
 
Months 0 3 6 9 12 15 18 21 24 27 30 
Number at 
risk  (PFS) 
54 21 10 6 5 3 2 1 0 0 0 
Number at 
risk  (LPFS) 
54 25 11 8 8 5 3 2 0 0 0 
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Table 7.8. Kaplan-meier analysis and univariate Cox proportional hazards model of survival by 
baseline characteristics in the colorectal population (statistically significant p-values in bold) 
Subgroup n (pts) 
n 
(events) 
Median OS 
in months 
OS 
95% CI 
Hazard ratio (95% 
CIs) 
p-value 
Number of lines of previous chemotherapy (including biologics); log-rank test p=0.098 
1 line* 32 19 11.3 4.9-17.6 Ref Ref 
2 lines  210 127 7.0 6.2-7.8 1.506 (0.926-2.448) 0.099 
3 lines 85 58 8.9 6.7-11.2 1.143 (0.680-1.921) 0.614 
≥4 lines 33 27 7.3 5.1-9.4 1.732 (0.959-3.127) 0.069 
Primary tumour in situ; log-rank test p=0.079 
Yes 117 82 7.4 6.0-8.7 1.282 (0.973-1.689) 0.077 
No 217 136 8.9 7.4-10.3 Ref Ref 
Prior biologic therapy 1; log-rank test p=0.783 
No 189 112 7.6 6.6-8.6 Ref Ref 
Yes 190 128 7.4 6.5-8.4 1.036 (0.803-1.338) 0.783 
ECOG performance status; log-rank test p=0.180 
0* 192 124 8.4 6.9-9.8 Ref Ref 
1 162 96 6.6 5.5-7.7 1.252 (0.956-1.640) 0.103 
2 13 12 6.3 2.0-10.6 0.854 (0.465-1.567) 0.610 
Presence of extrahepatic metastases; log-rank test p=0.021 
Yes* 151 100 7.1 5.7-8.4 Ref Ref 
No 225 137 8.1 6.9-9.2 0.738 (0.568-0.957) 0.022 
Age (continuous) 0.997 (0.985-1.008) 0.562 
Age (categories); log-rank test p=0.316 
<65 years* 172 113 8.2 6.9-9.5 Ref Ref 
≥65 years 206 126 7.4 6.4-8.3 1.140 (0.882-1.473) 0.317 
Prior liver procedures; log-rank test p=0.114 
Yes* 104 63 7.1 6.2-7.9 1.262 (0.944-1.685) 0.116 
No 275 177 9.7 8.9-10.4 Ref Ref 
Number of liver tumours; log-rank test p=0.008 
1-5* 107 58 11.3 8.7-13.8 Ref Ref 
6-10 50 28 6.7 3.8-9.5 1.666 (1.059-2.621) 0.027 
>10 167 117 7.3 6.2-8.3 1.608 (1.171-2.208) 0.003 
Sex ; log-rank test p=0.012 
Female 129 96 6.4 5.2-7.7 1.389 (1.073-1.800) 0.013 
Male 250 144 8.2 7.2-9.2 Ref Ref 
Percentage tumour to liver volume (continuous) 1.023 (1.016-1.030) <0.001 
Percentage tumour to liver volume; log rank test p<0.001 
≤25% 226 135 9.4 8.0-10.9 Ref Ref 
>25% to 50% 80 57 5.3 4.4-6.2 1.955 (1.424-2.685) <0.001 
>50% 22 17 5.3 6.8-8.2 2.994 (1.791-5.005) <0.001 
*Reference category for univariate Cox regression analysis. ECOG, Eastern Cooperative Oncology Group; HR, 
hazard ratio; OS, overall survival.  
  
                                                          
1
 Includes bevacizumab, cetruximab, aflibercept. 
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Figure 7.6. Kaplan-Meier curve of OS in patients following SIRT (CRC cohort); results from patients 
with extrahepatic metastatic disease and patients without extrahepatic metastatic disease shown 
separately; hazard ratio (95% CIs) shown with p-value. 
 
 
Figure 7.7. Kaplan-Meier curve of OS in patients following SIRT (CRC cohort); results from patients 
with 1-5 liver tumours, 6-10 liver tumours, or >10 liver tumours are shown separately; hazard ratio 
(95% CIs) shown with p-value.  
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Figure 7.8. Kaplan-Meier curve of OS in patients following SIRT (CRC cohort); results from male and 
female patients shown separately; hazard ratio (95% CIs) shown with p-value. 
 
Figure 7.9. Kaplan-Meier curve of OS in patients following SIRT (CRC cohort); results patients with 
a tumour to liver volume percentage of ≤25%, 26-50%, and >50% shown separately; hazard ratio 
(95% CIs) shown with p-value. 
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Figure 7.10. Mean EQ-5D-5L scores and EQ-VAS at baseline and four follow-up time points in the 
CRC cohort (SD error bars; non-paired samples) 
 
 
Figure 7.11. Mean EQ-5D-5L scores and EQ-VAS at baseline and four follow-up time points in the 
ICC cohort (SD error bars; non-paired samples) 
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Table 7.9. Changes in EQ-5D-5L scores from baseline to four follow-up time points in the CRC 
cohort 
Change in EQ-5D-5L 
score 
n 
Baseline 
score (mean 
(SD)) 
Post-SIRT 
score 
(mean (SD)) 
Mean difference (95% CIs); p-
value 
Baseline to 3 months 120 0.85 (0.14) 0.81 (0.17) 0.042 (0.012-0.072); p=0.006 
Baseline to 6 months 32 0.86 (0.12) 0.83 (0.13) 0.029 (-0.026-0.084); p=0.290 
Baseline to 12 months 8 0.83 (0.16) 0.80 (0.05) 0.032 (-0.050-0.113); p=0.389 
Baseline to 24 months 0 - - - 
 
Table 7.10. Changes in EQ-VAS from baseline to four follow-up time points in the CRC cohort  
Change in EQ-VAS n 
Baseline 
score (mean 
(SD)) 
Post-SIRT 
score 
(mean (SD)) 
Mean difference (95% CIs) 
p-value 
Baseline to 3 months 122 76.8 (15.6) 73.7 (17.3) 3.05 (0.22-5.88); p=0.035 
Baseline to 6 months 31 82.0 (10.4) 77.3 (15.6) 4.74 (-1.21-10.70); p=0.114 
Baseline to 12 months 9 86.1 (10.2) 73.3 (16.4) 12.78 (-3.43-28-98); p=0.107 
Baseline to 24 months 0 - - - 
 
Table 7.11. Changes in EQ-5D-5L scores from baseline to four follow-up time points in the ICC 
cohort  
Change in EQ-5D-5L 
score 
n 
Baseline 
score (mean 
(SD)) 
Post-SIRT 
score 
(mean (SD)) 
Mean difference (95% CIs); p-
value 
Baseline to 3 months 15 0.84 (0.13) 0.86 (0.14) -0.016 (-0.075-0.044); p=0.584 
Baseline to 6 months 1 - - - 
Baseline to 12 months 1 - - - 
Baseline to 24 months 0 - - - 
 
Table 7.12. Changes in EQ-VAS from baseline to four follow-up time points in the ICC cohort  
Change in EQ-VAS n 
Baseline 
score (mean 
(SD)) 
Post-SIRT 
score 
(mean (SD)) 
Mean difference (95% CIs) 
p-value 
Baseline to 3 months 16 71.75 (20.45) 77.0 (12.9) -5.25 (-14.0-3.5); p=0.223 
Baseline to 6 months 2 - - - 
Baseline to 12 months 1 - - - 
Baseline to 24 months 0 - - - 
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7.3.7 Safety 
7.3.7.1 Day-of-treatment complications 
Severe complications and incidents associated with the microsphere product were recorded at the 
time of the SIRT procedure1. A total of 11 patients (3%) experienced severe day-of-treatment 
complications in the CRC cohort, and 1 (2%) in the ICC cohort (Table 7.13). In one reported product-
related incident the microspheres were spilled and the procedure had to be cancelled. Severe AEs 
within the first week after SIRT were rare; 3 patients experienced grade ≥3 fatigue in the 7 days after 
SIRT, and 1 patient experienced grade ≥3 abdominal pain in the first week after SIRT across (CRC and 
ICC cohorts combined). 
7.3.7.2 Deaths related to complications 
The SIRT registry included a field for the reason for death but this was poorly defined. Four patients 
(2 CRC, 2 ICC) had “complication” recorded as the cause of death. Details of these complications 
were as follows: i) one ICC patient had “tumour lysis syndrome” recorded and died 15 days following 
SIRT; ii) one ICC patient had “portal vein thrombosis and liver decompensation” recorded and died 
45 days after SIRT; iii) one CRC patient had “mild RILD developed at week 10; responding initially but 
then had upper GI bleed from duodenal ulcer; decompensated and developed fulminant 
hepatorenal failure” recorded and died 117 days following SIRT; iv) a CRC patient had “jaundice and 
biliary dilatation; following MRCP [Magnetic resonance cholangiopancreatography] patient 
developed bleeding and did not recover” recorded and died 184 days following SIRT. Relatedness of 
complications to the SIRT procedure was not recorded.  
7.3.7.3 Adverse events at follow-up 
AEs were recorded at follow-up visits every 2 to 3 months until progression. Amongst CRC patients, 
143 patients experienced an AE2. A total of 253 AEs were recorded of which 19 (8%) were grade 3 or 
above (Table 7.14). A total of 30 ICC patients experienced a total of 49 AEs, of which 4 (8%) were 
grade 3 or above (Table 7.14). Relatedness to the SIRT intervention was not recorded in the registry. 
The most common events were mild (grade 1-2) fatigue and abdominal pain in both cohorts. No 
severe cases of radiation induced liver disease (RILD), gastrointestinal ulceration, radiation 
pneumonitis, radiation cholecystitis, or radiation pancreatitis were recorded in either cohort.  
Events categorised as “other” with a free-text description accounted for 53 (21%) of the total in the 
CRC population. Most common AEs of grade 1 and 2 categories were anorexia (8 events), diarrhoea 
(7 cases), abdominal pain (6), and mucositis (2 cases). Seven events of grade ≥3 were recorded in the 
“other” category in CRC patients which were as follows: acute kidney injury (grade 3; occurred 28 
days after SIRT), bowel obstruction (grade 3; 21 days after SIRT); liver abscess (grade 3; 138 days 
after SIRT), skin rash (grade 3; 90 days after SIRT), delirium/dementia (grade 4; 79 days after SIRT), 
pulmonary emboli (grade 4; 47 days after SIRT); sepsis (grade 4; 18 days after SIRT). In the ICC group 
                                                          
1
 The registry did not record a grade for day-of-treatment complications, instead the question was worded as 
“were any severe day of treatment complications experienced?” 
2
 Percentages are not given because patients with a short follow-up period should not be included in the 
denominator.  
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16 events were recorded under in the “other” category which were in most cases gastrointestinal-
related such as diarrhoea, constipation, anorexia, and indigestion/reflux.  One grade 3 event was 
recorded in the “other” category which was diarrhoea & abdominal cramping (date unknown).  
A total of 430 events were recorded as abnormal laboratory values across the CRC and ICC cohorts 
(Table 7.15). The most common event categories were raised aspartarte aminotransferase (22%), 
raised  alanine aminotransferase (20%), and hypoalbuminemia (18%). In the CRC cohort, 18 of the 
353 events (5%) were grade ≥3  (mostly hyperbilirubinemia (8 cases), hypoalbuminemia (4 cases), 
and decreased neutrophil count (3 cases).  In the ICC cohort, 3 of the 77 (4%) events were grade ≥3 
(Table 7.15).  
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Table 7.13. Number of patients with severe day-of-treatment complications, product incidents 
recorded at time of procedure, and all causality adverse events in CRC and ICC populations 
(percentage of patients within each cohort shown) 
Event type Number of CRC patients (n=399) Number of ICC patients (n=61) 
Severe day-of-treatment complications 
Yes 11 (3%)1 1 (2%)2 
No 375 (94%) 58 (95%) 
Missing 13 (3%) 2 (3%) 
Product incident 
Yes 1 (0.3%)3 0 
No 300 (75%) 39 (64%) 
Missing 98 (25%) 22 (36%) 
 All causality adverse events (at least 1 event) 
Yes 143 (36%) 30 (49%) 
No 256 (64%) 31 (51%) 
 
Table 7.14. Total number of all-cause adverse events and grade ≥3 events recorded across all 
follow-ups in CRC and ICC cohorts (does not include day of treatment complications recorded in 
procedural data; percentage of total number of AEs shown) 
Category of event 
CRC cohort ICC cohort 
All adverse 
events 
(percentage of 
all AEs) 
Grade ≥3 
adverse events 
All adverse 
events 
(percentage 
of all AEs) 
Grade ≥3 
adverse events) 
Fatigue 89 (35%) 8 16 (33%) 2 
Abdominal pain 58 (23%) 3 11 (22%) 0 
Nausea 22 (9%) 0 2 (4%) 0 
Vomiting 14 (6%) 0 0 0 
Fever 10 (4%) 1 2 (4%) 1 
Gastritis 5 (2%) 0 0 0 
Gastrointestinal ulcer 1 (0.4%) 0 0 0 
RILD 1 (0.4%) 0 1 (2%) 0 
Radiation pneumonitis 0 0 0 0 
Radiation cholecystitis 0 0 1 (2%) 0 
Radiation pancreatitis 0 0 0 0 
Other 53 (21%) 7 (see below) 16 (33%) 1 
Total 253 (100%) 19 49 (100%) 4 
RILD: radiation-induced liver disease 
  
                                                          
1
 5 cases of severe abdominal pain; 1 minor vascular; 1 missing; 5 severe “other” (hypertension, chest pain, 
allergy to visipaque, syncope, rigors, unwell). 
2
 Severe abdominal pain. 
3
 Procedure cancelled due to spillage. 
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Table 7.15. Total number of abnormal laboratory value events by CRC, ICC, and all patients and by 
grade ≥3.  
Category of abnormal 
laboratory result event 
CRC cohort ICC cohort All patients 
All events Grade 
≥3 
All 
events 
Grade ≥3 All 
events 
Grade ≥3 
AST increased 79 (22%) 0 17 (22%) 1 96 (22%) 1 
ALT increased 73 (21%) 1 14 (18%) 0 87 (20%) 1 
Hypoalbuminemia 67 (19%) 4 12 (16%) 0 79 (18%) 4 
Hyperbilirubinemia 44 (12%) 8 10 (13%) 2 54 (13%) 10 
INR increased 1 (0.3%) 0 0 0 1 (0.2%) 0 
Neutrophil count decreased 10 (3%) 3 1 (1%) 0 11 (3%) 3 
Platelet count decreased 28 (8%) 0 12 (16%) 0 40 (9%) 0 
Other 51 (14%) 2 11 (14%)  0 62 (14%) 2 
TOTAL 353 
(100%) 
18 77 
(100%) 
3 430 
(100%) 
21 
ALT, alanine aminotransferase; AST, aspartate aminotransferase. 
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7.4 Discussion 
This is the largest UK study to examine the survival of patients with unresectable, chemotherapy-
refractory metastatic CRC and primary ICC treated with selective internal radiation therapy (SIRT).  
7.4.1 Overall survival 
The primary outcome of interest was OS. The estimate of 7.6 months OS for the CRC cohort fitted 
within the lower end of the range of previously published data. Subgroup analyses showed that male 
patients survived significantly longer than females. Also patients without extrahepatic disease had a 
significantly better overall survival than those with extrahepatic disease, as did patients with smaller 
numbers of tumours, and patients with a smaller tumour to liver volume percentage. Our systematic 
review (Section 4) reported that OS from 23 included studies ranged from 6.0 to 12.7 months 
(weighted mean 9.6 months). Interpretation of any survival benefit from SIRT is challenging in the 
absence of a control group treated with best supportive care.  
The results from the CtE cohort are in accord with those from the SIRT arm of the retrospective 
comparative cohort from Seidenticker et al. (2012) whose study reported an OS of 8.3 months in the 
SIRT arm compared to 3.5 months in the best supportive care arm, which was a statistically 
significant improvement (HR 0.26; p<0.001). The CtE CRC cohort had similar baseline characteristics 
compared with patients in Seidensticker et al. (2012). The higher OS estimate from the SIRT arm in 
the Bester et al. (2012) study of 11.9 months may be explained by the high proportion of patients 
with an ECOG performance score of 0 (85%) compared to 50% in the CtE cohort; in addition the 
Bester et al. study may include a higher proportion of chemotherapy naive patients (in the combined 
CRC and non-CRC group this value was 14%).  
Our review of survival estimates in a similar population of CRC patients treated in control arm of 
clinical trials and receiving BSC (Section 5) reported that median OS estimates ranged from 2.4 to 6.6 
months across seven identified studies, with a pooled estimate of 5.3 months. Direct comparisons of 
SIRT data (from observational studies and CtE) with data from patients treated with BSC from higher 
quality RCTs are not appropriate and should be interpreted with extreme caution. Differences in 
study designs and patient selection between the identified RCTs (drugs versus BSC) and this 
observational cohort are very likely to influence outcomes across the study 
NICE recently recommended trifluridine–tipiracil for chemotherapy-refractory CRC patients (i.e. 
those previously treated with other therapies such as fluoropyrimidine-, oxaliplatin- or irinotecan-
based chemotherapies, and biological agents) (NICE 2016). The clinical evidence was based on two 
RCTs (Mayer et al. 2015; Yoshino et al. 2012); median overall survival was extended by 2.0 months 
2.4 months, respectively. The NICE committee concluded that the survival benefit of trifluridine–
tipiracil, although relatively small, was clinically meaningful.  
In the ICC cohort, the median OS of 8.7 months was much lower than the pooled estimate of 15.3 
months presented from our systematic review (Section 4). This is likely to be in part due to the 
inclusion of chemotherapy naive patients in several previous studies.  Many of the identified studies 
were small and had wide confidence intervals around their OS estimates. No comparative studies of 
SIRT in the ICC population were identified, and neither were any studies that reported overall 
 
 
Page 103 of 175 
 
Commissioning through Evaluation: SIRT 
Full evaluation report 
survival in patients with chemotherapy-refractory ICC who received BSC. To provide some context, 
extrapolated results, likely to involve bias, indicate that patients receiving BSC following first-line 
progression survive approximately 4 months. ICC patients receiving second-line chemotherapy 
regimens survive for a median of 7.2 months (Lamarca et al. 2014a). 
The results from the CtE study were at the lower end of the range from previous studies, which may 
be explained in part by pragmatic design of this service evaluation. The results reported may reflect 
more accurately the survival of patients subjected to standard care alongside SIRT. In an 
observational registry study, high levels of missing data can be problematic. This was exacerbated in 
this CtE because of the absence of a follow-up phase after the last patient received the SIRT 
procedure. As such patients treated shortly before the data was extracted for analysis would almost 
inevitably be censored or excluded from survival estimates; although sensitivity analysis using 
patients treated at least 1 year before the study end indicated that results were robust. In this study, 
with date of death not recorded, we used as a proxy the last date recorded in the registry of having 
interaction with the healthcare team. In fact, some of these patients may have lived longer but their 
date of death was not recorded. No external validation of the date of death recorded in the registry 
was possible further reducing the reliability of this outcome. The ECOG scores of mostly 0 and 1 do 
not suggest that the CtE patients’ performance was considerably worse than in previous studies. In 
addition the presence of limited extrahepatic disease in around 40% of CRC patients and 36% of ICC 
patients is in line with the proportions observed in previous studies. Importantly, no sample size 
calculations were conducted for subgroup analysis therefore there is a greater risk of falsely 
accepting the null hypothesis in an underpowered comparison.   
7.4.2 Progression free survival 
The PFS in the CRC cohort of 3.0 months was at the lower end of the range from previous studies of 
2.8 to 9.2 months (Section 4). No previous studies reported PFS in the ICC population. LPFS was 3.7 
months in the CRC cohort in the CtE study which was comparable to the range of 2.0 to 9.0 months 
from previous studies that reported this outcome. PFS estimates from the CtE study (and other 
studies) should be interpreted with caution given the inherent risk of bias in this measure, which 
may be further compounded by the observational design of the CtE study.    
PFS and TTP rely on objective tumour response assessments. Tumour response as defined by RECIST 
criteria (Eisenhauer et al. 2009) is useful as a consistent measure for what happens to a tumour 
during therapy (Booth and Eisenhauer 2012). PFS also offers a useful outcome when longer follow-
up is impractical. PFS may, however, be unreliable if its associated pitfalls (described below) are not 
adequately accounted for (Korn and Crowley 2013; Sridhara et al. 2013). Firstly, PFS may not 
correspond to a measurable improvement in survival or HRQoL, which are arguably more meaningful 
outcomes to patients.  Secondly, progression in the CtE study is recorded as interval-censored data, 
and the frequency of assessments impacts directly on the PFS estimate. SIRT CtE clinicians report 
that their assessment schedule is every 2-3 months, but the registry data suggests that missing data 
is a considerable issue. PFS relies not only on accurate recording of the date of progression but also 
the preceding non-progressed result. Assuming that progression occurred on the date when it was 
confirmed by clinical assessment results in an inflated PFS estimate. Use of midpoint intervals (i.e. 
the midpoint between the date of the assessment prior to progression and the date of the 
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assessment at which progression was observed) may reduce the PFS and LPFS estimates reported 
here. Also, PFS includes death as an event in the absence of a progression date. Missing progression 
data (unrecorded assessments) introduce further bias which may inflate PFS estimates further.  
Finally, the assessment criteria not set out in advance in a protocol in the CtE study, which may lead 
to variation in assessments. In the CRC cohort, use of the RECIST criteria was recorded in 85% of 
imaging scans, although this did not include the version which changed from 1.0 to 1.1 in recent 
years. Even a set protocol (a tightly prescribed procedure) would entail subjective clinical judgment.  
This could be ameliorated by using an independent (blinded) assessor, and possibly some 
arrangements to resolve discrepancies. An approach not applied routinely in the CtE study.  
The CtE study reports a 0.7 month improvement in liver-specific PFS compared to PFS, which may 
mirror results observed in the RCT by Hendlisz et al., although such small changes cannot be 
interpreted reliably and may not be clinically relevant. The authors report that use of RECIST is an 
insensitive assessment criteria for SIRT-treated tumours because of issues such as necrosis which 
renders volumetric analyses insensitive (Hendlisz, Van den Eynde, Peeters, Maleux, Lambert, 
Vannoote, De, Verslype, Defreyne, Van, Delatte, Delaunoit, Personeni, Paesmans, Van Laethem, & 
Flamen 2010). The authors recommend metabolic-based imaging such as FDG-PET.  
7.4.3 Health related quality of life 
Improved HRQoL is a potential benefit of SIRT. Average changes in EQ-5D-5L and EQ-VAS from 
baseline to follow-up in the CtE study were challenging to interpret and likely limited by the small 
sample size due to rapid drop-out of patients in these measures after receiving SIRT. Changes were 
very small and ranged over less than 5% of the EQ-5D-5L scale. The minimally important difference 
(MID) defined as the smallest change in a patient reported outcome measure (PROM) that is 
perceived by patients as beneficial or that would result in a change in treatment. The MID for EQ-5D-
5L in cancer patients is between 0.10 and 0.12 (over a scale range of approximately 0 to 1) (Pickard 
et al. 2007); the statistically significant reduction in EQ-5D-5L from baseline to 3 months in the CRC 
group was small (0.042) and below the MID threshold. No EQ-VAS scores differences between 
baseline and follow-up reached statistical significance. The palliative nature of SIRT in this patient 
group whose HRQoL may be declining consistently over time makes interpretation of the results 
difficult and detection of any trend over time impossible. Importantly, without a control group we 
could not observe whether SIRT resulted in any improvement in HRQoL.  
EQ-5D-5L is a validated generic HRQoL measurement tool which can produce useful utility 
measurements for the purposes of economic analysis. It was selected because NICE recommends its 
use in economic assessments. However, a generic tool may lack the sensitivity to detect changes in 
HRQoL which result from control of hepatic tumour burden. The non-blinded nature of this study 
may introduce bias because the measurement of HRQoL is subjective and may be influenced by 
patients’ expectations about SIRT. Use of disease specific tools (such as the Functional Assessment of 
Cancer Therapy-colorectal (FACT-C) and hepatic (FACT-H)) may improve the likelihood of detecting 
clinically relevant changes in HRQoL.  
No studies were identified in our systematic review that provide robust evidence on the impact of 
SIRT on patients’ HRQoL (a single study in the CRCLM population assessed QoL but results were 
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poorly reported). This absence of evidence on QoL highlights the need to collect high quality data on 
this outcome using validated disease-specific tools.  
7.4.4 Safety 
Severe complications on the day of treatment were rare in the CRC and ICC groups; abdominal pain 
was the most common event. Adverse events in the follow-up period occurred in 36% of CRC 
patients and 49% of ICC patients treated with SIRT. However, unequal follow-up will impact on this 
rate. A total of 19 grade ≥3 AEs occurred in 399 CRC patients; in the ICC group 4 grade ≥3 AEs 
occurred in 61 patients. These were mostly abdominal pain and fatigue. Clinically important events 
such as RILD, radiation pneumonitis, radiation cholecystitis, and radiation pancreatitis were very rare 
or not reported at all. Two patients experienced mild (grade 1) RILD 84 days and 194 days following 
SIRT. These rates are much lower than the grade 3–4 toxicity rate of 26% reported in the systematic 
review by Zacharias et al. (2015). This difference may be explained by the very short follow-up 
period of patients recruited most recently to the CtE study, and the inclusion of several 
chemotherapy-related AEs by Zacharias et al. (2015). The rates were comparable in number and 
type to those reported in the review by Saxena et al. (2014). The registry did not record the 
relatedness of the event to the SIRT treatment. Because patients were not followed-up by the SIRT 
centres past progression it is unlikely that this study will capture events in the post-progression 
phase of the disease. The lack of defined grading criteria is a weakness which is likely to introduce 
variability across the 10 sites. Although it is likely that many of the sites used the Common 
Terminology Criteria for Adverse Events (CTCAE) this cannot be relied upon. Unusually the registry 
records only day-of-treatment complications when they are classified as “severe”; again the grading 
criteria are not defined, but non-severe events are not recorded.   
7.4.5 Strengths & limitations 
The study of more than 450 patients is the largest UK-based cohort and worldwide comes second 
only in size to the Kennedy et al. (2015) retrospective non-comparative cohort study conducted in 
the US. This is the first project within the CtE programme to report results and it shows that large 
scale prospective collection of observational data to a registry across several centres is feasible. The 
presented results are generalisable and have been obtained from patients treated under standard 
care arrangements in the NHS. The drawbacks associated with clinical trial effects are unlikely to be 
an issue. In addition, the conduct and analysis have been independent of the two device 
manufacturers; the analysis and reporting has been entirely independent of manufacturers, clinical 
teams, and NHS England. The authors of this evaluation report have no conflicts of interest.   
Limitations of this study have been described above in relation to the individual outcome measures. 
A number of additional limitations and learning points have been identified. Importantly, research 
questions were not defined in advance of data collection activities; this was partly a consequence of 
classifying the project as service evaluation rather than research. As such, the practicalities of 
collecting the necessary data, and definitions of outcome measures were not adequately considered. 
External validation of each patient against the CtE eligibility criteria was not possible, and from the 
information gathered in the SIRT registry it was not possible to confirm that patients who received 
only 1 previous line of chemotherapy were in fact intolerant to standard chemotherapy. 
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Anonymisation of the registry was necessary to meet information governance rules; the result 
however was that external validation of date of death (and other outcomes) against routinely 
collected datasets could not be carried out. Ultimately the absence of a contemporaneous 
comparator group (preferably patients receiving best supportive care) hampers the interpretation of 
results from the CtE cohort. This in turn limits the usefulness of the study to clinical practice. A 
prospective comparative matched-pair cohort, such as Seidensticker et al. (2012,) would provide 
comparative evidence on the survival benefit of SIRT in salvage mCRC and ICC populations. As is 
noted in Fleming et al. 2009 “except in settings where huge treatment effects can be expected, ITT 
analyses of data from RCTs are required to distinguish the effects of treatment from the influence of 
prognostic factors”. The recent publication of high quality randomised controlled trials necessary to 
produce a positive recommendation for trifluridine–tipiracil indicates the feasibility of such an 
approach to evidence generation for SIRT in this patient population (NICE 2016), although the ethical 
challenges of such a design are well-recognised. 
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8 Cost-effectiveness of SIRT in unresectable, chemotherapy-
refractory metastatic colorectal cancer 
8.1 Summary 
8.1.1 Published evidence on the cost-effectiveness of SIRT 
A systematic review of economic literature on the cost-effectiveness of SIRT yielded 144 studies. 
One study was relevant to the decision problem and selected for inclusion in the review (Pennington 
et al. (2015)). This study describes a 3-state partitioned survival model comparing the cost-
effectiveness of SIRT to BSC in patients with inoperable chemotherapy-refractory colorectal cancer 
liver metastases. The model calculated an increase in life years of 1.12 years in patients treated with 
SIRT (mean survival 2.09 years) compared to BSC (0.97 years). It also demonstrated a total cost of 
£35,487 for SIRT and £12,730 for BSC; the difference was driven primarily by the initial cost of the 
SIRT procedure and the monthly costs for monitoring and treatment during the additional survival 
time in SIRT patients. Quality adjusted life years (QALYs) were improved in the SIRT group by 0.81 in 
the model compared to BSC (1.50 vs 0.69), and the improved survival resulted in a cost per QALY 
gained (or incremental cost-effectiveness ratio [ICER]) of £28,216.   
This manufacturer-funded model used an appropriate structure and included relevant costs with 
most assumptions well described. The model was limited by the paucity of high quality comparative 
evidence. The overall survival time used for SIRT patients was longer than the alternative studies, 
and this is likely to favour SIRT. Sensitivity analysis was carried out to test the robustness of the 
model’s results to changes in key inputs, although the cost of SIRT (another key driver) was 
inadequately explored. The choice of inputs and ranges used for sensitivity analysis may 
underestimate the overall cost per QALY and ICER and the uncertainty reported in the model. 
Alternative approaches used in external assessment centre model highlight the impact of these 
choices.  
8.1.2 De novo cost-effectiveness model of SIRT compared to best supportive care by the 
external assessment centre 
Methods: A new model was created by the external assessment centre to estimate the cost-
effectiveness of SIRT compared with BSC in patients with unresectable, chemotherapy-refractory 
CRC. Model inputs were derived, where available and reliable, from the SIRT CtE registry data. 
Published studies, NICE technology appraisals, and clinical opinion were also used as sources of 
model inputs.  
The model used a 3-state partitioned survival analysis where the three health states were 
progression-free, progressed, and death. The time horizon was five years, the cycle length was one 
month, the perspective was from the NHS and personal social services, and a 3.5% discount rate was 
applied. Kaplan-Meier curves from the SIRT CtE registry data for OS and PFS were extrapolated using 
a Weibull distribution. In the base case, hazard ratios for OS and PFS were taken from available 
published comparative studies and used to create a survival curve corresponding to a BSC cohort. A 
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SIRT procedure cost (including work-up) of £21,870 was used to reflect the NHS England tariff used 
in the CtE project. A cost of chemotherapy was applied to both SIRT and BSC arms based on the 
assumption that a proportion of patients receive standard chemotherapy and a small proportion 
receive more expensive drug therapies such as biologics. In addition costs associated with 
monitoring and treating adverse events were applied. Utilities derived from HRQoL data from the 
SIRT CtE registry were not reliable and therefore published utilities were applied to the progression-
free and progressed states. Key assumptions were described.    
Results 
The ICER for SIRT was £85,350 in the base case of the external assessment centre’s model. 
Treatment with SIRT resulted in an increase in QALYs of 0.32 (0.58 vs 0.26). The model showed that 
SIRT was £27,406 more expensive than BSC (£31,028 vs £3,623 discounted costs). This was primarily 
due to high initial procedure costs in the SIRT arm.  
The cost of the SIRT procedure and the increased length of survival were the main drivers in the 
model. There was uncertainty around certain inputs such as the cost of chemotherapy and the 
utilities used for in the progression-free and progressed states. The former had a very low impact on 
the ICER, the latter had a moderate impact. Probabilistic sensitivity analysis showed that all 
simulations resulted in additional benefits in QALYs from SIRT compared to BSC for additional costs. 
The cost-effectiveness plane showed that 0% of simulations fell under the WTP threshold of £20K, 
0.7% fell under the £30K threshold, and 11.0% fell under the £50K threshold.  
Discussion 
The de novo cost-effectiveness model by the external assessment centre demonstrates that SIRT is 
unlikely to be considered cost effective in the UK (by the usual WTP threshold used by NICE) when 
the technology is used in patients with CRC which has failed standard available therapies. The ICER 
for SIRT compared to BSC may be lower when used in patients with a longer life expectancy where 
the initial procedure cost is spread over a longer period.  
The model was limited by the absence of a control group in the SIRT CtE registry data and 
uncertainty around the length of survival in the BSC arm. The hazard ratio from a retrospective 
cohort study was used to create survival estimates for the BSC arm which risks inflating the survival 
benefit from SIRT  
In the absence of high quality granular information, assumptions were made in relation to the cost 
of chemotherapy which may not accurately reflect clinical practice. The variability in the definition 
and application of BSC in practice, particularly following the recent introduction of trifluridine-
tipiracil to the patient pathway, impacts the generalisability of the model outputs.  
The higher base case ICER in the external assessment centre model of £85K compared to that of the 
published model by Pennington et al. of £28K can be primarily attributed to a higher cost for the 
SIRT procedure and a longer OS estimate in the model by Pennington et al. (2015).  The Pennington 
et al. model used a study which appeared to be a population with higher performance status and 
possibly more chemotherapy-naive patients compared with the SIRT CtE registry population. The 
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higher cost of SIRT (absent from the BSC arm) used in the current model was spread over a shorter 
survival time producing a higher cost per QALY.  
There is inadequate data to make a reliable conclusion about the generalisability of the model to the 
ICC population. Available data from the CtE registry indicate that several inputs are similar to those 
in the CRC population. The longer OS in the ICC cohort may slightly reduce the ICER in this group.   
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8.2 Objectives of section 
The aim of this section of the SIRT CtE evaluation report is to provide evidence on the cost-
effectiveness of SIRT for the treatment of unresectable and chemotherapy-refractory metastatic 
colorectal cancer (mCRC). There are three specific objectives: 
1) To undertake a systematic literature review to identify published cost-effectiveness 
evaluations of SIRT in patients with unresectable and chemotherapy-refractory mCRC. 
2) To conduct a targeted literature review (building upon those presented in sections 4 and 5) 
to identify evidence to inform the model inputs.  
3) To develop an economic model to estimate the cost-effectiveness of SIRT compared to best 
supportive care in the treatment of patients with mCRC. Results will be presented as an 
incremental cost-effectiveness ratio (ICER) describing cost per quality adjusted life year 
(QALY) gained with a range of scenarios and appropriate sensitivity analyses exploring 
uncertainty. 
In addition, this section will describe the costs associated with SIRT in the treatment of patients with 
unresectable, chemotherapy-refractory intrahepatic cholangiocarcinoma (ICC). 
8.3 Systematic literature review on the cost-effectiveness of SIRT 
8.3.1 Literature search methodology 
A literature search was designed to capture evidence relating to the clinical effectiveness of SIRT 
(described in Section 4). This same search encompassed cost-effectiveness evidence. A total of 1170 
studies were retrieved following deduplication. These studies were reviewed for relevance to clinical 
and cost-effectiveness. To identify economic studies, a simple search was run within Reference 
Manager ({cost} OR {economic} OR {model} using the “all non-indexed fields” search function). A 
total of 144 references were identified and sifted by one researcher using title and abstract (JW). 
Eight studies were identified as being potentially relevant (Beg et al. 2014; Bester et al. 2013a; 
Cosimelli et al. 2013; Loveman et al. 2014; Pennington et al. 2014; Pennington 2015; Sella and Rilling 
2011; Wasan 2014). Following a full text review, one study was identified as relevant and retained 
for full quality appraisal (Pennington 2015). Quality appraisal was based on NICE’s cost-effectiveness 
model appraisal guidance (NICE 2014b). The quality appraisal and results are presented below. Two 
studies (Loveman et al. 2014; Wasan 2014) were identified as potential sources of costs but were 
either out of scope or did not contain primary research. Five studies were excluded as they were 
conference abstracts with limited information available to adequately assess study quality.     
8.3.2 Description and critical appraisal of included study 
8.3.2.1 Results from the Pennington et al. (2015) cost-effectiveness model 
Pennington et al. (2015) describes a 3-state partitioned survival model comparing the cost-
effectiveness of SIRT to BSC in patients with inoperable chemotherapy-refractory colorectal cancer 
liver metastases. The model uses one-day cycles over a lifetime horizon (an unusually short cycle 
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length) from an NHS perspective. The key outcomes were life years gained, QALYs gained, cost per 
life year and cost per QALY gained. As such, the study is directly applicable to the evaluation of the 
SIRT commissioning through evaluation programme.  
Key results from Pennington et al. (2015) are presented below. 
- An increase in life years of 1.12 years in patients treated with SIRT (mean survival 2.09 years) 
compared to BSC (0.97 years) resulted from fitting a parametric curve to OS Kaplan-Meier curve. 
- SIRT increased QALYs by 0.81 (1.50 vs 0.69).  
- The total cost was £35,487 for SIRT and £12,730 for BSC, a difference of £22,757. This was driven 
by the high cost of initial SIRT treatment vs no initial costs for BSC and the monthly costs for 
monitoring and chemotherapy accumulated by SIRT patients during their additional survival 
time.  
- The improved survival in the SIRT arm resulted in a cost per QALY gained of £28,216, and cost 
per life year gained of £20,323.  
- Scenario analysis showed the model was robust to changes in key parameters with ICERs 
between £25,015 and £28,817. 
- There was a 57% probability of SIRT being cost-effective at a willingness to pay (WTP) threshold 
of £30K/QALY, and a 0% at a WTP threshold of £20K/QALY (read from graph). 
-  A tornado diagram demonstrated that parameters relating to the OS curve had the largest 
impact on the ICER. The authors applied a scale parameter to the survival curve for SIRT and 
varied this in sensitivity analysis. It is difficult to visualise how the scale parameter affects the 
survival curve, but the impact on the results of the model was a variation in the ICER between 
approximately £20,000 and £68,000.  
8.3.2.2 Appraisal of Pennington et al. (2015) cost-effectiveness model 
Pennington et al. (2015) used an appropriate model structure for the decision problem in question, 
and the study is relevant to the SIRT CtE evaluation. The 3-state partitioned survival model, defined 
health states as progression free, progressed disease, and death. This type of model does not look at 
the probability of moving from one state to another. Instead it directly uses the number of patients 
in each state during a cycle applying data from a survival curve. It does not consider the route by 
which patients arrive at each state. 
The model was produced by BresMed (Sheffield, UK) and funded by Sirtex Medical Ltd (the 
manufacturer of SIR-spheres). One author was employed by Sirtex Ltd, and others were advisors for 
the company. The study’s first author (RP) has not contributed to this critical appraisal. A read-only 
Excel model was supplied to Cedar by Sirtex Medical Ltd.  
Utility values were assigned to the progression free, progressed, and death states; these were not 
specific to the treatment type. There is no published evidence on the impact of SIRT on HRQoL in 
this population and therefore utility values were appropriately taken from a NICE HTA systematic 
review and cost-effectiveness model of biologic drugs used after first line therapy (Hoyle et al. 
2013a; Hoyle et al. 2013b).  
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The authors chose the retrospective matched-pair study by Bester et al. (2012) as the source of 
survival data (described in Section 4.4.4). The reasons given were the more generalisable definition 
of BSC than the chemotherapy regimen in control group of the RCT by Hendlisz et al. (2010), the risk 
of confounding from the RCT’s cross-over design, and underpowering of the RCT to detect a survival 
benefit. Whilst this justification is valid, the limitation associated with the retrospective, 
observational study design of Bester et al. (2012) makes the survival benefit attributed to SIRT less 
reliable. The authors do not provide a reason why Bester et al. (2012) was selected over 
Seidensticker et al. (2012). The longer survival times in the former study tend to favour SIRT in the 
model by reducing the ICER as the initial cost of SIRT is spread over a longer time period. 
The authors fitted a log-normal curve to the Kaplan-Meier survival data from a retrospective 
matched pair study by Bester et al. (2012) to account for patients alive at the end of the study. The 
small number of patients in the standard care arm (n=29) produced high uncertainty in the tail of the 
survival curve which may have a large impact on the model results. 
The authors assumed that there were equal patient numbers in progression free and progressed 
states at any point in time which may not be appropriate. As costs were assumed to be the same in 
each state, the total cost is unaltered, as shown by the sensitivity analysis. Additionally, the authors 
use the same utility values for both arms to represent progression-free, progressed disease and 
death. SIRT may offer local liver control following extra-hepatic progression which may produce 
different QOL utilities across the arms. However, there is no published data on the effect of SIRT on 
QoL or symptom control in the salvage setting. 
The cost of work-up procedures for patients who do not go on to have SIRT was not included in the 
model. However, the model includes patients who require multiple SIRT treatments (based on 2.2% 
at Christie Hospital), and patients who require more than one work-up procedure.  
The model included costs for the SIRT work up and procedure (£14,248), BSC, monitoring, further 
treatment, adverse events, and death. SIRT costs were derived from NHS reference costs and 
equipment costs from the Christie NHS Hospital. Adverse event rates (grade 3 and 4) were taken 
from a Phase III randomised controlled trial (Hendlisz et al. 2010). An end of life cost of £5,800 was 
applied to reflect the cost of palliative care.  Ongoing care costs including monitoring and 
chemotherapy were assumed to continue at a constant value for the patient’s entire lifetime. The 
costs for SIRT and work up used by Pennington et al. were derived using a micro-costing approach. 
This is a reasonable method, however the full details of this are not available and uncertainty was 
not explored in sensitivity analysis. 
One-way sensitivity analysis and probabilistic sensitivity analysis were used to investigate the 
robustness of the ICER when parameter uncertainty was considered. In one-way sensitivity analysis 
the authors varied the cost of SIRT by just ±£2, therefore uncertainty in the cost of SIRT was not fully 
explored, nor was cost of SIRT identified as a key driver of the model. Varying the key driver of SIRT 
overall survival resulted in ICER values between approximately £20,000 and £68,000. Given the 
selection of the most optimistic inputs for SIRT it is likely that the cost per QALY gained of £28,216 is 
overly optimistic.  
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Summary of strengths 
- An appropriate model structure was chosen. 
- The patient population was relevant to the current decision problem. 
- Most relevant costs were included. 
- Most assumptions were well described. 
- Most parameters were explored appropriately in sensitivity analysis. 
Summary of limitations 
- High quality clinical evidence was unavailable. The lack of comparative evidence on survival, and 
the impact of SIRT on quality of life reduces the reliability of cost-effectiveness estimates. 
- The assumption used for time spent in progression-free and progressed (i.e. 50% of patients in 
either state at any time) is unlikely to reflect real life.  
- The following limitations in the model are likely to favour SIRT:  
o The study from which OS was taken has a longer survival time than Seidensticker et al., 
which was an alternative source. A longer OS will reduce the ICER, as the cost of 
treatment is spread over a longer time. 
o The cost of SIRT was inadequately explored in the sensitivity analysis. 
o The cost of providing work-up for patients who do not receive SIRT was not included. 
8.4 Directed search for model inputs 
In addition to the systematic search for cost-effectiveness literature on SIRT described above, a 
pragmatic, directed information search was used to identify model inputs. Key sources of 
information are described below, including the new primary data collected from the SIRT CtE registry 
study, and systematic searches for effectiveness data on both SIRT and BSC, described in detail in 
earlier chapters.  
8.4.1 De novo data collected from the SIRT CtE registry study (see section 7) 
Data gathered in the SIRT CtE registry study was considered highly relevant to the cost-effectiveness 
question. Data was prospectively collected from 399 patients with unresectable, chemotherapy-
refractory colorectal cancer treated with SIRT at 10 NHS centres in England onto a registry (full 
methods and results are described in section 7). Outcomes which were of relevance to the model 
were OS, PFS, complications, adverse event rates and types, and utility data derived from EQ-5D-5L 
questionnaires. In addition, details about the SIRT procedure, length of hospitalisation, concomitant 
chemotherapy, post-SIRT chemotherapy, frequency of imaging scans and follow-up appointments 
were recorded. No comparator data were collected in this study.  
8.4.2 Systematic review of the efficacy of SIRT in CRC patients (see section 4) 
A systematic review was carried out to summarise the clinical evidence on the efficacy of SIRT in 
patients with unresectable, chemotherapy-refractory mCRC (section 4). Three comparative studies 
were identified (1 RCT and 2 retrospective cohorts) and 21 non-comparative studies. All studies 
underwent critical appraisal. Results from the three comparative studies identified during this 
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review (Bester et al. 2012; Hendlisz et al. 2010; Seidensticker et al. 2012) were used to inform model 
parameters for SIRT and BSC including OS, PFS, adverse event rates, and ongoing treatment 
frequency and type.  
8.4.3 Rapid review of the efficacy of best supportive care in CRC patients (see section 5) 
A literature review was conducted to identify studies which report the survival of patients with 
unresectable, chemotherapy-refractory mCRC who have received BSC (section 5). This strategy was 
designed to identify high quality comparative studies in which BSC was the control arm, and which 
presented OS or PFS. Individual studies underwent critical appraisal and were used to inform survival 
estimates in the best supportive care arm of the model. 
8.4.4 Identification of relevant NICE guidance 
The NICE website was searched for guidance relevant to the decision problem. The following 
technology appraisals (TAs) were considered relevant and likely to include evidence to inform the 
model:  
 Technology appraisal guidance [TA405] Trifluridine–tipiracil for previously treated 
metastatic colorectal cancer (August 2016) (NICE 2016). This technology appraisal 
evaluated the clinical and cost evidence on Trifluridine–tipiracil compared to BSC in patients 
with CRC which has progressed following treatment with standard chemotherapy. Whilst the 
intervention does not match the decision problem on SIRT the population is similar.  
 
 Technology appraisal guidance [TA242] Cetuximab, bevacizumab and panitumumab for 
the treatment of metastatic colorectal cancer after first-line chemotherapy: Cetuximab 
(monotherapy or combination chemotherapy), bevacizumab (in combination with non-
oxaliplatin chemotherapy) and panitumumab (monotherapy) for the treatment of 
metastatic colorectal cancer after first-line chemotherapy (January 2012) (NICE 2012). This 
technology appraisal evaluated the use of a range of biologic therapies compared to BSC for 
the treatment of patients who have failed at least one previous line of chemotherapy. The 
evidence includes an independent systematic review and economic model conducted by 
Peninsula Technology Assessment Group (PenTAG) and commissioned by the NIHR HTA 
programme (Hoyle et al. 2013a). Key results from a sub population of patients who have 
progressed following three or more previous lines of chemotherapy were also published in a 
peer reviewed journal (Hoyle et al. 2013b). The authors kindly provided a copy of the 
executable Microsoft Excel model to Cedar.   
8.4.5 Clinician questionnaire  
A questionnaire was designed by Cedar to obtain clinical feedback about usual practice in the UK 
regarding the treatment pathway for patients treated with SIRT and best supportive care (Appendix 
6). Responses were collated and used to inform the model. 
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8.5 De novo cost-effectiveness model by the external assessment centre 
A full cost-effectiveness model comparing SIRT to BSC in patients with colorectal cancer was 
undertaken by an independent external assessment centre (Cedar, Cardiff & Vale University Health 
Board).  
8.6 Methods 
8.6.1 Population 
The population modelled matched that of patients with unresectable, chemotherapy-refractory CRC 
recruited into the SIRT CtE registry study. This comprised patients with metastatic colorectal cancer 
which progressed following treatment with at least two lines of standard chemotherapy. All patients 
entered the model at the point at which they received SIRT treatment or continued with BSC, and 
are followed to progression based on the actual data from the SIRT CtE study and comparator data 
from the literature. 
8.6.2 Intervention and comparator 
The intervention was SIRT treatment, as described in previous sections. The comparator was best 
supportive care (BSC); however this is not clearly defined in practice. Published literature and clinical 
advice indicate that wide variations exist based on patient and clinician preference, regional and 
temporal variations. 
8.6.3 Patient pathway 
The patient pathway was based on SIRT CtE registry data, questionnaires to clinicians and published 
information, with the intention of reflecting current practice within the NHS.  
For the SIRT arm, patients receive a work-up procedure followed by treatment in the first one-
month cycle of the model. Approximately 5%  of patients receive a work-up procedure without 
progressing to SIRT (to reflect patients who are found to be ineligible for SIRT following their work-
up procedure, based on the clinician questionnaire); 8%  require more than one work up, usually for 
additional embolisation (source: CtE registry data); 3% require two complete SIRT procedures 
(source: CtE registry data). 
Following SIRT treatment, patients will have regular follow-up appointments and scans, and a 
proportion will also have chemotherapy treatment (source: CtE registry data and clinician 
questionnaire). 
The comparative arm is BSC. Due to the variation in practice, assumptions have been made for the 
model based on clinician questionnaires and published literature (Table 8.1). It has been assumed 
that the BSC arm has the same level of monitoring and chemotherapy as SIRT. This is investigated 
further in alternative scenarios.  
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8.6.4 Model structure 
A three state model was created in Microsoft Excel, applying partitioned survival state analysis 
commonly used for cost-effectiveness models in oncology populations. The three states, and patient 
movement between them are shown in Figure 8.1.  
- Progression free: This was the entry state for all patients, and is defined as no progression 
since entry into the model.  SIRT treatment occurs at entry to the model for the SIRT arm. 
- Progressed: At disease progression (hepatic or extrahepatic) identified by a clinician. 
- Death: Patient has died 
The time horizon was five years, which reflects a lifetime horizon for this patient population. The 
cycle length for the model was one month, which was sufficiently short to see differences between 
the two treatment arms. An NHS and personal social services perspective was used, together with a 
3.5% discount rate as is standard for the NICE reference case.  
The partitioned survival analysis considers the actual number of patients in each state at each 
month, and does not calculate the transition probabilities between each state. This can give simpler 
calculations and reflects the availability of survival data from clinical trials. In the case of SIRT CtE, 
survival data was available for PFS, and for OS. Survival data for BSC was available from published 
papers.  
 
Figure 8.1. Three state model for cancer progression 
8.6.5 Key assumptions 
- Quality of life decreases when the patient moves from progression free to progressed state. 
- There is a proportionate hazard assumption between SIRT CtE survival and BSC survival. 
- Costs of progression-free treatment are comprised of monitoring costs and chemotherapy 
costs. 
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- Monitoring and chemotherapy costs are the same in BSC and SIRT during the progression-
free state. 
- A proportion of patients will have a limited number of chemotherapy cycles (up to 4 cycles, 
if they continue in the progression-free state). 
- Patients who live longer than 4 months in the progression-free state will not have further 
chemotherapy. There is no chemotherapy in the progressed state. 
- Costs  (including nursing time, hospitalisation, and interventions) in progressed state are the 
same for SIRT and BSC patients. 
8.6.6 Model inputs (base case) 
Model inputs are described in detail below. Table 8.1 summarises the inputs that were used in the 
model; full details on the information sources that were considered, together with considerations on 
their appropriateness for use in this model are presented in Appendix 7. 
Table 8.1. Summary of model and inputs. 
Input 
Base Case 
value 
Source 
Time horizon 5 years Based on observed survival times 
Discount rate 3.5% NICE reference case 
Perspective 
NHS and 
personal 
social 
services 
NICE reference case 
Survival (mean, months) 
SIRT overall survival 9.8 SIRT CtE data, Weibull distribution fitted 
BSC overall survival 4.2 0.27 hazard ratio (Seidensticker et al. 2012) 
SIRT progression free survival 4.3 SIRT CtE data, Weibull distribution fitted 
BSC progression free survival 2.7 0.51 hazard ratio (Hendlisz et al. 2010) 
Procedure costs (per patient) 
SIRT procedure, including work-
up 
£21,870.00 
CtE Tariff, using 2016-17 NHS tariff (source: NHSE 
England pricing) 
Patients receiving work-up and 
not proceeding to SIRT 
£298.79 
Weighted cost per patient: 5% of total patients routed 
to SIRT (source: clinician questionnaire) 
SIRT patients receiving 2 work-
up procedures, 1 SIRT 
£454.16 
Weighted cost per patient: 8% of patients receiving SIRT 
(source: SIRT CtE registry data) 
SIRT patients receiving 2 
complete SIRT treatments 
£656.1 
Weighted cost per patient: 3% of patients receiving SIRT 
(source: SIRT CtE registry data) 
Total SIRT Procedure £23,279.05 
Total cost used in model, per patient, including all 
weighted costs above. 
Chemotherapy costs (per patient; each cost is a cost per chemotherapy cycle applied once per month), 
see section 8.6.9 for details 
Cost of standard chemotherapy 
regimen (e.g. FOLFOX) 
£978.00 
Based on NHS Reference Costs 2015-16 (Department of 
Health 2016) 
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Cost of biologic drug cycle, or 
similarly priced regimen 
£2,770.00 
Based on NHS Reference Costs 2015-16 (Department of 
Health 2016) 
Cost of first cycle of 
chemotherapy 
£396.06 
Assumption: 32% receive standard chemotherapy (e.g. 
FOLFOX); 3% receive biologic drug, or similarly priced 
regimen 
Cost per cycle, for subsequent 
3 chemotherapy cycles 
£286.84 
Assumption: 18% receive standard chemotherapy (e.g. 
FOLFOX); 4% receive biologic drug, or similarly priced 
regimen 
Cost of chemotherapy after 4 
months 
£0.00 
This assumption was made due to lack of high quality 
data for both SIRT and BSC arms. Other models 
assumed either no chemotherapy, or chemotherapy for 
patient lifetime. SIRT CtE data did not support fully 
either assumption. The impact on the ICER is very low 
due to short survival times, and is tested in sensitivity 
analysis 
Monitoring Costs (per patient, per month) 
SIRT monitoring  £161.00 
CtE questionnaire plus NHS Reference Costs 2015-16 
(Department of Health 2016). Assume until progression. 
BSC monitoring  £161.00 Assume same as SIRT 
Costs per patient in each state 
Progression free Not fixed Monitoring costs plus chemotherapy costs 
Progressed £952.05 
Taken from Remak and Brazil (2004), supportive care 
costs. Assumption of same costs for BSC and SIRT arms. 
Inflated to 2016 
Transition to death £875.31 
Taken from Remak & Brazil (2004), using stated 
monthly cost for end of life, and stated length of end of 
life stage. Inflated to 2016 
 Death £0.00  Any costs are in the transition element. 
Adverse Events 
SIRT adverse events £21.20 
AEs from CtE data, costed using NHS Reference costs 
(Department of Health 2016) and costs from Mickisch 
et al. (2010), inflated to 2016. Relatedness of AEs to 
SIRT not captured in registry. 
BSC adverse events £21.20 
Assumed to be the same (cost of SIRT-specific AEs not 
known). See section 8.5.13 for further details. The 
impact of this assumption on the ICER is likely to be 
very low, and is tested in sensitivity analysis. 
 Quality of Life 
Progression free 0.75 From Hoyle, 2013b 
Progressed 0.69 From Hoyle, 2013b 
Transition to death 0.10 
From Pennington et al. applied for 1 month, on 
transition to death 
AE, adverse event; BSC, best supportive care; CtE, commissioning through evaluation; ICER, incremental cost-
effectiveness ratio.  
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8.6.7 Survival  
8.6.7.1 Extrapolation of OS and PFS data from the SIRT CtE registry  
Kaplan-Meier survival analysis was used to analyse data from the SIRT CtE registry study for OS and 
PFS from patients treated with SIRT. The SIRT CtE registry data was considered the best source of OS 
and PFS data for the SIRT arm of the model. It was a large dataset collected recently in the NHS 
setting and from a population relevant to the economic evaluation.  
A Weibull curve was fitted to the SIRT CtE data for OS and PFS. For OS, a Weibull distribution was 
both graphically and using the Akaike information criterion (AIC) a reasonable option, however for 
PFS the fit was less close (Figure 8.2; Table 8.2). The requirement to meet the assumption of 
proportional hazards to use published hazard ratios restricted the choice of methods for curve 
fitting. The limitations of this approach were recognised but no other data was available. The mean 
values used for OS and PFS in the sensitivity analysis include the range that would have been seen 
using an alternative distribution.  
8.6.7.2 Survival data for the BSC arm of the model 
No comparator data were collected during the SIRT CtE registry study, therefore previously 
published work was used.  The best option for obtaining OS and PFS data for the BSC arm of the 
model was to use hazard ratios from published evidence applied to the SIRT CtE registry data. The 
options considered to obtain survival data for BSC were two observational studies (Bester et al. 
2012; Seidensticker et al. 2012) and one RCT (Hendlisz et al. 2010; Table 8.3). A number of 
considerations were taken into account and described below.  
- The Hendlisz et al. (2010) RCT was excluded as a source of OS data for the BSC arm because a 
cross-over design was used whereby patients from the control group were permitted to receive 
SIRT following progression which would confound estimates of OS. In addition, the RCT only 
reported a median value for OS with no Kaplan-Meier curve.  
- Bester et al. (2012) was excluded because patients with CRC recruited to the SIRT group of the 
Bester et al. study were likely to have better health at baseline compared to those in the SIRT 
CtE cohort (85% of the SIRT group in Bester et al. were ECOG 0 compared to 50% in the SIRT CtE 
cohort, and the performance status for BSC group was not reported). The OS curve for SIRT 
patients in Bester et al. showed longer survival than the SIRT CtE registry data suggesting that 
the BSC population may not be comparable to the SIRT CtE registry data (Figure 8.3) 
- The Kaplan-Meier OS curve for the SIRT CtE registry data was more similar to that of the 
Seidensticker et al. (2012) OS data than the extrapolated curve for OS fitted to patient data from 
the Bester et al. study (extrapolated data was taken from the Pennington et al. 2015 model with 
permission; Figure 8.3). As a result, Seidensticker et al. was chosen as the source for the hazard 
ratio to apply to OS data from the SIRT CtE registry data to create a survival curve for the BSC 
arm of the model.  
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Access was requested to patient level data for all three papers, but was not granted. Therefore 
Seidensticker et al. data was taken electronically from the published graph and data points 
reproduced using DataThief (Tummers 2006). 
Neither Bester et al. (2012) nor Seidensticker et al. (2012) reported survival curves or hazard ratios 
for PFS therefore the hazard ratio from Hendlisz et al. (2010) was used. The hazard ratio from 
Hendlisz et al. was applied to the SIRT CtE registry data to create a PFS curve for the BSC arm of the 
model. The PFS curve is not affected by the cross-over design because cross-over occurred after 
progression. The SIRT PFS curve for Hendlisz et al. (2010) was similar to SIRT CtE data. A limitation of 
using Hendlisz et al. as a source is the fact that the control arm received a fluorouracil chemotherapy 
regimen rather than BSC.  
A hazard ratio of 0.27 from Seidensticker et al. (2012) was applied to the extrapolated overall 
survival curve from the CtE registry data in order to create a corresponding curve for the BSC arm of 
the model (Tables 8.1 and 8.3; Figure 8.4). Similarly, a hazard ratio of 0.51 from Hendlisz was applied 
to the PFS data from the CtE registry (Figure 8.4). It was not possible to directly fit curves to the 
Seidensticker et al. (2012) and Hendlisz et al. (2010) data because patient-level data was not 
available, and because the original data would have led to some points in time having progression 
free survival greater than OS. The final extrapolated SIRT CtE for OS and PFS curves and 
corresponding BSC curves created using hazard ratios used in the base case model are shown in 
Figure 8.4 
Table 8.2. Mean survival and AIC value using alternative distributions fitted to CtE data 
 OS,  SIRT CtE PFS,  SIRT CtE 
 AIC Mean (months) AIC Mean (months) 
Exponential 751.8229 11.22597 830.9573 4.29868 
Weibull 673.6352 9.823486 742.4854 4.251284 
Loglogistic 648.0379 10.41232 629.95 3.961386 
Lognormal 644.3761 10.10061 657.05 4.153542 
AIC, Akaike information criterion (lower values indicate better fit); OS, overall survival; PFS, progression free 
survival  
Table 8.3. Summary of survival data available from different sources 
Study 
Overall survival (months) Progression free survival (months) 
SIRT Comparator SIRT Comparator 
Median Mean Median Mean Median Mean Median Mean 
SIRT CtE 
registry 
7.6 9.8 - - 3.0 4.188 - - 
Bester et al. 
(2012) 
11.9 NR 6.6 NR NR NR NR NR 
Seidensticker 
et al. (2012) 
8.3 NR 3.5 NR 5.5 NR 2.1 NR 
Hendlisz et 
al. (2010)  
10 * NR 7.3 NR 4.5 NR 2.1 NR 
*Cross over design permitted patients randomised to control group to receive SIRT following progression. NR, 
not reported. 
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Figure 8.2. Extrapolated curves fitted to SIRT CtE survival data using various distributions  
 
 
Figure 8.3. Overall survival for SIRT patients from different data sources 
 
Overall Survival     Progression Free Survival 
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Figure 8.4. OS and PFS curves for SIRT and BSC arms used for base case model 
 
8.6.8 SIRT procedure costs 
The cost of the SIRT procedure was based on the current NHSE England tariff of £21,870, calculated 
using NHS Reference Costs 2015-16 (Department of Health 2016). This was then weighted to reflect 
scenarios in which patients’ treatment deviates from the usual format of one work-up followed by 
one SIRT procedure. The following alternative scenarios were costed.   
- 5% of total patients routed to SIRT receive a work-up, but do not proceed to receive SIRT. This 
was due to findings at work-up showing ineligibility for SIRT or progression of disease between 
an initial assessment and work-up (source: clinician questionnaire). 
- 8% of patients receiving SIRT received two work-ups. A second work-up may be required to carry 
out additional embolisation (source: SIRT CtE registry data). 
- 3% of patients receiving SIRT had two complete SIRT procedures; it is assumed that this involved 
an additional work up as well as the procedure. Sequential SIRT procedures are required in 
certain circumstances (source: SIRT CtE registry data). 
As a result of weighting the additional scenarios, the total cost per person for SIRT and work-up used 
in the model was £23,279.05 (Table 8.1). 
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Data collected from the CtE registry was not detailed enough to enable a micro-costing approach for 
the SIRT procedure. 
8.6.9 Chemotherapy costs 
The SIRT CtE registry captured data on the use of chemotherapy and biologic drugs either 
concurrently with SIRT, or after SIRT treatment. There was considerable variation in descriptions of 
drug regimens, and some missing data. Furthermore, the level of detail required to cost each 
patient’s individual treatment was unavailable for the entire patient group. For this reason, the CtE 
registry data was used only as a basis for an assumption on the cost of drug treatment.  
The results of the SIRT CtE data for chemotherapy are described in Section 7, Table 7.4. These show 
that 35% of patients received chemotherapy (including biologics) concurrently with SIRT, with only 
4% missing data. Following SIRT, 22% patients were recorded as receiving chemotherapy (including 
biologics). However, 24% had missing data. Most of these patients received a standard 
chemotherapy regimen such as FOLFOX, or other similarly priced fluoropyrimidine-, oxaliplatin- or 
irinotecan-based regimens. A small number were receiving more expensive regimens including 
biologics such as cetuximab + irinotecan, or regimens such as trifluridine–tipiracil.  
It was assumed that in the first month following SIRT, 32% of patients had one cycle of FOLFOX 
(£978) or similarly priced regimen and 3% had one cycle of a regimen priced to include a biologic 
(£2,770; Table 8.4); this is based on the figure of 35% patients who received concomitant 
chemotherapy in the SIRT CtE cohort. The costs were calculated using NHS Reference costs 2015-16 
(Department of Health 2016; Table 8.4) and calculated by combining the cost code for procuring the 
drug, with the cost of delivery, according to the type of regimen (full details are available from HSCIC 
[201]). Based on these weighted values, a cost of £396.06 per patient for the first cycle of 
chemotherapy was applied in the model (Table 8.1).  
In the next 3 months following SIRT, of those patients who were still in the progression-free state, 
18% had one cycle of FOLFOX or similarly priced regimen (£978) and 4% had 1 cycle of a regimen 
priced to include a biologic (£2,770). This gave a weighted value for subsequent chemotherapy 
cycles of £286.84 per patient which was used in the model (Table 8.1). 
Once patients progressed, it was assumed that they were no longer receiving chemotherapy.  
We are aware that these assumptions do not accurately reflect routine clinical practice as 
chemotherapy cycles are not necessarily monthly, and the treatment options available are more 
varied and complex. However, in the absence of more detailed and reliable data, this method was 
chosen as a necessary compromise which avoids front-loading the cost of drugs at the start of the 
model, which would overestimate costs for patients who die before receiving chemotherapy, and 
avoids distributing chemotherapy over the patients’ entire life span which would overestimate costs 
in patients who live longer. 
It is assumed for the base case that the same costs for chemotherapy apply to SIRT and BSC. This 
assumption will result in a slightly higher cost for SIRT chemotherapy than for BSC chemotherapy, 
because fewer BSC patients remain in the progression-free state for 3 months or longer. 
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Table 8.4. Cost of relevant drug regimens from NHS Reference costs 2015-16  
Drug regimen 
Procuring drugs 1st drug delivery 
2nd drug 
delivery 
Per 
cycle 
cost NHS Code Cost NHS Code Cost Cost 
FOLFOX SB06Z £462 SB14Z £304 £212 £978 
Cetuximab + irinotecan + 
capecitabine 
SB10Z £2,466 SB14Z £304 n/a £2,770 
8.6.10 Monitoring costs (progression-free state only) 
Monitoring costs have been based on responses to the clinician questionnaire (Appendix 6) and SIRT 
CtE registry data on the number of MRI and PET scans carried out. As standard, patients were 
followed-up every 2 to 3 months with a CT scan. SIRT CtE registry data from the first and second 
follow-up appointments indicated that in addition to CT scans, 2.1% of patients received a MRI scan 
and 12.0% received a PET scan at each follow-up. Costs are taken from NHS Reference costs 2015-16 
(Department of Health 2016) (Table 8.5). The following assumptions were used in the model.  
All patients would receive a follow-up examination every 2.5 months including: 
- an appointment with a consultant  
- a CT scan  
- 2% would have an MRI scan  
- 12% would have a PET scan 
For the base case a cost of £161 per patient, per month was used for monitoring (Table 8.1). It was 
assumed that the same monitoring costs apply to the SIRT and BSC arms of the model. Alternative 
costs have been used during sensitivity analysis. These include outpatient visits every 2 weeks for 
the BSC patients (source: SIRT data working group). 
Table 8.5. Costs of monitoring used in the model 
 Item 
Frequency for SIRT 
patients , every 2-3 
months 
Cost per 
item 
Monthly 
cost 
NHS Ref Code 
CT scan of chest, 
abdomen, pelvis 
1 £121 £48 RD26Z 
MRI scan 
1 for 2% of patients 
– CtE data 
£213 £2 RD05Z 
PET scan 
1 for 12% of 
patients –CtE data 
£944 £45 RN031 
Outpatient 
consultant visits  
1 163 £65 WF10A 
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Laboratory tests 1 2.08 £1 
Weighted cost of 
DAPS01-09 
 Total (per patient)   £161  
 
8.6.11 Costs of supportive care in the progressed state 
Costs of supportive care during the progressed state are taken from a study on breast cancer patient 
care (Remak & Brazil 2004), inflated to 2016 prices (Table 8.6). This source was also used in a 
previous HTA (Hoyle et al. 2013) in a similar patient population as this SIRT CtE study. The original 
data came from a questionnaire to clinicians on the proportion of different interventions at different 
stages in progression of disease. The total of £672.73 was inflated from 2000 to 2016 to give a 
monthly cost of £952.05 which was used in the base case (Table 8.1). 
Table 8.6 Costs per patient during progressed state, taken from Remak & Brazil (2004). 
Item Cost 
Radiotherapy £17.80 
Medication £62.90 
Special interventions £101.66 
Scans and laboratory tests £77.77 
Hospitalisations 42% £157.40 
Outpatient visits Specialist (90%) 
£255.20 MacMillan nurse (65%) 
District nurse (50%) 
TOTAL £672.73 
8.6.12 Costs at end of life 
The study by Remak and Brazil (2004) calculated a cost of end of life, which inflated to 2016, was 
£875.31 and used in the base case (Table 8.1). It was assumed that supportive care for breast cancer 
is similar to mCRC, and that procedures are still similar to those recorded in 2000. The study was 
used in previous models for mCRC, and is in line with other costs reported. For example, using 
Round et al. (2015) a study used in the NICE technology appraisal of trifluridine-tipiracil (TA405 (NICE 
2016)) the costs during palliative care 1 would equate to £927.5 per month (having removed the end 
of life cost of £875.31). Thus, although neither Remak and Brazil (2004) nor Round et al. et al. (2015) 
were ideal sources of costs for patients in the progressed stage, the similarity of monthly costs 
between these sources provided confidence that the figure was a reasonable estimation of the real 
cost. Sensitivity analysis encompassed the variation between the two studies.  
It was assumed that the same costs apply to the SIRT and BSC arms of the model. 
                                                          
1
 Defined as the period from the point when the patient starts to take strong opioids, expected to be 6.6 
months for mCRC with a total cost for health and social care of £6910. 
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8.6.13 Adverse events 
The only information source with adverse events data on SIRT compared with BSC was Hendlisz et al. 
(2010). There were a number of limitations with using AE data from Hendlisz et al. (2010) such as the 
small sample size, differences between the control arm (active chemotherapy) and the definition of 
BSC used in this model. As a result, we decided not to use these data in the model. 
Since AE data were collected as part of the SIRT CtE registry study, this was used to calculate costs 
for those events at Grade 3 or over, using NHS reference costs (Department of Health 2016), or 
where these were not available, costs from (Mickisch et al. 2010) (Table 8.7). In the absence of 
further information, an assumption was made for the costs of “other adverse events” as twice the 
cost of fatigue (the highest cost of any of the included events).  A one-off cost per patient of £21.20 
was used for adverse events in the base case (Table 8.1).  
There were no grade ≥3 occurrences of radiation induced liver disease (RILD) seen in the SIRT CtE 
study. No RILD events were reported in 21 patients in Hendlisz et al. (2010), 3 cases were reported in 
29 patients in Seidensticker et al. (2012), and 1 case was reported in 339 patients in Bester et al. 
(2012). Advice from clinicians was that treating severe RILD would be costly if it were to occur. An 
investigation of the impact of a rare high cost event was therefore carried out and results indicated 
that it would have a minimal impact on the results of the model overall. For example, if the 
treatment cost was assumed to be £8,000, with an event probability of 1%, this would add an 
additional £80 on to the cost per patient. Although this increases the AE cost by several times, it is 
only applied once at the model start, and has very little impact on the total procedural cost.  
The relatedness of adverse events to SIRT was not captured in the SIRT CtE registry. No data were 
available on BSC patients in the SIRT CtE registry. The variance in approaches reported in other 
economic evaluations is detailed in Appendix 7, with adverse event-related costs ranging from 
£42.55 to £2,760. This may be more, less or the same as the AE cost used for the intervention, in 
different models. Due to uncertainty in the direction of change of AE costs between SIRT and BSC, an 
assumption was made in the model that the costs of AEs were the same (and using cost calculated 
from the SIRT CtE registry data [Table 8.7]). One way sensitivity analysis uses a large range to 
investigate the implications of this choice. 
Table 8.7 Costs of adverse events used in the model (data from SIRT CtE cohort).  
Adverse event 
type 
Number of 
grade ≥3 
AEs  
% of 
patients 
Cost per 
event 
Cost inflated to 
2017 and 
converted to £* 
Cost of AE per 
patient (grade 
≥3) 
Abdominal pain 3 0.8% £139.52 £141.81 £1.07 
Fatigue 8 2.0% €3721 £332.92 £6.68 
Fever 1 0.3% £158.43 £161.03 £0.40 
Other 7 1.8% £744.00 £665.84 £13.05 
TOTAL 19 4.8%   £21.20 
*EPPI Cost converter: http://eppi.ioe.ac.uk/costconversion/default.aspx 
                                                          
1
 Original source uses euros 
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8.6.14 Quality of life 
Quality of life data were collected during the SIRT CtE registry study. However, there were concerns 
about missing data and the appropriateness of the study design for this outcome.  In the CRC cohort, 
only 32% of patients had an EQ-5D-5L measurement at 3 months which dropped further to 3% at 12 
months (see Section 7.3.6). The mean pre- and post-progression utility scores in the CRC cohort 
were 0.82 (SD 0.17; n=68) and 0.77 (SD 0.16; n=105), respectively. The SIRT CtE registry study was 
not designed to collect post-progression data and therefore there is a high risk of bias in this 
measure. Furthermore, the SIRT CtE data does not provide information for patients treated with 
BSC. 
Utilities data used in previous models (Hoyle et al. 2013a; Pennington 2015) were therefore used in 
the current model. The progression free utility value used was 0.75, and the progressed disease 
utility value was 0.69 (Table 8.1). Values were taken from the BSC arm of a study of mCRC, 
comparing cetuximab to BSC (Karapetis et al. 2008). In the absence of reliable utility values from 
patients treated with SIRT an assumption was made that the same utility values for progression-free 
and progressed disease were applied to both the SIRT and BSC arms of the model, as described by 
Pennington et al. (2015). The potential impact of SIRT on quality of life would be reflected in the 
model from the longer time spent in the progression-free state. Other sources of utility values are 
described in Appendix 7. For example, NICE’s technology appraisal TA405 {NICE, 2016 10 /id} used a 
value of 0.75 for the progression-free state and 0.59 for the progressed state, taken from the 
CORRECT study of regorafenib monotherapy for previously treated metastatic colorectal cancer 
{Grothey, 2013 316 /id} demonstrating comparable values with those used in our de novo model.  
A pre-death transition utility value of 0.10 was applied for 1 month on transition to death as 
described in Pennington et al. (2015). This was applied to both arms and because all patients die 
within the time horizon it does not impact on the incremental results.  
8.7 Sensitivity analysis methods 
8.7.1 Deterministic one-way sensitivity analysis  
Deterministic one-way sensitivity analysis varies one input at a time, with all other inputs staying at 
the same value. This was used to examine the variables with the most influence on the model results 
given the uncertainty surrounding the input parameters. Low and high values which vary around a 
base case value were tested (Table 8.8).  
Survival curves were also investigated using one-way sensitivity analysis.  For SIRT, a hazard ratio of 
0.8 and 1.2 were applied to the base case curve (Table 8.8). For BSC, the hazard ratios used to create 
a BSC curve were altered by ±20%. It should be noted that both PFS and OS are varied at the same 
time, by the same HR, while SIRT and BSC are varied separately. The variations in the HR applied to 
the survival curves resulted in the mean survival times that are shown in table 8.9.  
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Table 8.8. Cost and utility values used in one way sensitivity analysis 
Model input Base case Low High Notes 
Costs 
Initial cost of SIRT procedure  £23,279 £14,747 £26,000 
Low value reported in 
Pennington (2015), inflated 
to 2016; high value was 
estimated. 
Cost of first cycle of chemotherapy £396.06 £0 £600 
Lowest value chosen as no 
chemotherapy; high value 
assumed based on monthly 
values in Pennington (2015)  
Cost per cycle, for subsequent 3 
chemotherapy cycles 
£286.84 £0 £600 
Lowest value chosen as no 
chemotherapy; high value 
assumed based on monthly 
values in Pennington (2015) 
Monitoring £161 £73 £500 
Low value based on 
quarterly visits and no PET 
scans; high value based on 
clinical advice on additional 
monitoring visits 
Adverse events in SIRT arm £21.20 £0 £2,760 
Lowest value chosen; high 
value from Hoyle (2013) 
Adverse events in BSC arm £21.20 £0 £2,760 
Lowest value chosen; high 
value from Hoyle (2013) 
Costs per patient in progressed 
state 
£952.05 £200 £1,039 
Low value estimate 
informed by TA405 
monthly cost (but does not 
include lump sum); high 
value from Hoyle (2013) 
Transition to death £875.31 £0 £7,000 
Lowest value chosen; high 
value from NICE (2016) 
Utilities 
Progression free state 0.75 0.6 0.9 ±20% 
Progressed state 0.69 0.552 0.828 ±20% 
Hazard ratios 
SIRT HR applied to base case 1* 0.8 1.2 ±20% 
Overall survival for BSC 0.26 0.208 0.312 ±20% 
Progression free survival for BSC  0.51 0.408 0.612 ±20% 
*patient-level data was used to estimate survival for SIRT cases therefore there was no HR used in the base 
case; 1 is the reference value which was varied in the one-way sensitivity analysis. 
 
Table 8.9. Mean overall survival from variation in hazard ratios used in sensitivity analysis 
  Base case Low SIRT High SIRT Low BSC High BSC 
SIRT OS 9.82 8.54 11.02 no change no change 
SIRT PFS 4.25 3.67 4.80 no change no change 
BSC OS 4.21 no change no change 3.66 4.72 
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BSC PFS 2.72 no change no change 2.35 3.07 
BSC, best supportive care; OS, overall survival; PFS, progression-free survival. 
8.7.2 Scenario analyses 
Eight scenarios were used to examine the effect of different assumptions on the results produced by 
the model. The following scenarios were explored: 
1. Higher monitoring costs for BSC, reflecting clinical advice that patients have outpatient 
appointments every two weeks. 
2. Chemotherapy continuing at a constant cost (£286.64) throughout progression-free state for 
both SIRT and BSC arms. 
3. No chemotherapy for the entire model duration (£0) for both SIRT and BSC arms. 
4. Higher BSC costs, reflecting clinical opinion that a greater proportion of BSC patients would have 
chemotherapy, and that this would result in additional monitoring requirements, and additional 
adverse events. Costs included were an additional outpatient visit each month, cost of adverse 
events doubled compared to SIRT at £42.40 and cost of chemotherapy doubled at £573.68. 
5. Use of alternative lower initial cost of SIRT treatment of £14,747, as used by Pennington et al. 
(2015) inflated to 2016 
6. Use of longer survival data taken from Bester et al. (2012). 
7. Use of longer survival data from Bester et al. 2012 AND a lower initial cost of SIRT treatment, as 
used by Pennington et al. (2015). 
8. Use of longer survival data from Bester et al. 2012 AND a lower initial cost of SIRT treatment, as 
used by Pennington et al. (2015) with a 10 year time horizon. The extended time horizon was 
required to fully explore the impact of longer overall survival estimates on the model outcomes. 
8.7.3  Probabilistic sensitivity analysis  
Probabilistic sensitivity analysis (PSA) uses a distribution curve for each input to be varied. Every 
time that the model is run, a different value for every input is randomly generated based on these 
distributions. The model is run many times, and allows for investigation of the effect of all inputs 
varying at the same time, independently. All inputs to the SIRT cost-effectiveness model were varied 
in the PSA (Table 8.10) over 3,000 simulations. The time horizon was extended to 10 years to fully 
account for longer survival times during some simulations. In approximately 10% of simulations 
there was some cross-over of the survival curves, where PFS became greater than OS. This is not a 
clinically possible scenario and these simulations were excluded from the final results. 
8.8 Base case results 
The model base case results demonstrated a total treatment cost for SIRT of £31,028 compared to 
£3,623 for BSC over a patient’s lifetime. The incremental cost was £27,406 for SIRT. Extrapolated 
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survival data showed an improvement in mean OS of 5.6 months in the SIRT arm (SIRT 9.8 months; 
BSC 4.2 months). 
The model estimated an improvement in quality adjusted life years (QALYs) of 0.321 for SIRT 
patients compared to BSC patients (0.58 vs 0.26). The incremental cost-effectiveness ratio (ICER) was 
calculated to be £85,350 (Table 8.11).  
 
The state curves, or time spent in each stage of the model are displayed in Figure 8.5. All patients 
begin in the progression-free state and move into the progressed state. Simultaneously, patients can 
move into the death state until all patients have died. BSC patients were found to spend less time in 
the progressed state compared with SIRT patients as overall mortality is higher. 
 
Table 8.10. Probabilistic sensitivity analysis inputs  
Survival Mean 
Standard 
Error 
Distribution 
type 
Survival curve for SIRT OS (gamma coefficient) 1.5059 0.188 lognormal 
Survival curve for SIRT PFS (gamma coefficient) 1.5899 0.199 lognormal 
Survival curve for BSC OS (HR OS) 0.26 0.033 lognormal 
Survival curve for BSC PFSS (HR PFS) 0.51 0.064 lognormal 
Costs 
Initial SIRT cost £23,279.05 29,09.88 gamma 
Initial chemotherapy cost (1st cycle only) for BSC 
and SIRT 
£396.06 49.51 gamma 
Chemotherapy cost for subsequent 3 cycles for 
BSC and SIRT 
£286.84 35.86 gamma 
Monitoring cost for BSC and SIRT £161 20.13 gamma 
Progression cost for BSC and SIRT £952.05 119.01 gamma 
Utilities 
Utility, progression free state, for BSC and SIRT 0.75 0.1 beta 
Utility, progressed state, for BSC and SIRT 0.69 0.1 beta 
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Figure 8.5. State curves of progression free, progressed, and death for base case for SIRT and BSC 
arms  
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Table 8.11. Base case results from cost-effectiveness model per patient over lifetime horizon (5 
years) 
 
Total cost 
Quality adjusted life years 
(QALYs) 
Incremental 
cost-
effectiveness 
ratio (ICER) 
 
SIRT BSC 
Incremental 
cost 
SIRT BSC 
Incremental 
QALYs 
Base 
Case 
£31,028 £3,623 £27,406 0.583 0.262 0.321 £85,350 
 
8.9 Sensitivity analysis results 
8.9.1 Deterministic one-way sensitivity analysis 
Inputs were varied in one-way sensitivity analysis as described previously (Table 8.8). The impact on 
the model is shown in a tornado diagram (Figure 8.6). The SIRT initial treatment cost and the length 
of survival are the main drivers in the model. This is expected since the SIRT initial treatment cost is 
high relative to subsequent costs, and the shorter the survival time, the higher proportion of the 
total cost is derived from the initial treatment. With a shorter survival time, there is a lower 
accumulation of cost in the BSC arm, since this has no large initial cost. Therefore at shorter survival 
times the cost difference between the two arms will be greater. The impact of monitoring costs, 
transition to death, and cost of chemotherapy were very small.  
8.9.2 Scenario analyses results 
Eight scenarios described in section 8.6.2 were examined (results in Table 8.12). Applying higher 
monitoring costs to the BSC arm (reflecting comments from clinicians that some patients receiving 
chemotherapy may have more appointments) had limited impact on the model results (scenario 1; 
ICER £82,531). Changing the model to apply the cost chemotherapy throughout the progression-free 
state had little impact on the overall results (scenario 2; ICER: £86,263), due to the short amount of 
time that most patients spend in this state (Table 8.12). For the same reason, the increase in 
chemotherapy costs, monitoring costs, and adverse events for BSC patients also has little impact on 
the result (scenario 4; ICER £79,259). Removing the cost of chemotherapy entirely from the SIRT and 
BSC arms of the model had a very small impact (scenario 3; ICER £84,916).  
As was shown by the deterministic sensitivity analysis, the strongest drivers on the model are the 
cost of the initial SIRT treatment, and the length of survival. The ICER calculated in the base case is 
much higher than that reported in a previous model by Pennington et al. (£85,254 current model vs 
£28,216 in Pennington). The previous model used survival data from Bester et al. (2012), which gave 
a longer mean survival time than the SIRT CtE data, possibly due to the inclusion of healthier 
patients. The impact of lowering the initial cost of the SIRT procedure of £14,747 (scenario 5; ICER 
£58,779) and using survival data from Bester et al. (scenario 6; ICER £53,709) individually had a 
moderately high impact on the model. When the survival data from Bester et al. was used together 
with the lower SIRT initial treatment cost (scenario 7) the resulting ICER was reduced considerably to 
£37,121. In scenario 8, the time horizon was extended from 5 years to 10 years to fully account for 
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the impact of longer survival. This reduced the ICER to £31,888 which is close to that reported in the 
Pennington et al. base case. With longer survival time, the impact of the initial treatment cost over 
the whole lifetime is reduced, while more QALYs are accumulated resulting in a reduced ICER. 
8.9.3 Probabilistic sensitivity analysis 
Mean values from 3,000 simulations were calculated during the probabilistic sensitivity analysis 
(Table 8.13). The mean ICER from the PSA was £83,506. The individual results of the 3,000 
simulations are shown in the cost-effectiveness plane which also depicts results in relation to 
willingness to pay (WTP) thresholds of £20K, £30K, £40K, and £50K per QALY gained (Figure 8.7). The 
cost-effectiveness plane demonstrates that all simulations resulted in ICERs located in the North-
East quadrant, i.e. additional QALY benefits for SIRT compared to BSC at an additional cost.  
The PSA showed that the probability of SIRT being cost-effective compared to BSC is 0% at a WTP 
threshold of £20K, 0.7% at a WTP threshold of £30K and 11% at a WTP threshold of £50K (Figure 
8.7).  
In the depicted cost-effectiveness plane, results where SIRT is considered cost-effective at a certain 
WTP threshold would be situated underneath the WTP line. Furthermore, the cost-effectiveness 
acceptability curve (CEAC) shows the probability of either SIRT or BSC being cost-effective at WTP 
thresholds of £0 to £200,000 per QALY gained (Figure 8.8). While the probability of BSC being cost-
effective decreases as the WTP for a QALY increases, SIRT becomes more cost-effective.  
 
Figure 8.6. Tornado diagram from one way sensitivity analysis. 
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Table 8.12. Results of scenarios analyses modelled 
Scenario 
Total cost 
Quality adjusted life years 
(QALYs) 
Incremental 
cost-
effectiveness 
ratio (ICER) SIRT BSC Increment SIRT BSC Increment 
Base Case  £31,028 £3,623 £27,406 0.583 0.262 0.321 £85,350 
1. Higher BSC 
monitoring costs 
£31,028 £4,528 £26,500 0.583 0.262 0.321 £82,531 
2. Chemotherapy 
continues 
throughout 
progression free 
state 
£31,447 £3,748 £27,99 0.583 0.262 0.321 £86,263 
3. No chemotherapy 
for the entire 
model duration 
(£0) 
£29,985 £2719 £27,266 0.583 0.262 0.321 £84,916 
4. BSC costs 
increased for 
chemotherapy, 
monitoring and 
AEs 
£31,028 £5,579 £25,450 0.583 0.262 0.321 £79,259 
5. SIRT initial 
treatment of 
£14,747 
£22,496 £3,623 £18,873 0.583 0.262 0.321 £58,779 
6. Bester OS data 
used for SIRT and 
BSC 
£35,838 £6,893 £28,944 1.182 0.643 0.539 £53,709 
7. Bester OS plus 
initial cost of SIRT 
of £14,747 
£27,306 £6,893 £20,412 1.182 0.643 0.539 £37,877 
8. Bester OS plus 
initial cost of SIRT 
of £14,747 (10 
year time horizon) 
£29,117. £7,336 £21,780 
1.373 0.689 0.683 £31,888 
AEs, adverse events; BSC, best supportive care; ICER, incremental cost-effectiveness ratio; OS, overall survival; 
QALYs, quality adjusted life years. 
Table 8.13. Mean values from probabilistic sensitivity analysis (3,000 simulations) 
 
Total cost 
Quality adjusted life years 
(QALYs) 
Incremental 
cost-
effectiveness 
ratio (ICER) 
 
SIRT BSC Increment SIRT BSC Increment 
Mean 
values from 
PSA, 3,000 
simulations 
£32,457 £3,905 £28552 0.656 0.27 0.390 £83,506 
BSC, best supportive care; ICER, incremental cost-effectiveness ratio; PSA, probabilistic sensitivity analysis; 
QALYs, quality adjusted life years. 
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Figure 8.7. Cost-effectiveness plane, showing incremental cost-effectiveness of SIRT compared to 
BSC with a range of willingness-to-pay thresholds (WTP) displayed. Points displayed at 0 are 
excluded scenarios 
 
Figure 8.8. Cost-effectiveness acceptability curve for SIRT and BSC 
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8.10 Discussion 
This independent de novo economic model was created for the SIRT CtE project, and is the second 
cost-effectiveness model on this decision problem. In this analysis, SIRT was likely to be clinically 
effective (increased QALYs) for an additional cost. ICER values were high when compared to BSC for 
patients who have unresectable CRC liver metastases which has progressed following at least two 
lines of standard chemotherapy, and is unlikely to fall below a willingness to pay threshold of £50K. 
Key drivers of the model were the cost of the SIRT procedure, and the length of overall survival; the 
application of SIRT in patients with longer life expectancy may decrease the cost per QALY gained as 
initial SIRT costs are spread over a longer period of time. 
If a subgroup of patients was shown to have a longer survival time (such as those with limited 
tumour burder), the cost-effectiveness is likely to be improved for this group. This is shown in the 
sensitivity and scenario analysis. 
In the cost-effectiveness plane, results occupy the North-East quadrant indicating QALY benefit at an 
additional cost.  This result is dependent on the assumption of improved OS reported in the two 
retrospective comparative cohort studies. These studies are prone to bias which may make their OS 
and PFS findings unreliable; this in turn introduces uncertainty into the cost-effectiveness model. 
There is no high quality RCT evidence demonstrating a survival benefit; one small RCT (Hendlisz et al. 
2010) showed a significant improvement in PFS.  
NICE recently recommended trifluridine-tipiracil in patients with mCRC which has progressed 
following standard chemotherapy, and reported an ICER of £49,392 per QALY (NICE 2016). This 
recommendation is based on a discount agreed in the patient access scheme. The introduction of 
this new drug to the patient pathway adds uncertainty to the model outputs. If trifluridine-tipiracil 
becomes standard practice in the NHS, it would be a relevant comparator to SIRT. This scenario was 
not modelled because of the absence of any data comparing SIRT to trifluridine-tipiracil and 
uncertainty around the comparability of populations. 
8.10.1 Strengths of the analysis 
The strengths of this economic evaluation include that key inputs of efficacy, chemotherapy costs, 
and AE costs for the SIRT arm were based on patient-level data from a large UK cohort; this resolves 
issues of generalisability/relevance when efficacy data is taken from RCTs with restrictive eligibility 
criteria. Efficacy and cost inputs for BSC and the cost of SIRT were based on assumptions and 
summary data. Most other inputs were based on evidence identified from systematic reviews. The 
model was created by an independent research group with comprehensive quality assurance from 
external researchers of the model structure and inputs. All assumptions were described, and where 
possible checked with clinical advisors to ensure that they reflected clinical practice. Extensive 
sensitivity analyses were carried out to test the robustness of model outcomes, varying model inputs 
across a plausible range as well as structural elements. The model was compared to a published 
model and differences in outcomes were identified and justified. Scenario analysis using key inputs 
from the published model replicated the base case results fairly closely which further validates the 
de novo model.     
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8.10.2 Limitations of the analysis 
The key limitation of the model was the unavailability of comparative survival data in the SIRT CtE 
registry or from high quality RCTs (the available RCT was confounded by cross-over). Coupled with 
the lack of patient-level data from Bester et al. (2012) and Seidensticker et al. (2012) meant that 
hazard ratios for OS and PFS from Seidensticker et al. (2012) and Hendlisz et al. (2010) were applied 
to SIRT CtE data to create BSC survival estimates. Hazard ratios based on matched-pair cohorts can 
be prone to bias and risk inflating the survival benefit.  
Data on resource use were inadequately collected during the SIRT CtE registry study. Data on 
chemotherapy, adverse events data, monitoring, and treatment during the progressed state were 
not captured accurately enough to inform the model and had to be supplemented using published 
evidence, clinical advice, and assumptions. 
Utilities were captured using the EQ-5D-5L tool in the SIRT CtE registry cohort. However, the general, 
non-disease specific nature of this outcome measure, poor compliance, and high levels of missing 
data made this an unreliable source. As a result, utilities values were taken from published sources 
and assumed to be equal for both treatment arms which might not reflect any potential 
improvement or disutility in HRQoL as a result of SIRT. However, utility inputs only moderately 
impacted on the ICER values in the one-way sensitivity analysis.  
There is no single, well defined, pathway for patients receiving BSC. Advice from clinical advisors was 
that treatment type and duration varied depending on patients’ preference and characteristics as 
well as clinician preference. As a result the patient pathway for BSC was challenging to model and 
may lack generalisability to clinical practice.  
There is a high degree of uncertainty in the overall cost of chemotherapy in both SIRT and BSC arms, 
but impact on the results is minimal due to the short progression free survival time for the 
population modelled.  
Probabilistic sensitivity analysis does not change the assumption that costs of chemotherapy, 
monitoring, adverse events and care during the progressed state are equal, although this is 
investigated in the scenario analysis. Probabilistic sensitivity analysis occasionally resulted in 
simulations where the PFS artificially exceeded the OS. These simulations were excluded from the 
final results. In addition, a five year time horizon was chosen as being greater than life time for the 
base case model, however, sensitivity analysis scenarios using Bester survival data require a longer 
time horizon than 5 years. An extended time horizon of 10 years was used in a scenario analysis, and 
in the probabilistic sensitivity analysis.   
8.10.3 Key differences between the de novo model and published study 
The higher base case ICER in the current de novo model (£85K) compared to Pennington et al. (£28K) 
was mainly due to the following.   
- A shorter OS estimate was used in the de novo model based on SIRT CtE registry data 
(extrapolated mean OS 9.8 months) whereas Pennington et al. used OS data from Bester et 
al. (mean OS 25.1 months) which appeared to be a less severely unwell population with 
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higher performance status and more chemotherapy-naive patients compared to the SIRT CtE 
registry population. This meant the cost of SIRT is spread over a shorter period in the de 
novo model, thus increasing the cost per QALY gained. 
- A higher procedure cost of £21,870 was used in the de novo model compared to £14,248 
used in the Pennington et al. model. The higher cost was derived from the NHS England tariff 
used in the CtE study, whereas Pennington et al. used NHS reference costs combined with 
bottom-up costings provided by The Christie NHS hospital.  
Scenario analyses explored the impact of using longer survival time and lower cost of SIRT in the de 
novo model (to reflect those used in Pennington et al.). The ICER was reduced to approximately 
£37,877 in this scenario, and further reduced to £31,888 when the time horizon was extended to 10 
years (a more appropriate value for a patient group with longer expected survival time). The 
remaining difference was due to slightly different assumptions in the calculation of chemotherapy 
and monitoring costs.  
8.11 Generalisability of the model to an intrahepatic cholangiocarcinoma population 
In light of the absence of any published comparative data in the ICC population and the much 
smaller cohort of ICC patients in the SIRT CtE registry (n=61), it was decided not to conduct de novo 
modelling in this group. The median OS results from the SIRT CtE registry are slightly higher for the 
ICC group but with wider confidence intervals, 8.7 months (95% CIs 5.3-12.1) and based on only 33 
events. All other inputs being equal to the CRC population (including hazard ratios used to 
demonstrate a survival benefit), this longer survival would be expected to marginally reduce the 
ICER for the ICC population, but would depend on the impact of extrapolating a survival curve to the 
Kaplan-Meier data.  
The SIRT CtE data indicates that more ICC patients require 2 SIRT session (8% ICC vs 3% CRC) which 
indicated that the cost of SIRT may be higher in the ICC group. The time spent in hospital was similar 
to the CRC cohort, as were the proportions of complications and adverse events. Fewer patients in 
the ICC group required chemotherapy concomitantly with SIRT or after SIRT but within the structure 
of the current model this is unlikely to significantly affect the results. These findings should be 
interpreted cautiously due to the small sample size.  
There is insufficient information available to adequately address whether the costs associated with 
BSC in the ICC population mirror those in the CRC group.  
There is no data available to indicate whether SIRT provides a survival benefit compared with BSC in 
the ICC group. As a result, the assumption of clinical effectiveness required to justify cost modelling 
for an intervention likely to be more expensive than BSC cannot be reliably made.     
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9 Provider feedback and implementation considerations 
Clinical teams at the ten CtE provider centres were given the opportunity to feed back about their 
experiences of implementing SIRT in the NHS.  
9.1 Questions 
The following questions were provided as prompts:  
 Selection criteria; were they clear and appropriate or do they need further clarification? 
 Is the protocol for work up of patients appropriate or does it need further clarification? 
 Were appropriate patients referred to the specialist centres or is more work needed to 
improve the quality and nature of referrals for SIRT? 
 Do the hospitals have data on referrals received per month in order to inform NHSE planning 
if SIRT is accepted for regular commissioning? 
9.2 Feedback 
The following feedback was received and collated.  
A representative from Nottingham University Hospitals NHS Trust provided the following feedback: 
 The selection criteria were considered to be clear and appropriate, and consistent with the 
inclusion/exclusion criteria expected from randomised clinical trials. 
 A standardised work-up framework was considered to be a good idea to ensure consistency 
across sites and to specify the minimal work up requirements needed. 
 Their experience was that referrals from external centres needed more work after 
commencement of the commissioning programme to both foster investment in the scheme 
and ensure the appropriateness of referrals. External site training was felt to be important to 
facilitate appropriate referrals, both of appropriate patients and in the provision of 
appropriate levels of information to be able to discern if the patient is eligible. 
 The respondent confirmed that referrals for the procedure and the reasons the patients 
were not eligible or were unable to proceed are recorded locally. 
A respondent from Leeds Teaching Hospitals NHS Trust provided the following information: 
 Many more patients were referred to the site than were treated. A record has been kept 
locally of reasons for non-treatment and outcomes for those who were treated or who had 
surgery compared to others. 
  
A respondent from Royal Free London NHS Foundation Trust provided the following information: 
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 A total of 63 patients were treated during the CtE project from a total of 133 referrals. 
Seventy patients were ineligible due to clinical progression or not fitting the referral 
guidelines (30% were patients who had not received both lines of chemotherapy; 10% 
progressed within the timeframe of assessment to therapy such that they became ineligible; 
60% had disease which was clinically unsuitable for therapy (usually the volume was too 
large or there was ascites / bone mets) but which warranted discussion to exclude SIRT as a 
useful modality). 
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Megan  Dale, Cedar 
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Dr Peter Littler, The Newcastle upon Tyne Hospitals 
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Elizabeth Marouzet, University Hospital Southampton 
Wendy Martin, King’s College Hospital 
Dr Homoyon Mehrzad, Queen Elizabeth Hospital 
Dr Jamie Mills, Nottingham University Hospitals 
Dr Rebecca Muirhead, Oxford University Hospital Trust  
Dr Hannah Patrick, NICE 
Dr Andreas Prachalias, King’s College Hospital 
Stephanie Raphael-Morgan, King’s College Hospital 
Dr Teikchoon See, Cambridge University Hospital Trust 
Professor Ricky Sharma, University College London (formerly Oxford University Hospital Trust)  
Professor Nick Slevin, NHS England/The Christie 
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Appendix 2: Literature search strategy for systemic review on SIRT 
Database: Ovid MEDLINE(R) <1946 to January Week 3 2016> 
 1     Yttrium/ (2393) 
2     exp Yttrium Radioisotopes/ (2426) 
3     yttrium*.tw. (3255) 
4     (90Y or Y-90).tw. (1684) 
5     SIR-Sphere*.tw. (67) 
6     TheraSphere*.tw. (46) 
7     (sirtex or nordion).tw. (40) 
8     SIRT.tw. (493) 
9   (selective* adj3 internal* adj3 radiotherap*).tw. (49) 
10     (selective* adj3 internal* adj3 radiation* adj3 therap*).tw. (174) 
11     (internal* adj3 radiation* adj3 therap*).tw. (266) 
12     radioemboli*.tw. (626) 
13     or/1-12 (7547) 
14     (liver adj2 metasta*).tw. (19428) 
15     mCRC.tw. (1136) 
16     ((unresectable or non-rectable) adj (liver or heaptic) adj (tumo?*s or malignanc*)).tw. (150) 
17  (inoperable adj (hepatic or liver) adj tumo?r*).tw. (26) 
18     (bile duct adj (cancer or neoplasm)).tw. (886) 
19     Liver Neoplasms/sc (25346) 
20     Bile Duct Neoplasms/ (11474) 
21     Cholangiocarcinoma/ (6043) 
22     Cholangiocarcinoma*.tw. (7164) 
23     or/14-22 (47672) 
24     13 and 23 (505) 
25     limit 24 to yr="2011-Current" (253) 
26     Economics/ (26624) 
27     exp "costs and cost analysis"/ (193223) 
28     Economics, Dental/ (1874) 
29     exp economics, hospital/ (21007) 
30     Economics, Medical/ (8842) 
31     Economics, Nursing/ (3931) 
32     Economics, Pharmaceutical/ (2599) 
33     (economic$ or cost or costs or costly or costing or price or prices or pricing or 
pharmacoeconomic$).ti,ab. (463242) 
34     (expenditure$ not energy).ti,ab. (18698) 
35     value for money.ti,ab. (966) 
36     budget$.ti,ab. (18471) 
37     or/26-36 (592821) 
38     ((energy or oxygen) adj cost).ti,ab. (2790) 
39     (metabolic adj cost).ti,ab. (858) 
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40     ((energy or oxygen) adj expenditure).ti,ab. (17142) 
41     or/38-40 (20048) 
42     37 not 41 (588352) 
43     letter.pt. (868989) 
44     editorial.pt. (368875) 
45     historical article.pt. (325566) 
46     or/43-45 (1547448) 
47     42 not 46 (558537) 
48     exp animals/ not humans/ (4175116) 
49     47 not 48 (520990) 
50     bmj.jn. (63068) 
51    "cochrane database of systematic reviews".jn. (10964) 
52  health technology assessment winchester england.jn. (889) 
53     or/50-52 (74921) 
54     49 not 53 (516307) 
55     24 and 54 (4) 
56     25 or 55 (254)  
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Appendix 3: Literature search strategy for best supportive care 
evidence 
Search strategy for review of best supportive care in the metastatic colorectal cancer population 
Search strategy 
Ovid MEDLINE(R) <1946 to August Week 4 2016> 
1     (liver adj2 metasta*).tw. (20550) 
2     (inoperable adj (hepatic or liver) adj (tumo?r* or malignanc* or cancer* or carcinoma*  
or neoplasm*)).tw. (52) 
3     ((unresectable or non-resectable) adj (liver or hepatic) adj (tumo?r* or malignanc* or  
cancer* or carcinoma* or neoplasm*)).tw. (395) 
4     (or/1-3) and (colorectal or rectal or rectum or colon).tw. (9169) 
5     (("metastatic colorectal cancer" or mCRC) and (hepatic or liver)).tw. (1076) 
6     Liver Neoplasms/sc and (colorectal or rectal or rectum or colon).tw. (10378) 
7     or/4-6 (12855) 
8     Palliative Care/ (45330) 
9     Supportive care.tw. (9662) 
10     8 or 9 (54116) 
11     7 and 10 (320) 
12     limit 11 to (english language and yr="2006 -Current") (96) 
 
Search results 
Date Database 
Name 
Database 
Host 
Searcher Total Number 
of records 
retrieved 
Total number 
of records from 
database after 
de-duplication 
07/09/16 Medline Ovid HM 96 93 
07/09/16 Medline 
In Process 
Ovid HM 5 5 
07/09/16 Embase Ovid HM 174 159 
07/09/16 Cochrane 
Library: 
CDSR 
OTHER 
REVIEWS 
CENTRAL 
NHE EED 
Wiley HM 14 10 
07/09/16 EconLit EBSCOHos
t 
HM 1 1 
07/09/16 Scopus Elsevier HM 152 138 
07/09/16 Pubmed 
(‘epub 
ahead of 
print’ 
only) 
 HM 7 7 
     Total = 362 
Six additional studies were identified from supplementary searching and based on advice 
from clinical experts. 
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Search strategy for review of best supportive care in the intrahepatic cholangiocarcinoma 
population 
Search strategy 
Ovid MEDLINE(R) <1946 to January  Week 3 2017> 
1     (bile duct adj (cancer* or neoplasm*)).tw. (938) 
2     Bile Duct Neoplasms/ (12222) 
3     Cholangiocarcinoma/ (6672) 
4     Cholangiocarcinoma*.tw. (7931) 
5     or/1-4 (15869) 
6     Palliative Care/ (46116) 
7     Supportive care.tw. (9926) 
8     6 or 7 (55127) 
9     5 and 8 (850) 
10     limit 9 to (english language and yr="2006 -Current") (240) 
 
Search results 
Date Database 
Name 
Database 
Host 
Searcher Total Number 
of records 
retrieved 
Total number of 
records from 
database after 
de-duplication 
01/02/17 Medline Ovid HM 240 234 
01/02/17 Medline In 
Process 
Ovid HM 5 5 
01/02/17 Embase Ovid HM 572 543 
01/02/17 Cochrane 
Library: 
CDSR 
OTHER 
REVIEWS 
CENTRAL 
NHE EED 
Wiley HM 41 33 
01/02/17 EconLit EBSCOHos
t 
HM 0 0 
01/02/17 Scopus Elsevier HM 223 128 
01/02/17 Pubmed 
(‘epub ahead 
of print’ only) 
 HM 3 3 
     Total = 753 
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Appendix 4: Less relevant ongoing clinical trials on SIRT 
Identifier Title Status 
Enrolm
ent 
Study type Design 
Start 
date 
Estimated 
completion 
date 
Primary 
Completion 
Date 
Outcome 
measures 
Popula
tion 
Relevance Location 
NCT0251
2692 
90Y Transarterial Radioembolization 
(TARE) Plus Gemcitabine and Cisplatin in 
Unresectable Intrahepatic 
Cholangiocarcinoma 
Recruiting  20 Interventional Single arm 2015 
Not 
reported 
2018 Toxicity ICC Non comparative  USA 
NCT0219
5011 
Safety Study of Regorafenib and SIR-
Sphere Microspheres Radioembolization 
in Patients With Refractory Metastatic 
Colorectal Cancer With Liver Metastases 
Recruiting 50 Interventional 
Comparison 
between drug 
regimes 
2014 2017 2017 
Safety, response 
rate, PFS, OS 
CRC Non comparative USA 
NCT0191
2053 
Efficacy Study of Intra-hepatic 
Administration of Therasphere in 
Association With Intravenous 
Chemotherapy to Treat 
Cholangiocarcinoma 
Not 
recruiting 
41 Interventional Single arm 2013 2018 2017 
Response rate, 
toxicity/safety 
ICC Non comparative  France 
NCT0117
7007 
Intra-arterial Y-90 TheraSpheres for 
Hepatic Metastases From Solid Tumors 
Not 
recruiting 
50 Interventional Single arm 2010 2014 2014 TTP, safety, OS Mixed Non comparative USA 
NCT0109
8422 
A Study of Yttrium-90 Radioactive Resin 
Microspheres to Treat Colorectal 
Adenocarcinoma Metastatic to the Liver 
Status 
unknown 
10 Interventional Single arm 2010 2015 2015 
PFS, OS, tumour 
response, safety, 
mortality 
CRC Non comparative USA 
NCT0097
2036 
Selective Internal Radiation Therapy (SIRT) 
in Patients With Unresectable Colorectal 
Cancer Liver Metastases Who Failed Prior 
Intraarterial Pump Chemotherapy 
Status 
unknown 
32 Interventional Single arm 2009 2014 2014 
Safety, toxicity, 
tolerated dose 
CRC Non comparative USA 
NCT0085
8429 
Yttrium Y 90 Glass Microspheres and 
Capecitabine in Treating Patients With 
Liver Cholangiocarcinoma or Liver 
Metastases 
Not 
recruiting 
30 Interventional Single arm 2009 2018 2017 
Safety, toxicity, 
tolerated dose 
ICC Non comparative USA 
NCT0076
6220 
Yttrium Microspheres With Cetuximab 
Plus Irinotecan for Patients With 
Advanced Colorectal Cancer Mets to Liver 
Withdrawn 
prior to 
enrollment 
0 Interventional Single arm 2009 2012 2012 PFS CRC 
Withdrawn prior to 
enrolment  
USA 
NCT0073
5241 
FOLFOX6 Plus Sir-Spheres Microspheres 
Plus Avastin in Patients With 
Nonresectable Liver Metastases From 
Colorectal Carcinoma 
Withdrawn 
prior to 
enrollment 
0 Interventional Single arm 2008 2009 2009 
Toxicity and 
safety 
CRC 
Withdrawn prior to 
enrolment 
USA 
NCT0040
8551 
Chemotherapy and Internal Radiation in 
Treating Patients With Colorectal Cancer 
That Has Spread to the Liver 
Recruiting 20 Interventional 
Comparison 
between drug 
regimes 
2005 
 
2009 
Response rate, 
toxicity, PFS, 
downstaging 
CRC 
Non comparative 
(SIRT) 
USA 
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Identifier Title Status 
Enrolm
ent 
Study type Design 
Start 
date 
Estimated 
completion 
date 
Primary 
Completion 
Date 
Outcome 
measures 
Popula
tion 
Relevance Location 
NCT0053
2740 
Radiolabeled Glass Beads in Treating 
Patients With Metastatic Liver Cancer 
That Cannot Be Removed by Surgery 
Recruiting 
(early 
results 
published) 
500 Observational 
Prospective 
observational 
2004 2019 2018 
Patient 
experience and 
toxicity 
CRC Non comparative USA 
Acronyms: CRC, colorectal cancer; ICC, intrahepatic cholangiocarcinoma; mCRC, metastatic colorectal cancer; OS, overall survival; PFS, progression free survival; QoL, 
quality of life; RCT, randomised controlled trial; TTP, time to progression. 
 
 
 
Page 157 of 175 
 
Commissioning through Evaluation: SIRT 
Full evaluation report 
Appendix 5: SIRT registry data dictionary 
Question Type Selection 
PATIENT SECTION   
Patient's general practitioner's postcode Text  
Is the patient receiving SIRT within a clinical trial?  Radio Buttons Yes,No,Unknown 
Name of clinical trial Text  
Deceased date Date  
Reason for death Checkbox Extra-Hepatic Disease Progression,Intra-Hepatic Disease 
Progression,Complication,Unrelated,Other 
Complication details Comment  
Unrelated details Comment  
Other details Comment  
Lost to follow-up date Date  
Patient notes Comment  
What type of Liver Cancer? Radio Buttons Primary,Secondary/Metastatic 
Pre-SIRT Diagnosis Primary SelectList Cholangiocarcinoma,Hepatocellular Carcinoma,Primary Other 
Pre-SIRT Diagnosis Primary Other Text  
Pre-SIRT Diagnosis Secondary/Metastatic SelectList Breast Cancer,Cancer of Unknown Primary,Colorectal 
Cancer,Gastric Cancer,Head & Neck Cancer,Lung 
Cancer,Melanoma,Neuroendocrine Tumor,Oesophageal 
Cancer,Pancreatic Cancer,Renal Cell 
Carcinoma,Sarcoma,Secondary/Metastatic Other 
Pre-SIRT Diagnosis Secondary/Metastatic Other Text  
Histological types Text  
Date of Primary Diagnosis Date  
Date of Metastatic Diagnosis Date  
Was the Primary Tumor reseCtEd? Radio Buttons Yes,No 
Prior Hepatic Procedures? Radio Buttons Yes,No 
Prior Treatment Hepatic Surgery Date Date  
Type of surgery Radio Buttons Open,Laparoscopy 
Was it major surgery (>3 segments)? Radio Buttons Yes,No 
Was it RO resection? Radio Buttons Yes,No,Unknown 
Liver Transplant Date Date  
Surgical Other Text  
Surgical Other Date Date  
Surgical Notes Comment  
Radiofrequency Ablation Date Date  
Radiofrequency Ablation Checkbox Radiofrequency Ablation 
Microwave Ablation Checkbox Microwave Ablation 
Microwave Ablation Date Date  
Percutaneous Ethanol Injection Checkbox Percutaneous Ethanol Injection 
Percutaneous Ethanol Injection Date Date  
Irreversible Electroporation Checkbox Irreversible Electroporation 
Irreversible Electroporation Date Date  
Cryoablation Checkbox Cryoablation 
Cryoablation Date Date  
Ablative Other Text  
Ablative Other Date Date  
Chemoembolization (TACE) SelectList Select...,Conventional TACE,Drug-Eluting TACE,Other 
Other Text  
TACE Date Date  
TACE Type SelectList Select...,Cisplatin,Doxorubicin,Doxorubicin + cisplatin + FUDR or 
5FU,Doxorubicin + cisplatin + mitomycin C,Epirubicin,Mitomycin 
C,Other 
TACE Type Other Text  
Hepatic-Arterial Chemotherapy SelectList Select...,FUDR or 5FU,Irinotecan,Oxaliplatin,Other 
Hepatic-Arterial Chemotherapy Date Date  
Other Hepatic-Arterial Chemotherapy Text  
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Portal Vein Embolization Checkbox Portal Vein Embolization 
Portal Vein Embolization Date Date  
Bland Embolization Checkbox Bland Embolization 
Bland Embolization Date Date  
Vascular Other Text  
Vascular Other Date Date  
Selective Internal Radiation Therapy (SIRT) SelectList Select...,SIR-Spheres,TheraSphere,Other 
SIRT Date Date  
SIRT Other Text  
EBRT Date Date  
External Beam Radiation Therapy (EBRT/SBRT) Checkbox External Beam Radiation Therapy (EBRT/SBRT) 
Radiation Therapy Other Text  
Radiation Therapy Other Date Date  
Prior Systemic Chemotherapy? Radio Buttons Yes,No 
How many lines? SelectList 1,2,3,4,5,6,>6 
Line 1 Comment  
Start Date Date  
End Date...[continued for 6 lines] Date  
Additional lines Comment  
End Date Date  
Start Date Date  
Prior Adjuvant Therapy? Radio Buttons Yes,No 
How many lines? SelectList 1,2,3 
Line 1 Comment  
Start Date Date  
End Date...[continued for 3 lines] Date  
TREATMENT SECTION   
Date EQ-5D-5L questionnaire was filled out Date  
Mobility SelectList I have no problems in walking about,I have slight problems in 
walking about,I have moderate problems in walking about,I have 
severe problems in walking about,I am unable to walk about 
Self-Care SelectList I have no problems washing or dressing myself,I have slight 
problems washing or dressing myself,I have moderate problems 
washing or dressing myself,I have severe problems washing or 
dressing myself,I am unable to wash or dress myself 
Usual Activities (e.g. work, study, housework, SelectList I have no problems doing my usual activities,I have slight 
problems doing my usual activities,I have moderate problems 
doing my usual activities,I have severe problems going my usual 
activities,I am unable to do my usual activities 
Pain / Discomfort SelectList I have no pain or discomfort,I have slight pain or discomfort,I have 
moderate pain or discomfort,I have severe pain or discomfort,I 
have extreme pain or discomfort 
Anxiety / Depression SelectList I am not anxious or depressed, I am slightly anxious or depressed, 
I am moderately anxious or depressed,I am severely anxious or 
depressed,I am extremely anxious or depressed 
Scale SelectList 1-100 
First Name (Treating IR) Text  
Last Name Text  
BSA m^2 (Body Surface Area) Numeric  
Lung Shunt Study % Numeric  
Lung Shunt Study Date Date  
ECOG Performance Status SelectList 0-4 
Portal Vein SelectList Patent,Segmental Thrombosis,Lobar Thrombosis,Main 
Thrombosis 
Liver Tumor Location Radio Buttons Left,Right,Bilobar 
How many Liver Tumors? SelectList 1,2,3,4,5,6,7,8,9,10,>10,Other,Uncountable 
Number of Liver Tumors Numeric  
Does the patient have active extra-hepatic disease 
now? 
Radio Buttons Yes,No 
Location Checkbox Bone,Brain,Lung,Lymph Nodes,Other 
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Other Location Comment  
Does the patient have cirrhosis? Radio Buttons Yes,No 
Cause of cirrhosis SelectList Hepatitis-B,Hepatitis-C,Alcohol,NASH,Other 
Other Comment  
Is the Liver grossly abnormal? Radio Buttons Yes,No 
Does the patient have ascites? Radio Buttons Yes,No 
Ascites Type SelectList Mild,Moderate,Severe,Other 
Other Comment  
Has the patient had any arteries embolized before 
SIRT therapy? 
Radio Buttons Yes,No 
Arteries embolized before SIRT therapy Radio Buttons Yes,No 
What was the intent of SIRT? SelectList Bridge to liver surgery,Bridge to liver transplant,Down-
sizing/down-staging, Ablation,Palliative 
Concomitant Chemotherapy? Radio Buttons Yes,No 
Chemo Comment  
Start Date Date  
End Date Date  
This SIRT treatment is targeted to Radio Buttons Whole Liver (single catheter),Whole Liver (split 
administration/single session),Whole Liver (sequential lobar/ two 
sessions),Right Lobe,Left Lobe,Segmental 
Date of SIRT administration Date  
Date of second SIRT administration Date  
Brand of SIRT used SelectList SIR-Spheres microspheres - Y-90 resin microspheres,TheraSphere 
- Y-90 glass microspheres,Other 
Methodology for determining the dose SelectList BSA,Modified BSA,Empiric,Partition Model,Other 
Methodology for determining the dose SelectList Manufacturers Recommendation,Other 
Other method for determining dose Text  
SIRT batch number Text  
Did you measure the whole liver or the right and 
left lobe separately? 
Radio Buttons Whole,Right and Left 
Whole Liver % Numeric  
Right Lobe % Numeric  
Left Lobe % Numeric  
Whole Liver % Numeric  
Right Lobe % Numeric  
Left Lobe % Numeric  
Were all Liver Tumors targeted? Radio Buttons Yes,No,Unknown 
Liver segments not treated by SIRT Checkbox I,II,III,IVa,IVb,V,VI,VII,VIII 
Did you prescribe the whole liver or the right and 
left lobe separately? 
Radio Buttons Whole,Right and Left 
Whole Liver Numeric  
Right Lobe Numeric  
Left Lobe Numeric  
Unit of Measure Radio Buttons GBq,mci 
Was the delivered activity within 90% of the 
prescribed activity? 
Radio Buttons Yes,No 
Whole Liver Numeric  
Right Lobe Numeric  
Left Lobe Numeric  
Unit of Measure Radio Buttons GBq,mci 
Reason for non-delivery Checkbox Dissection,Slow flow/Stasis,Spasm,Other 
Other Reason Comment  
How many administrations were delivered to the 
patient? 
SelectList 1,2,3 
Serum BilirubinUnit of Measure? Radio Buttons mg/dL,µmol/L 
Total Bilirubin (mg/dL) Numeric  
Total Bilirubin (µmol/L) Numeric  
Date Date  
Albumin (g/dL) Numeric  
Date Date  
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ALT (SGPT) (U/L) Numeric  
Date Date  
AST (SGOT) (U/L) Numeric  
Date Date  
Creatinine (mg/dl) Numeric  
Date Date  
Creatinine (mg/dl) Numeric  
Date Date  
Platelets (x10<sup>9</sup>/L) Numeric  
Date Date  
Leukocytes (x10<sup>9</sup>/L) Numeric  
Date Date  
Neutrophils (x10<sup>9</sup>/L) Numeric  
Date Date  
Date Date  
Tumor Marker Other Text  
Date Date  
Length of Hospital Stay for SIRT Treatment SelectList Outpatient,1 night,2 nights,3 nights,4 nights,>4 nights 
Were any severe day of treatment complications 
experienced? 
Radio Buttons Yes,No 
Please select all treatment complications that 
occurred. 
Checkbox Vascular,Severe Abdominal Pain,Severe Vomiting,Severe Other 
Severity SelectList Minor@A - No therapy no consequence B - Nominal therapy no 
consequence; includes overnight admission for observation only 
,Major@C - Require therapy; minor hospitalization {<48 hours} D - 
Require major therapy; unplanned increase in level of care; 
prolonged hospitalization {>48 hours} E - Permanent adverse 
sequelae F - Death 
Grade SelectList Grade 3,Grade 4 
Was there a product incident or complaint 
associated with the treatment? 
Radio Buttons Yes,No 
 Checkbox SIR-Spheres 
Sign-Off Date Date  
Date EQ-5D-5L questionnaire was filled out Date  
FOLLOW-UP SECTION   
Mobility SelectList As previous 
Self-Care SelectList As previous 
Usual Activities (e.g. work, study, housework, SelectList As previous 
Pain / Discomfort SelectList As previous 
Anxiety / Depression SelectList As previous 
Scale SelectList 1-100 
Follow-Up Date Date  
ECOG Performance Status SelectList 0-4 
Follow-Up Notes Comment  
Were any clinical adverse events experienced? Radio Buttons Yes,No 
Please select all adverse events that occurred. Checkbox Abdominal Pain,Fatigue,Fever,Nausea,Vomiting,Gastritis,GI 
Ulceration,Radioembolisation-Induced Liver Disease,Radiation 
Pneumonitis,Radiation Cholecystitis,Radiation Pancreatitis,Other 
Onset Date Date  
Grade SelectList Grade 1-5 
Were any laboratory values abnormal? Radio Buttons Yes,No 
Please select all laboratory values that were 
abnormal. 
Checkbox Hypoalbuminemia,Hyperbilirubinemia,ALT increased,AST 
increased,INR increased,Neutrophil count decreased,Platelet 
count decreased,Other 
Onset Date Date  
Grade SelectList Grade 1-5 
Are imaging data available? Radio Buttons Yes,No 
Extra-Hepatic tumor response SelectList Select..., Complete Response (CR)@: Disappearance of all target 
lesions.,Partial Response (PR), Stable Disease (SD),Progressive 
Disease (PD),Unevaluable 
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Hepatic tumor response SelectList Select..., Complete Response (CR)@: Disappearance of all target 
lesions.,Partial Response (PR), Stable Disease (SD),Progressive 
Disease (PD),Unevaluable 
Imaging criteria used SelectList Select...,RECIST,mRECIST,EASL,Choi,Other 
Imaging Date Date  
Imaging method SelectList Select...,CT Scan,MRI,PET 
Other imaging criteria Text  
Post SIRT Hepatic Procedures? Radio Buttons Yes,No 
Post Treatment Hepatic Surgery Date Date  
Type of surgery Radio Buttons Open,Laparoscopy 
Was it major surgery (>3 segments)? Radio Buttons Yes,No 
Was it RO resection? Radio Buttons Yes,No,Unknown 
Liver Transplant Date Date  
Surgical Other Text  
Surgical Other Date Date  
Surgical Notes Comment  
Radiofrequency Ablation Checkbox Radiofrequency Ablation 
Radiofrequency Ablation Date Date  
Microwave Ablation Checkbox Microwave Ablation 
Microwave Ablation Date Date  
Percutaneous Ethanol Injection Checkbox Percutaneous Ethanol Injection 
Percutaneous Ethanol Injection Date Date  
Irreversible Electroporation Checkbox Irreversible Electroporation 
Irreversible Electroporation Date Date  
Cryoablation Checkbox Cryoablation 
Cryoablation Date Date  
Ablative Other Text  
Ablative Other Date Date  
Chemoembolization (TACE) SelectList Select...,Conventional TACE,Drug-Eluting TACE,Other 
Other Text  
TACE Date Date  
TACE Type SelectList Select...,Cisplatin,Doxorubicin,Doxorubicin + cisplatin + FUDR or 
5FU,Doxorubicin + cisplatin + mitomycin C,Epirubicin,Mitomycin 
C,Other 
TACE Type Other Text  
Hepatic-Arterial Chemotherapy SelectList Select...,FUDR or 5FU,Irinotecan,Oxaliplatin,Other 
Hepatic-Arterial Chemotherapy Date Date  
Other Hepatic-Arterial Chemotherapy Text  
Portal Vein Embolization Checkbox Portal Vein Embolization 
Portal Vein Embolization Date Date  
Bland Embolization Checkbox Bland Embolization 
Bland Embolization Date Date  
Vascular Other Text  
Vascular Other Date Date  
Selective Internal Radiation Therapy (SIRT) SelectList Select...,SIR-Spheres,TheraSphere,Other 
SIRT Date Date  
SIRT Other Text  
EBRT Date Date  
External Beam Radiation Therapy (EBRT/SBRT) Checkbox External Beam Radiation Therapy (EBRT/SBRT) 
Radiation Therapy Other Text  
Radiation Therapy Other Date Date  
Post Systemic Chemotherapy? Radio Buttons Yes,No 
How many lines? SelectList 1,2,3,4,5,6,>6 
Line 1 Comment  
Start Date...continues for 6 lines Date  
End Date Date  
Serum BilirubinUnit of Measure? Radio Buttons mg/dL,µmol/L 
Total Bilirubin (mg/dL) Numeric  
Total Bilirubin (µmol/L) Numeric  
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Date Date  
Albumin (mg/L) Numeric  
Date Date  
ALT (SGPT) (U/L) Numeric  
Date Date  
AST (SGOT) (U/L) Numeric  
Date Date  
Creatinine (mg/dl) Numeric  
Date Date  
Platelets (x10<sup>9</sup>/L) Numeric  
Date Date  
Leukocytes (x10<sup>9</sup>/L) Numeric  
Date Date  
Neutrophils (x10<sup>9</sup>/L) Numeric  
Date Date  
Tumor Marker Other Text  
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Appendix 6: Resource use questionnaire sent to clinicians 
Questionnaire to SIRT CtE clinicians – Resource use 
 
This questionnaire related to the treatment of patients with unresectable metastatic colorectal 
cancer which has progressed on at least two lines of standard chemotherapy. 
 
Please provide responses based on your experience in the NHS. 
 
PRE-SIRT WORK UP 
 
1. During the pre-SIRT work-up procedure, which of the following elements would typically be 
included? 
Elements of work up procedure (NHS Ref costs suggested) Y/N Comments 
Please provide any further 
information or costs 
Angiography, including embolization where required  
(RD32Z Contrast Fluoroscopy Procedures with duration of more 
than 40 minutes) 
  
Injection of 99mTc MAA  
(SC53Z Preparation for Intraluminal Brachytherapy, inpatient) 
  
Cost of 99mTcMAA   
SPECT Scan  
(RN04A SPECT-CT of one area, 19 years and over) 
  
CT Scan  
(RD20A Computerised Tomography Scan of one area, without 
contrast, 19 years and over) 
  
Liver ultrasound   
PET-CT   
Outpatient attendance   
CEA test   
Liver function tests   
   
Please add more rows if required   
 
2. Is a typical work-up procedure done as an outpatient, day-case or inpatient procedure? What is 
would be the typical length of stay? 
 
 
3. What consumables are used in a typical work-up procedure, which you would not expect to be 
included in NHS Reference Costs? Please estimate a cost if possible.  
 
 
 
 
4. From your experience, what proportion of patients receives a work-up procedure and do not 
receive a SIRT procedure? 
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5. From your experience, what proportion of patients requires more than 1 work-up procedure? 
 
 
6. In cases where more than one work up procedure is required, are all of the elements in Q1 
repeated? 
 
 
 
SIRT PROCEDURE 
 
7. During the SIRT procedure, which of the following elements would typically be included? 
 
Elements of SIRT procedure (NHS Ref costs suggested) Y/N Comments 
Please provide any further 
information or costs 
Angiography, including embolization where required  
(RD32Z Contrast Fluoroscopy Procedures with duration of more 
than 40 minutes) 
  
Injection of Y-90 microspheres  
(SC53Z Preparation for Intraluminal Brachytherapy, inpatient) 
  
Cost Y-90 microspheres (including administration set)   
SPECT Scan  
(RN04A SPECT-CT of one area, 19 years and over) 
  
CT Scan  
(RD20A Computerised Tomography Scan of one area, without 
contrast, 19 years and over) 
  
PET scan   
Disposal of radioactive waste   
Overnight stay   
Outpatient attendance   
   
Please insert rows as required   
 
8. Is a typical SIRT procedure done as an outpatient, day-case or inpatient procedure? What is 
would be the typical length of stay? 
 
 
9. What consumables are used in a typical SIRT procedure, which you would not expect to be 
included in NHS Reference Costs? Please provide any details available. 
 
 
 
 
10. Please describe procedures used to treat the following adverse events that may occur soon after 
SIRT. 
Adverse events from SIRT Resources used to treat 
 
 
Page 165 of 175 
 
Commissioning through Evaluation: SIRT 
Full evaluation report 
Fatigue  
Nausea  
Abdominal pain  
Radiation pneumonitis  
Gall bladder inflammation  
RILD  
GI ulceration  
Pancreatitis  
Fever  
Anaemia  
Diarrhoea   
Anorexia  
  
Please insert rows as required  
 
11. Do patients typically receive concomitant chemotherapy with SIRT? 
 
 
FOLLOW-UP AFTER SIRT 
 
12. Following SIRT, what procedures are typically used prior to disease progression? 
Resources used during follow-up after SIRT Y/N Comments 
Please provide any further 
information or costs 
Chest, abdo, pelvis CT scan (please describe frequency)   
MRI scan (please describe frequency)   
PET scan (please describe frequency)   
Chemotherapy (please describe regimen)   
Outpatient consultant visits    
Laboratory tests   
   
   
Please insert rows as required   
 
13. Do patients typically receive chemotherapy following SIRT? Please describe typical regimens.  
 
 
BEST SUPPORTIVE CARE  
 
14. What is the most appropriate comparator to SIRT before disease progression? i.e. in the absence 
of SIRT how would you manage these salvage/3rd line patients? Please describe chemotherapy 
regimens if appropriate. 
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15. Please describe the resources/procedures used to provide best supportive care prior to disease 
progression. 
 
 
 
 
 
16. Please describe typical adverse events associated with best supportive care (or an alternative 
comparator to SIRT) and the procedures used to treat them. 
Adverse events from BSC Resources used to treat 
Fatigue  
Nausea/vomiting  
Abdominal pain  
Fever  
Anaemia  
Diarrhoea   
Anorexia  
  
Please insert rows as required  
 
 
MANAGEMENT AFTER DISEASE PROGRESSION 
 
17. How are patients managed following disease progression? Would you describe this as best 
supportive care (BSC)? 
Please describe resources associated with provision of best supportive care following disease 
progression 
 
 
18. Following disease progression, would patients previously treated with SIRT be managed in the 
same way as patients previously treated with best supportive care? Please describe patient 
management. 
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Appendix 7: Sources for model inputs, and summary of available information 
Input Value Source Appraisal 
Overall survival 
(OS) 
 
SIRT 
 Median OS: 7.6 months 
(95% CIs 6.9 – 8.3)  
Primary CtE registry 
data 
Benefits 
Patient-level data. In line with scope of decision problem. Contemporary data from NHS setting.  De novo 
extrapolation of survival data possible.  
Limitations 
No comparator data. Unpublished data and no independent peer review.  
SIRT 
Median OS: 11.9 months 
(95% CIs 10.1-14.9) 
Mean OS: 25.2 months 
BSC 
Median OS: 6.6 months 
(95% CIs not reported) 
Mean OS: 11.6 months 
HR:0.57 (95% CIs 0.41-
0.82) 
Bester et al. (2012) 
retrospective matched-
pair cohort. Survival 
curve from Bester et al. 
(2014) was 
extrapolated and 
presented in 
Pennington et al. 
(2015).  
Benefits 
This peer reviewed study includes comparator data. Access to previously extrapolated data in Pennington 
et al. (2015) model has been kindly provided. Study cohort similar to CtE cohort. 
Limitations 
Observational design which is at increased risk of bias. Very small (n=29) control arm. Small numbers at 
end of curve gives rise to high uncertainty. Retrospective matched-pairs. Relies on assumption that 
extrapolation carried out by authors of Pennington et al. (2015) was correct. Cedar did not have access to 
patient-level data. BSC poorly defined. Date of SIRT doesn’t have an equivalent in the BSC arm. Unclear 
how well the patients match to CtE patients. 85% of patients had ECOG 0 suggesting this population is 
healthier than that in the CtE study (50% of CtE patients were ECOG 0). All pts failed multiple lines but the 
authors do not report how many lines (14% chemo naive in the combined non-CRC and CRC group; 
proportion of chemo-naive patients in CRC-only group is not reported). ECOG scores of BSC patients were 
not reported. Patient characteristics are not directly compared for CRC subgroup. 
SIRT 
Median OS: 8.3 months 
(95% CIs 6.6-10.2) 
BSC 
Median OS: 3.5 months 
(95% CIs 1.9-5.7) 
HR: 0.26 (95% CIs 0.15-
0.48) 
Seidensticker et al. 
(2012) retrospective 
matched-pair cohort. 
Benefits 
Includes comparator data. Cohort similar to CtE cohort. Performance status equivalent to ECOG 0-2. At 
least 2 failed lines of chemo (median 3). 
Limitations 
Observational design which is at increased risk of bias. Very small (n=29) control arm. Small numbers at 
end of curve make results unreliable. Risk of selection bias. Cedar did not have access to patient-level 
data, therefore extrapolation would need to come from tracing of curve in paper. Retrospective matched-
pairs. BSC poorly defined. 31% received chemotherapy after SIRT. Possible error in the description of OS 
(authors state: “The primary endpoint was overall survival (OS) from the date of progression of the liver 
before radioembolization or prior commencement of BSC assessed radiologically until further progression 
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(after radioembolization or BSC), evaluated by radiological imaging or clinically.”) 
SIRT & FU 
Median OS: 10 months 
(95% CIs not reported) 
FU alone 
Median OS: 7.3 months 
(95% CIs not reported) 
HR: 0.92 (0.47-1.78) 
p=0.80 
Hendlisz et al. (2010) 
randomised controlled 
trial 
Benefits 
Includes comparator data. Randomised study therefore reduced risk of selection bias and effect of 
confounders. Patients resistant or intolerant to standard chemotherapy (FU, OXA, IRI) therefore similar 
cohort to SIRT CtE study. 
Limitations 
Small study (SIRT n=21 vs chemo n=23). No access to patient level data and no overall survival curve 
presented. FU chemotherapy rather than BSC in control arm (FU alone may not represent standard 
practice in UK). Control patients permitted to cross over to SIRT arm following progression which is likely 
to significantly affect OS estimates. Majority of patients were ECOG 0. Total number of previous chemo 
lines not reported. Patients with extrahepatic metastases were excluded (in CtE group these pts were 
included if metastases were liver dominant). Patients in both arms received further treatment. 
SIRT 
Pooled median OS: 9.6 
(range 6.0-12.7). 
 
Cedar systematic 
review 
Benefits 
Pooled analysis across 23 studies (n=2517). Large cohort of patients well matched to CtE cohort. 
Limitations 
No access to patient-level data. No comparator. Data was based on retrospective and prospective single-
arm observational studies.  
BSC 
Pooled median OS: 5.3 
(range 2.4-6.6). 
Cedar systematic 
review  
Benefits 
Pooled analysis across 7 studies to produce large cohort (n=1156) 
Limitations 
Data from control arm of RCTs (non-SIRT intervention). BSC may not represent care in real-life setting. No 
access to patient-level data. Population may differ from SIRT CtE cohort. Likely to effect from RCT design 
(“trial effect”).  
BSC 
Mean OS: 6.2 months 
Hoyle et al. (2013) 
model for NICE TA  
Benefits 
Extrapolated curves from Hoyle et al. (2013) model available. Model is based on NHS setting. 
Limitations 
Data from the control arm of one RCT (non-SIRT intervention). May not be comparable to SIRT.  
Progression free 
survival (PFS) 
SIRT 
Median PFS: 5.5 months 
(95% CIs not reported) 
Seidensticker et al. 
(2012) retrospective 
matched-pair cohort. 
Benefits 
Comparator data available. RECIST criteria used (although later it says where progression was defined as a 
clinically significant change in symptoms or CEA levels, or confirmed by radiological imaging, and this may 
apply to BSC arm only).   
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BSC 
Median PFS: 2.1 months 
(95% CIs not reported) 
(no statistical comparison) 
Limitations 
See above for further points. 31% received chemotherapy after SIRT (the authors do not report that this 
was after progression so may affect PFS). PFS measured from “progression” to “further progression” 
which is not how other studies record it. No Kaplan-Meier curve for PFS.  
SIRT & FU 
Median PFS: 4.5 months 
(95% CIs not reported) 
FU alone 
Median PFS: 2.1 months 
(95% CIs not reported) 
HR 0.51 (95% CIs 0.28-
0.94) p=0.03 
Hendlisz et al. (2010) 
randomised controlled 
trial 
Benefits 
PFS measured using RECIST criteria. Cross over was only permitted after progression was documented, 
therefore limited impact PFS results.  
Limitations 
See above for further notes. PFS data reported in Kaplan-Meier curve. Time to liver progression (TTLP) 
was primary outcome for trial.  TTP and TTLP calculated from randomisation to “first documented 
progression in the liver or first documented progression at any site, death, or date of last observation (in 
patients lost to follow-up)”
1
. 
 
Not reported Bester et al. (2012) Outcome not reported 
SIRT 
Pooled median 4.0 months 
(range 2.8 to 9.2 months) 
Cedar systematic 
review 
Benefits 
Pooled analysis from 9 studies (437 patients). Large cohort of patients well matched to CtE cohort. 
Limitations 
No access to patient-level data or survival curve. No comparator data. Based retrospective and 
prospective single-arm observational studies. Large range of PFS values from studies.  
BSC 
Pooled median 3.2 months 
(range 1-7.3 months) 
Cedar systematic 
review 
Benefits 
Pooled analysis across 5 studies to produce large cohort.  
Limitations 
Data from control arm of RCTs (non-SIRT intervention). BSC may not represent care in real-life setting. No 
access to raw data or survival curve. No comparator. Population may differ from SIRT CtE cohort. 
                                                          
1
 TTP is defined slightly differently to PFS. However in this case, TTP has the same definition as PFS (i.e. time to progression or death).   
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BSC 
Mean PFS: 2.7 months 
Hoyle et al. (2013) 
model for NICE TA  
Benefits 
Extrapolated curves from Hoyle et al. (2013) model available. Model is based on NHS setting. 
Limitations 
Data from the control arm of one RCT (non-SIRT intervention). May not be comparable to SIRT.  
Adverse events SIRT 
List of AE types with grade 
and proximity to SIRT 
Primary CtE registry 
data. 
Benefits 
As described above.  
Limitations 
CTCAE grading criteria not explicitly defined across study but assumed to have been used. Registry design 
means no validation of data as in a trial, therefore there is a risk of missing data. Relatedness to SIRT not 
captured.  
SIRT 
List of AEs with grade
1
 
(separated to SIRT-related 
and delayed 
complications) 
Bester et al. (2012) 
retrospective matched-
pair cohort. 
Benefits 
As described above. CTCAE criteria used.  
Limitations 
As described above. No AEs reported for comparator arm. No treatment described. No better than using 
CtE data. May be useful to compare to SIRT for reliability.  
SIRT 
List of AEs with grade. 
Likelihood of being related 
to SIRT is described.   
Seidensticker et al. 
(2012) retrospective 
matched-pair cohort. 
Benefits 
CTCAE criteria used. 
Limitations 
No AEs reported for comparator arm. No treatment described. Useful to compare to SIRT for validation 
purposes. 
SIRT & FU 
List of AEs with grade.  
Hendlisz et al. (2010) 
randomised controlled 
trial 
Benefits 
CTCAE criteria used.  
Limitations 
See above for further notes. Authors do not report whether AEs are related to the SIRT/FU or disease 
                                                          
1
 AEs in most studies are graded according to the CTCAE criteria. We could consider only costing AEs which are grade >2.  
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progression.  
BSC 
Cost of AE: £2760 
Hoyle et al. (2013) 
model for NICE TA 
Hoyle et al. uses a cost for AEs in the BSC arm but it’s not clear how this is calculated.  
BSC 
List of AEs of grade ≥3. 
Jonker et al. (2007) 
RCT of BSC vs 
cetuximab.  
Benefits 
Largest of BSC trials.  
Limitations 
Intervention is not SIRT. Trial setting may not be comparable to SIRT CtE cohort. Only reports Grade 3 and 
above. Does not report treatment. Patients in BSC did not received chemotherapy with which there may 
be associated AEs.  In real life setting BSC will comprise chemotherapy in some patients.  
Cost of initial 
SIRT treatment 
 
£21,870   SIRT CtE current 
payments 
Benefits 
Prices quoted for 2014-15. Current actually paid to SIRT CtE providers.  
Limitations 
Prices quoted for 2014-15. This is a tariff not a cost and therefore is may not reflect true cost, or potential 
future payments 
£14,248 (2013-14) 
 
Pennington et al. 
(2015) taken from 
reference costs from 
NHS reference costs 
and The Christie NHS 
Foundation Trust 
Includes work-up, treatment, hospital care (overnight for work up, 1.5 day stay for treatment) and 
additional equipment. Based on NHS reference cost and detailed NHS data. Appears to include 6.7% of 
patients with more than 1 workup, and 2.2% with more than 1 treatment. Needs to be inflated to current 
prices.  
SIRT 
Daily (2013-14) 
BSC 
Daily (2013-14) 
Costs from Pennington 
et al. (2015) model 
based on daily costs 
from Seidensticker et 
al. (2012). 
 Daily costs applied throughout patient lifetime 
 Chemotherapy regimen taken from another study (Seidensticker, 2012) whilst survival data are from 
Bester et al. (2015) 
 Chemo detail not in published paper (Seidensticker, 2012) 
 Not clear in model how data is being used 
 No mention of BSC chemo in published paper (Seidensticker, 2012) 
 The chemo regimens are included in the model, together with the total time spent on regimen by 
patients. This is used to give a total cost (with microcosting drug costs and NHS ref prices for 
administration).  
 The cost of each regimen is multiplied by the months/patient for which it was delivered to give a 
total cost of chemo per patient. This calculation appears to have missed out the cost of all 5-FU/FA 
therapy. Total cost including deliver is £4,712 per patient 
 This is then adjusted to give a price per patient per day (using total months survived for whole 
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cohort). This daily cost is applied to the model. 
 Because Bester et al. (2012) has much longer survival times than Seidensticker et al. (2012), the total 
chemotherapy cost in the model is greater - £13,400. 
Chemotherapy BSC 
No chemotherapy costs 
Hoyle et al. (2013)  No Chemotherapy in BSC arm, other arms are drug treatments with high costs (£20-50,000 per 
patient), 3
rd
 line treatments. 
 Assumes cost of any chemotherapy to be very small, and equal and not included. 
BSC 
No chemotherapy costs 
TA405 (NICE 2016)  No chemotherapy costs were included for BSC 
SIRT & BSC Primary CtE registry 
data. 
 2-3 months imaging and consultant appt until progression 
 Following progression hands over to normal clinical team, info not known 
Monitoring costs £125 per month (2013) Pennington et al. 
(2015) 
 Monthly oncology appt for each arm for entire patient lifetime 
 Based on NHS Reference costs 
 No imaging or testing costs included 
BSC £0 Hoyle et al. (2013)  No costs included for BSC until progression 
BSC 
£182 monthly 
TA405 (NICE 2016)  Based on estimated resource use of 1 oncology visit per month and 1 health visitor visit per 4 
months. 
 Use of estimated resources criticised by ERG. 
SIRT 
£625.1 per month (2013-
14)  
BSC 
£599.3 per month (2013-
14) 
Pennington et al. 
(2015) based on 
monthly oncology 
appointment for all 
and chemotherapy for 
some from 
Seidensticker et al.  
2012. 
 Costs applied for entire patient lifetime in Pennington model  
 Chemotherapy costs are included in this monthly cost 
 
Total Cost of 
ongoing SIRT 
cohort in non-
progressed state 
BSC 
£0 It is only costed after 
progression 
Hoyle et al. (2013)  
BSC 
£182 monthly 
TA405 (NICE 2016)  Based on estimated resource use of 1 oncology visit per month and 1 health visitor visit per 4 
months. 
 Use of estimated resources criticised by ERG. 
SIRT 
£625.1 per month (2013-
Pennington et al. 
(2015) based on 
 Costs applied for entire patient lifetime in Pennington model  
 See previous reservations on chemotherapy costs 
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14) 
BSC 
£599.3 per month (2013-
14) 
monthly oncology 
appointment for all 
and chemotherapy for 
some from 
Seidensticker et al.  
2012. 
 Hendlisz withdraws chemotherapy after disease progression 
 Need to check with clinicians if it is likely to continue 
 Needs to be inflated to current prices 
Cost of 
progressed state  
BSC 
£1039 per month (2011) 
Hoyle et al. (2013)  This includes medication, hospitalizations, hospice stays, outpatient visits, scans, and laboratory test 
 Was included for both arms 
 Based on study on breast cancer (Remak & Brazil 2004) 
 Costs were inflated to 2010 prices. 
 Intervention arm included £295/month for consultant visits and £37 a month for CT scan. 
 And assumes cost of any chemotherapy to be very small, and equal and not included. 
 Cost from (Remak & Brazil 2004), inflated to 2011. 
BSC 
£193 per month, plus 
£1528 on progression. 
TA405 (NICE 2016)  Some treatment assumed, given the initial lump sum applied. 
Cost of death All 
£5,800 
Pennington et al. 
(2015) 
 Applied on death 
No additional cost Hoyle et al. (2013)  The progressed state is costed at £1039 and described as palliative care. There is no additional cost 
upon death. 
All 
£6910 
TA405 (NICE 2016)  Applied on death 
 Includes health care, social care and charity care. 
 Criticised by ERG for including charity care. 
SIRT 
Events listed, but no costs 
Primary CtE registry 
data. 
 Will collect data on actual adverse events, but will not have costs attached. 
 Can use reference costs to find cost. 
Cost of AEs for 
SIRT and BSC  
SIRT  
£7.43 (2013-14) 
BSC  
£42.55 (2013-14) 
Pennington et al. 
(2015) total per patient 
costs for AE, based on 
Hendlisz data 
 Applied once at start of model 
 Based on Grade 3 and 4 AE only. 
 Note that cost in model is different from that in paper. 
 There were very few AE of grades 3 or 4 in Hendlisz 
Other Intervention  
£3671 
 Hoyle et al. (2013) 
total per patient costs 
for AE 
 Different interventions, not directly applicable 
 BSC based on data gathered in Karapetis RCT, calculated by Merck Sorono in their submission to 
NICE, reported by Hoyle, and used by PENTAG model. 
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BSC  
£2760 
 AE data not presented in Karapetis, but is presented in Jonkers (same trial), as numbers of patients 
experiencing AE, Hoyle uses number of AE, so hard to compare. 
 For PSA used gamma distribution and se of 20% of mean. 
 Includes grades 3 and 4. Grade 1 and 2 are assumed to be minor and require no intervention. 
 Included AE split to: non-serious (requiring outpatient treatment only), serious but not leading to 
hospitalisation, and serious leading to, or prolonging, hospitalisation. 
 Hoyle uses Merck Serano pricing, based on HRG groups. For AE not  requiring hospitalisation, the 
corresponding body type/system is matched to appropriate HRG code and a mean assigned to the 
body type/system AE. The average cost per body type/system ranges from £106 for ocular AEs to 
£259 for infection and influenza-like symptom AEs. A similar method was used for serious AEs 
requiring hospitalisation, but in-patient procedure costs based on the HRG codes were allocated.  
BSC 
£426  
TA405 (NICE 2016), 
total per patient costs 
for AE 
 Applied once for each patient on first cycle 
 Rates from RECOURSE trial 
QALYs for SIRT 
and BSC arms 
QALY for SIRT arm Primary CtE registry 
data. 
 EQ -5D-5L data collected but methodology limits its usefulness. Likely to be unreliable. Espectially for 
comparison of pre and post progression. No QALYs for pre-death state. Unlikely to capture 
deterioration in treatment as they are not followed up with EQ-5D-5L questionnaire after 
progression. High levels of missing data.  
QALY pre-progression 0.75 
QALY post progression 
0.69 
QALY for 28 days pre 
death 0.1 
Pennington et al. 
(2015) used Hoyle et 
al. (2013)  information, 
to make an estimate 
 Same data for used both arms 
QALY pre-progression0.75 
SE 0.08 
QALY post progression 
0.69 
se (0.07) 
Hoyle et al. (2013)   Took info from manufacturer and RCT (Karapetis et al. 2008),  a study for advanced colorectal cancer, 
but with different treatments 
 Used a range of values that varied over time 
 We can only use BSC values, other values are for a drug regime. Assumed utilities to reflect both 
health gain from treatment and disutility due to adverse events 
 For PSA set se as 10% of mean, to reflect wider uncertainty than the data from the RCT (Karapetis, 
Khambata-Ford, Jonker, O'callaghan, Tu, Tebbutt, Simes, Chalchal, Shapiro, & Robitaille 2008) 
QALY pre-progression 
0.74 
QALY post progression 
0.59 
 
TA405 (NICE 2016)  From CORRECT study (Grothey et al. 2013) for  Regorafenib monotherapy for previously treated 
metastatic colorectal cancer. 
 No explicit inclusion of adverse events, assumed they are captured in utilities 
 Values were very similar for both arms. 
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